Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 1 of 178 
Confidential and Proprietary   11 Febru ary 2020   
 
Nektar Therapeutics  
 
CLINICAL STUDY PROTOCOL  
 
A PHASE 1/2, OPEN -LABEL, MULTICENTER STU DY OF THE COMBINATIO N OF 
NKTR -214 AND NIVOLUM AB OR THE COMBINATION OF NKTR -214, NIVOLUMAB, AND 
OTHER ANTI -CANCER TH ERAPIES IN PATIENTS WITH SELECT LOCALLY ADVANCED 
OR METASTATIC SOLID TUM OR MALIGNANCIES  
Protocol Number:  16-214-02 
Protocol Amendment Date:  11 February 2020  
Protocol Amendment No.  7.0 
Supersedes:  Amendment 6.0 dated 18 June 2018  
Amendment 5.1 dated 09  January 2018  
Amendment 5.0 dated 05  December  2017 (US) 
Amendment 4.0 dated 22 June 2017 (Canada, Belgium, Ukraine, US)  
Amendment 3.2 dated 07 August 2017 (France) 
US IND Number:  125471 
EudraCT Number:  2016-003543-11 
Sponsor:  Nektar Therapeutics  
455 Mission Bay Boulevard South  
San Francisco, CA 94158 US A 
Sponsor’s Medical Contact 
and Study Medical Monitor:   
Nektar Therapeutics  
455 Mission Bay Boulevard South  
San Francisco, CA 94158 USA  
CONFIDENTIALITY STATEMENT  
The confidential information in this document is provided to you as an Investigator or consultant for review by 
you, your staff, and the applicable Institutional Review Board/Independent Ethics Committee and applicable 
Regulatory  Authorities.  Your acceptance of this document constitutes agreement that you will not disclose the 
information herein to others without written authorization from Nektar Therapeutics except to the extent necessary 
to obtain informed consent from persons who participate as patients in this study.  

Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 2 of 178 
Confidential and Proprietary   11 Febru ary 2020  INVESTIGATOR SIGNATU RE PAGE  
Nektar Therapeut ics 
TITLE:  A Phase 1/2, Open -label, Multicenter Study of the Combination 
of NKTR -214 and Nivolumab or the Combination of NKTR -214, 
Nivolumab, and Other Anti-Cancer Therapies  in Patients with 
Select Locally Advanced or Metastatic Solid Tumor Malignancies  
PROTOCOL NUMBER:  16-214-02 
PHASE OF STUDY:  Phase 1/2  
PROTOCOL DATE:  11 February 2020 
STUDY SPONSOR:  Nektar Therapeutics  
455 Mission Bay Boulevard South  
San Francisco, CA 94158 USA  
 
PRINCIPAL INVESTIGAT OR COMMITMENT:  
I, the undersigned Principal Investig ator, submit this statement of commitment as evidence that I 
understand my responsibilities pursuant to the Code of Federal Regulations (21 CFR § 312) and 
ICH E6 Good Clinical Practice guidelines, as well as with any and all applicable federal, state 
and/or local laws and regulations, and agree to conduct the study in accordance with the protocol 
referenced herein.  
   
Principa l Investigator Printed Name    
   
Principal Investigator Signature   Date  
 
Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 4 of 178 
Confidential and Proprietary   11 Febru ary 2020  LIST OF STUDY CONTAC TS 
Study Contact  Name  Contact Information  
Nektar Medical Monitor   Email:  
   
NKTR-214 Development Program 
Lead  
 Email:   
   
Serious AE,  
AEs of Special Interest, and 
Pregnancy Reporti ng  Email:  
 
   
 

Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 5 of 178 
Confidential and Proprietary   11 Febru ary 2020  TABLE OF CONTENTS   
INVESTIGATOR SIGNATU RE PAGE ................................ ................................ ...................... 2 
PRINCIPAL INVESTIGAT OR COMMITMENT:  ................................ ................................ ...2 
PROTOCOL APPROVAL PA GE ................................ ................................ ............................... 3 
LIST OF STUDY CONTAC TS ................................ ................................ ................................ ....4 
TABLE OF CONTENTS  ................................ ................................ ................................ .............. 5 
LIST OF TABLES  ................................ ................................ ................................ ....................... 10 
LIST OF FIGURES  ................................ ................................ ................................ ..................... 11 
LIST OF APPENDICES  ................................ ................................ ................................ ............. 11 
ABBREVIATIONS  ................................ ................................ ................................ ...................... 12 
1.0 STUDY SYN OPSIS  ................................ ................................ ................................ ......... 17 
1.1 Study Schematics  ................................ ................................ ................................ ...37 
1.2 Schedule of Events  ................................ ................................ ................................ .39 
2.0 INTRODUCTION ................................ ................................ ................................ ............ 48 
2.1 Background  ................................ ................................ ................................ ............48 
2.1.1  NKTR-214 Mechanism of Action  ................................ ......................... 48 
2.1.2  Rationale for the Combination of NKTR -214 and Immune 
Checkpoint Inhibitors  ................................ ................................ ............48 
2.1.3  Clinical Experience with IL -2 and Checkpoint Inhibitors  .................... 49 
2.1.4  Clinical Experience with NKTR -214 ................................ .................... 49 
2.1.4.1  Observed Events of Cerebrovascular Accident in Study 16 -
214-02 ................................ ................................ ............................ 50 
2.1.4.1.1  Observed Events of Cerebrovascular Accident Following 
Triplet Immunotherapy  ................................ ................................ ..51 
2.1.4.1.2  Observed Events of Cerebrovascular Accident Following 
Doublet Immunotherapy  ................................ ................................ 52 
2.1.4.2  Mitigation Measures  ................................ ................................ ......53 
2.1.5  Flat Dose Regimens with Nivolumab (360 mg q3w and 480 mg 
q4w) ................................ ................................ ................................ ......53 
2.1.6  Nivolumab Shorter Infusion Duration  ................................ .................. 54 
2.1.7  Nivolumab Safety Summary  ................................ ................................ .54 
2.1.8  Ipilimumab Shorter I nfusion Duration  ................................ .................. 55 
2.1.9  Ipilimumab Safety Summary  ................................ ................................ 55 
2.1.10  Safety Summary of Study Regimen in Patients with 1L 
Nonsquamous NSCLC  ................................ ................................ ..........55 
2.1.11  Safety Summary of Paclitaxel Formulations in Patients with 1L 
NSCLC ................................ ................................ ................................ ..56 
2.1.12  Safety Summary of Nab -Paclitaxel in Patients with TNBC  ................. 56 
Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 6 of 178 
Confidential and Proprietary   11 Febru ary 2020  2.1.13  Safety Summary of Eribulin in Patients with  TNBC ............................ 57 
2.2 Overall Benefit/Risk  ................................ ................................ .............................. 57 
2.3 Data Monitoring Committee  ................................ ................................ .................. 57 
3.0 STUDY OBJECTIVES  ................................ ................................ ................................ ....58 
3.1 Primary Objectives  ................................ ................................ ................................ .58 
3.2 Secondary Objectives  ................................ ................................ ............................. 58 
  
4.0 SELECTION OF STUDY P OPULATION  ................................ ................................ ...59 
4.1 Inclusion Criteria  ................................ ................................ ................................ ...59 
4.2 Exclusion Criteria  ................................ ................................ ................................ ..78 
5.0 TREATMENT PLAN  ................................ ................................ ................................ ......81 
5.1 Overview  ................................ ................................ ................................ ................ 81 
5.2 Screening Period  ................................ ................................ ................................ ....81 
5.3 Treatment Period  ................................ ................................ ................................ ....82 
5.3.1  Administration of Study Drug  ................................ ............................... 82 
5.3.2  Part 1:  Dose Escalation  ................................ ................................ ........83 
5.3.3  Rationale for Recommended Phase 2 Dose for Part 2  .......................... 86 
5.3.3.1  Update of Safety and Efficacy Data for Protocol Amendment 6 
(dated 18  June 2018) ................................ ................................ ......88 
5.3.4  Part 2:  Dose Expansion  ................................ ................................ ........89 
5.3.4.1  Other Anti -Cancer Study Drugs Administered in Part 2  ...............91 
5.3.4.1.1  Cohorts 3d.1 and 3d.2:  NSCLC (1L nonsquamous)  ..................... 91 
5.3.4.1.2  Cohort 3e:  NSCLC (1L squamous) ................................ ...............92 
5.3.4.1.3  Cohort 5b:  TNBC in Combination with Nab -Paclitaxel ...............92 
5.3.4.1.4  Cohort 5c:  TNBC in Combination with Eribulin  .......................... 92 
5.3.5  Part 3: Schedule Finding for Triplet (NKTR -214, Nivolumab, and 
Ipilimumab)  ................................ ................................ ........................... 92 
5.3.6  Part 4:  Dose Expansion of Triplet (NKTR -214 plus Nivolumab 
plus Ipilimumab)  ................................ ................................ ................... 95 
5.3.7  Monitoring, Vital Signs, and Hydration Guidelines  ............................. 95 
5.3.7.1  Frequent Vital Signs  ................................ ................................ ......96 
5.3.7.2  Hydration Guidelines  ................................ ................................ .....96 
5.3.7.3  Optional Home Health Visits  ................................ ......................... 97 
5.3.8  Duration of Treatment  ................................ ................................ ...........97 
5.3.9  Treatment Beyond Progression  ................................ ............................. 97 
5.4 End of Treatment (EOT)  ................................ ................................ ........................ 99 
5.4.1  Patients in Cohort 3d or Cohort 3e  ................................ ........................ 99 

Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 7 of 178 
Confidential and Proprietary   11 Febru ary 2020  5.5 Long-Term Follow -up ................................ ................................ ......................... 100 
5.6 End of Study  ................................ ................................ ................................ ........100 
5.7 Tumor and Radiographic Assessments  ................................ ................................ 100 
5.8 Pharmacokinetic Measurements  ................................ ................................ ..........101 
5.9 Immunogenicity Measu rements ................................ ................................ ...........102 
5.10   (Blood and Tumor Collection)  ................................ ..103 
  
5.10.2  Tumor Tissue Biopsy Collection Times and Analysis  ........................ 104 
5.10.3  Stool Sample Analysis  ................................ ................................ ........104 
5.11  Determination of Dose -Limiting Toxicities (DLTs)  ................................ ............105 
5.11.1  DLTs Related to Study Drug(s)  ................................ .......................... 105 
5.11.2  Grade 3 or 4 AEs  that Should Not be Considered a DLT  ................... 105 
5.12  Delayed Dose -Limiting Toxicities (DLTs)  ................................ .......................... 106 
5.13  Dose Delay and Reduction Criteria  ................................ ................................ .....106 
5.13.1  Nivolumab Dose Delay Criteria  ................................ .......................... 106 
5.13.2  Ipilimumab Do se Delay Criteria  ................................ ......................... 107 
5.13.3  NKTR-214 Dose Delay and Reduction Criteria  ................................ .108 
5.13.4  Monitoring and Management of Adrenal Insufficiency and 
Hypophysitis  ................................ ................................ ....................... 109 
5.13.5  Monitoring and Management of NKTR -214-induced Eosinophilia  ...109 
5.13.6  Monitoring and Management of Elevated Hepatic Transaminases  ....109 
5.13.7  Cohorts 3d.1 and 3d.2 (NSCLC) Dose Delay and Reduction 
Criteria for Platinum and Pemetrexed  ................................ ................. 110 
5.13.8  Cohort 3e (NSCLC) Dose Delay an d Reduction Criteria for 
Platinum and Taxane  ................................ ................................ ...........111 
5.13.9  Nab-Paclitaxel Dose Delay and Reduction Criteria  ............................ 113 
5.13.10  Eribulin Dose Delay and Reduction Criteria  ................................ ......113 
5.13.11  Criteria to Resume NKTR -214, Nivolumab, or Anti -Cancer Study 
Drugs ................................ ................................ ................................ ...114 
5.13.12  Permanent Treatment Discontinuation Criteria  ................................ ..115 
5.14  Management Algorithms for Immune -mediated AEs Associated with 
Immuno-Oncology A gents................................ ................................ ................... 118 
5.15  Treatment of NKTR -214, Nivolumab, or Ipilimumab -Related Infusion 
Reactions  ................................ ................................ ................................ ..............118 
5.16  Prior and Concomitant Medications  ................................ ................................ ....120 
5.17  Permitted Concomitant Medications/Treatment  ................................ .................. 120 
5.18  Prohibited and/or Restricted Concomitant Medications  ................................ ......121 

Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 8 of 178 
Confidential and Proprietary   11 Febru ary 2020  5.18.1  Prohibited Medications  ................................ ................................ .......121 
5.18.2  Blood Pressure Medications  ................................ ................................ 122 
5.18.3  Effect of NKTR -214 on the PK of Concomitant Medications  ............122 
5.19  Adverse Events  ................................ ................................ ................................ ....123 
5.20  Assigning Patient Numbers ................................ ................................ .................. 123 
6.0 INVESTIGATIONAL PROD UCT(S)/STUDY DRUGS  ................................ ............ 124 
6.1 NKTR-214 Drug Description and Formulation  ................................ ................... 124 
6.2 NKTR-214 Drug Packaging and Labeling  ................................ .......................... 124 
6.3 NKTR-214 Drug Reconstitution and Handling  ................................ ................... 124 
6.4 NKTR-214 Drug Storage  ................................ ................................ ..................... 125 
6.5 NKTR-214 Drug Shipment  ................................ ................................ .................. 125 
6.6 Nivolumab, Ipilimumab, and Other Anti -Cancer Study Drugs Formulation, 
Reconstitution, Storage, and Packaging ................................ ............................... 125 
6.7 Study Drug Accountability and Reconciliation  ................................ ................... 125 
7.0 ASSE SSMENT OF SAFETY OR AES AND SERIOUS AES  ................................ ...127 
7.1 AE Definition and Assessment  ................................ ................................ ............127 
7.2 Monitoring AEs  ................................ ................................ ................................ ...127 
7.3 Grading of AEs  ................................ ................................ ................................ ....128 
7.4 Causality Relationship of AEs  ................................ ................................ .............128 
7.5 AE Reporting and Follow -up ................................ ................................ ...............129 
7.6 Serious AE Definition  ................................ ................................ .......................... 129 
7.7 Serious AE Reporting  ................................ ................................ .......................... 130 
7.8 Serious AE Follow -up................................ ................................ .......................... 131 
7.9 Disease Progression and Death due to Disease Progression – Not Reportable 
as an AE/SAE  ................................ ................................ ................................ ......132 
7.10  Immune-mediated Adverse Events  ................................ ................................ ......132 
7.11  Adverse Events of Special Interest  ................................ ................................ ......132 
7.12  Potential Drug -Induced Liver Injury  ................................ ................................ ...132 
7.13  Pregnancy  ................................ ................................ ................................ .............133 
7.14  Clinical Laboratory Tests  ................................ ................................ ..................... 133 
7.15  Physical Examinations  ................................ ................................ ......................... 134 
7.16  Vital Signs  ................................ ................................ ................................ ............134 
7.17  Electrocardiograms  ................................ ................................ .............................. 134 
7.18  Echocardiograms ................................ ................................ ................................ ..135 
7.19  Pregnancy Tests  ................................ ................................ ................................ ...135 
8.0 ASSESSMENT OF EFFICA CY EVALUATIONS ................................ ..................... 136 
8.1 Definitions ................................ ................................ ................................ ............136 
Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 9 of 178 
Confidential and Proprietary   11 Febru ary 2020  8.1.1  Measurable Disease  ................................ ................................ .............136 
8.1.2  Non-measurable Disease  ................................ ................................ .....136 
8.2 Specifications by Methods of Measurements  ................................ ...................... 136 
8.2.1  Tumor Response Evaluation  ................................ ............................... 137 
8.2.1.1  Assessment of Over all Tumor Burden at Baseline and 
Measurable Disease  ................................ ................................ .....137 
8.2.1.2  Baseline Documentation of ‘Target’ and ‘Non -target’ Lesions  ..137 
8.2.1.3  Special Notes on the Assessment of Target Lesions  ................... 138 
8.2.2  Response Criteria using RECIST 1.1  ................................ .................. 138 
8.2.2.1  Evaluation of Target Lesions  ................................ ....................... 138 
8.2.2.2  Evaluation o f Non-Target Lesions  ................................ ...............139 
8.2.2.3  Confirmatory Measurement/Duration of Response  ..................... 139 
8.2.2.3.1  Confirmation  ................................ ................................ ................ 139 
8.2.2.4  Evaluation of Overall Response Using RECIST 1.1  ................... 139 
9.0 STATISTICAL METHODS PLANNED IN THE PROTO COL AND 
DETERMINATION OF SAM PLE SIZE  ................................ ................................ ....141 
9.1 General Considerations  ................................ ................................ ........................ 141 
9.1.1  Efficacy ................................ ................................ ............................... 141 
9.2 Determination of Sample Size  ................................ ................................ .............141 
9.3 Safety Monitoring  ................................ ................................ ................................ 146 
9.4 Replacement of Patients  ................................ ................................ ....................... 146 
9.5 Analysis Sets  ................................ ................................ ................................ ........146 
9.6 Planned Analyses  ................................ ................................ ................................ .147 
9.6.1  Demographics and Baseline Characteristics  ................................ .......147 
9.6.2  Safety ................................ ................................ ................................ ..147 
9.6.3  Efficacy ................................ ................................ ............................... 148 
9.6.4  Immunogenicity  ................................ ................................ .................. 149 
  
9.6.6  Pharmacokinetics  ................................ ................................ ................ 149 
9.7 Concomitant Medications  ................................ ................................ .................... 150 
9.8 Missing Data  ................................ ................................ ................................ ........150 
10.0  STUDY OR STUDY SITE TERMINATION  ................................ .............................. 151 
11.0  QUALITY CONTROL AND QUALITY ASSURANCE  ................................ ........... 152 
11.1  Changes to the Protocol  ................................ ................................ ....................... 152 
11.2  Monitoring  ................................ ................................ ................................ ...........152 
11.3  Direct Access to Source Data/Documents for Audits and Inspections  ................ 153 
12.0  ETHICS  ................................ ................................ ................................ .......................... 154 

Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 10 of 178 
Confidential and Proprietary   11 Febru ary 2020  12.1  IRB/IEC Approval  ................................ ................................ ............................... 154 
12.2  Written Informed Consent  ................................ ................................ ................... 154 
13.0  DATA HANDLING AND RE CORD KEEPING  ................................ ........................ 155 
13.1  Data Collection Instruments and Source Documents  ................................ ..........155 
13.1.1  Study Records  ................................ ................................ ..................... 155 
13.1.2  Data Coll ection Instruments  ................................ ................................ 155 
13.2  Retention of Essential Documents  ................................ ................................ .......155 
13.3  Confidentiality  ................................ ................................ ................................ .....156 
13.4  Security Measures  ................................ ................................ ................................ 156 
14.0  PUBLICATION POLICY  ................................ ................................ ............................. 157 
15.0  REFERENCES  ................................ ................................ ................................ ............... 158 
 
LIST OF TABLES  
Table 1: Schedule of Events for Part 1 ................................ ................................ .....39 
Table 2: Schedule of Events for Part 2 ................................ ................................ .....42 
Table 3: Schedule of Events for Parts 3 and 4  ................................ ......................... 45 
Table 4.  CVA Adverse Events in Study 16 -214-02 ................................ ................. 51 
Table 5: Part 1:  Dose Escalation Scheme  ................................ ............................... 84 
Table 6: Part 1:  Dose Escalation Guide  ................................ ................................ ..84 
Table 7: Part 1:  Treatment Cycle Duration and DLT Window  ............................... 85 
Table 8: Patient Exposure Supporting the RP2D  ................................ ..................... 86 
Table 9:  16-214-02: Overall Investigator -Assessed Tumor Response for 
Patients Treated at the NKTR -214 Recommended Phase  2 Dose and 
Nivolumab 360 mg q3w in the Dose Escalation Study Pha se ................... 89 
Table 10: Part 2 Treatment Cohorts (All Patients Receive NKTR -214 plus 
Nivolumaba) ................................ ................................ ............................... 90 
Table 11: Example of Concurrent and Staggered Schedule Scenarios for Triplet 
(Dosing Schedule 1)  ................................ ................................ ................... 93 
Table 12: Part 3, Cohort A:  Concurrent Dosing Schedules  ................................ ......94 
Table 13: Part 4 Indications and Dosing Schedules  ................................ ................... 95 
Table 14:  Dose Levels for Platinum and Pemetrexed  ................................ ..............110 
Table 15:  Recommended Dose Modifications for Hematologic Toxicity for 
Platinum and Pemetrexed  ................................ ................................ ........110 
Table 16:  Recommended Dose Modifications for Non -Hematologic Toxicity for 
Platinum and Pemetrexed  ................................ ................................ ........111 
Table 17:  Dose Levels Platinum and Taxane  ................................ ........................... 111 
Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 11 of 178 
Confidential and Proprietary   11 Febru ary 2020  Table 18:  Recommended Dose Modifications for Hematologic Toxicity Platinum 
and Taxane  ................................ ................................ ............................... 112 
Table 19:  Recommended Dose Modifications for Non -Hematologic Toxicity 
Platinum and Taxane  ................................ ................................ ................ 112 
Table 20:  Dose Recommendations for Eribulin  ................................ ....................... 114 
Table 21: Criteria to Determine Objective Tumor Response for Target Lesions 
per RECIST 1.1  ................................ ................................ ........................ 138 
Table 22: Criteria to Determine Tumor Response for Non -Target Lesions per 
RECIST 1.1  ................................ ................................ .............................. 139 
Table 23: Best Overall Response When Confirmation of C R and PR Required  .....140 
Table 24: True (Target) and Historic Objective Response Rate for Each 
Indication in Part  2 ................................ ................................ ................... 143 
Table 25: True (Target) and Historic Objective Response Rate for Each 
Indication in Parts  3 and 4 ................................ ................................ .......146 
Table 26:  Cerebrovascular Accident Adverse Event Management Algorithm  ........178 
 
LIST OF FIGURES  
Figure 1: Study Schematic for Parts 1 and 2  ................................ ............................. 37 
Figure 2: Study Schematic for Parts 3 and 4  ................................ ............................. 38 
 
LIST OF APPENDICES  
Appendix 1:  Clinical Laboratory Tests  ................................ ................................ .........162 
Appendix 2:  Schedule of Electrocardiogram, Vital Signs, Pharmacokinetics,  
, and Immunogenicity Sample Assessments  ........................... 165 
Appendix 3:  Cerebrovascular Accident Adverse Event Management Algorithm  ........178 
 

Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 12 of 178 
Confidential and Proprietary   11 Febru ary 2020  ABBREVIATIONS  
Abbreviation or Term  Definition  
1L first line 
2L second line  
3L third line 
5-FU fluorouracil  
ACTH adrenocorticotropic hormone  
AE adverse event  
AEC absolute eosinophil count  
AESI adverse event of special interest  
AJCC American Joint Committee on Cancer  
ALK anaplastic lymphoma kinase  
ALT (SGPT)  alanine aminotransferase (serum glutamic pyruvic transaminase)  
ALP alkaline phosphatase  
ANC absolute neutroph il count 
AST (SGOT)  aspartate aminotransferase (serum glutamic oxaloacetic transaminase)  
AUC area under the curve  
BOR best overall response  
BRAF proto-oncogene B -Raf 
BUN blood urea nitrogen  
C1D1, C2D1, C3D1, etc.  Cycle 1 Day 1, Cycle 2 Day 1, Cycle 3 Day 1, etc  
Cavgss steady-state average concentration  
Cmaxss steady-state peak concentration  
CBR clinical benefit rate  
CFR Code of Federal Regulations  
CI confidence interval  
cis cisplatin 
CL clearance  
Cmax maximum concentration  
CR complete respon se  
CRC colorectal carcinoma  
CrCl creatinine clearance  
CRF case report form  
CT computed tomography  
CTCAE Common Terminology Criteria for Adverse Events  
CTLA-4 cytotoxic T lymphocyte -associated protein 4  
CVA cerebrovascular accident  
D5W dextrose 5% in water for injection  
DCI data collection instrument  
Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 13 of 178 
Confidential and Proprietary   11 Febru ary 2020  Abbreviation or Term  Definition  
DILI drug-induced liver injury  
DLT dose-limiting toxicity  
dMMR mismatch repair deficient  
DOR duration of response 
DWI diffusion-weighted imaging  
ECG electrocardiogram  
ECHO echocardiogram  
eCOA electronic clinical outcomes assessments  
ECOG Eastern Cooperative Oncology Group  
eCRF electronic case report form  
EDC electronic data capture  
EGFR epidermal growth factor receptor  
EOT end of treatment  
FDA Food and Drug Administration  
FFPE formalin-fixed paraffin -embedded  
FNR false-negative rate  
FOLFIRI  5-fluorouracil, leucovorin, and irinotecan  
FOLFOX  fluorouracil, leucovorin, and oxaliplatin  
FPR false-positive rate  
GCP Good Clinical Practice  
GFR glomerular filtration rate  
GGT gamma-glutamyl transferase  
HBsAg hepatitis B surface antigen  
HCV hepatitis C virus  
HER2 human epidermal growth factor receptor 2 
Hgb hemoglobin  
HIV human immunodeficiency virus  
hr hour(s) 
HR hormone receptor  
ICF informed consent form  
ICH International Council fo r Harmonisation  
IEC independent ethics committee  
IHC immunohistochemistry  
IL-2 interleukin -2 
IL2R IL-2 receptor alpha subunit  
IL2R IL-2 receptor beta subunit  
imAE immune-mediated adverse event  
IND Investigational New Drug application  
Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 14 of 178 
Confidential and Proprietary   11 Febru ary 2020  Abbreviation or Term  Definition  
I-O immuno-oncology 
IRB institutional review board  
irRECIST  immune-related RECIST  
IV intravenous  
kg kilogram 
LDH lactate dehydrogenase  
LVEF left ventricular ejection fraction  
MAD maximally administered dose  
MCH mean corpuscular hemoglobin  
MCHC mean corpuscu lar hemoglobin concentration  
MCV mean corpuscular volume  
MedDRA  Medical Dictionary for Regulatory Activities  
MEK mitogen-activated protein kinase  
MEL melanoma  
min minute(s)  
mg milligram  
mL milliliter 
mm Hg millimeters of mercury  
mo month 
MRI magnetic resonance imaging  
MSI microsatellite  instability  
MTD maximum tolerated dose  
mTOR mammalian target of  rapamycin  
MUGA multigated acquisition  
N1 sample size at stage 1  
N2 sample size at stage 2  
NCI National Cancer Institute  
NKTR-214 bempegaldesl eukin (International Nonproprietary Name)  
NKTR-214/nivolumab/ipilimumab  triplet containing NKTR -214 and nivolumab and ipilimumab  
NE non-evaluable  
NK natural killer  
NSCLC non-small cell lung cancer  
NYHA New York Heart Association  
ORR objective respons e rate  
OS overall survival  
OTC over-the-counter 
PD progressive disease  
PD-1 programmed cell death protein 1  
Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 15 of 178 
Confidential and Proprietary   11 Febru ary 2020  Abbreviation or Term  Definition  
PD-L1 programmed cell death ligand 1  
PEG polyethylene glycol  
PFS progression -free survival  
PK pharmacokinetic  
pMMR mismatch repair profici ent 
PPK population pharmacokinetics  
PR partial response  
PSA prostate-specific antigen  
PT prothrombin time  
PTT partial thromboplastin time  
q1h × 2 every hour for 2 hours  
q1h × 3 every hour for 3 hours 
q1h × 4 every hour for 4 hours  
q2w every 2 wee ks 
q3w every 3 weeks  
q4w every 4 weeks  
q6w every 6 weeks  
QTcF Fridericia’s corrected QT interval  
RBC red blood cells  
RCC renal cell carcinoma  
RECIST Response Evaluation Criteria in Solid Tumors 
rhIL-2 recombinant human interleukin 2  
RP2D recommend ed Phase 2 dose  
S1 futility boundary at stage 1  
S2 futility boundary at stage 2  
SAE serious adverse event  
SAP statistical analysis plan  
SD stable disease  
SLD sum of the longest diameters  
SCLC small-cell lung cancer  
SOP standard operating procedure  
SUSAR suspected unexpected serious adverse reaction  
T1 efficacy boundary at stage 1  
T2 efficacy boundary at stage 2  
T1/2 terminal elimination phase half -life 
T3 triiodothyronine  
T4 free thyroxine  
TEAE treatment -emergent adverse event  
Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 16 of 178 
Confidential and Proprietary   11 Febru ary 2020  Abbreviation or Term  Definition  
TIL tumor infiltrating lymphocyte  
TIA transient ischemic attack  
TKI tyrosine kinase inhibitor  
Tmax time to maximum concentration  
TNBC triple-negative breast cancer  
TP total protein  
Treg regulatory T  cell 
TSH thyroid-stimulating hormone  
TTR time to response  
ULN upper limit of normal  
US United States of America  
Vd volume of distribution  
VEGF  vascular endothelial growth factor  
WBC white blood cell  
WCBP women of childbearing potential  
WFI Water for Injection 
 
Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 17 of 178 
Confidential and Proprietary   11 Febru ary 2020  1.0 STUDY SYNOPSIS  
Name of Sponsor:  Nektar Therapeuti cs 
Name of Finished 
Products:  Bempegaldesleukin ( NKTR-214 drug product)  
Opdivo® 
Yervoy® 
Abraxane® 
Paraplatin® 
Platinol® 
Alimta®   
Halaven®  
Taxol® 
Name of Active 
Ingredients:  NKTR-214 drug substance  
Nivolumab (anti -PD-1) 
Ipilimumab (anti -CTLA-4) 
Nab-paclitaxel (nanoparticle albumin -bound paclitaxel)  
Carboplatin  
Cisplatin 
Pemetrexed (folate antimetabolite)  
Eribulin mesylate (nontaxane, microtubule dynamics inhibitor)  
Paclitaxel  
Title of Study:  A Phase 1/2, Open -label, Multicenter Study of the Combination of NKTR -214 and 
Nivolumab or the Combination of NKTR-214, Nivolumab, and  Other Anti -Cancer 
Therapies in Patients with Select Locally Advanced or Metastatic Solid Tumor 
Malignancies  
Duration of Treatment:  Patients will be treated until disease progression , death, unacceptable toxicity, 
symptomatic deterioration, achievement of maximal response, the Investigator’s 
decision to dis continue treatment, patient decision to discontinue treatment or 
withdraw consent, lost to follow up, or Nektar Therapeutics decid es to terminate the 
trial.  Treatment may continue beyond progression if there is clinical benefit as 
determined by the Invest igator. 
Phase of Development:  Phase 1/2  
Objectives:  The primary objectives are:  
• To evaluate the safety and tolerability, and def ine the maximum tolerated dose 
(MTD) and/or recommended Phase  2 dose (RP2D) of NKTR -214 in combination 
with nivolumab or in combination with nivolumab and other anti -cancer therapies  
• To evaluate the efficacy of NKTR -214 in combination with nivolumab or in 
combination with nivolumab and other anti -cancer therapies by assessing the 
objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors 
version 1.1 (RECIST  1.1) at the RP2D  
The secondary objective is:  
• To evaluate the efficacy of NKTR -214 in combination with nivolumab or in 
combination with nivolumab and other anti -cancer therapies by assessing overall 
survival (OS), progression -free survival (PFS), clinical benefit rate (CBR), and 
duration of response (DOR)  
Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 19 of 178 
Confidential and Proprietary   11 Febru ary 2020  Study Design:  Part 1:  Dose Escalation (NKTR -214 plus nivolumab)  
NKTR-214, in escalating doses, will be combined with nivolumab.  The first 
NKTR-214 dose and schedule to be studied (i.e.,  0.006 mg/kg once every 3  weeks 
[q3w]) was determined based on an ongoing monotherapy trial with NKTR -214.  The 
dose escalation scheme is provided below.  
Part 1:  Dose Escalation Scheme  
Cohort  NKTR -214 Nivolumab q2w  Nivolumab q3w  
1 0.006 mg/kg q3w  240 mg  
2 0.006 mg/kg q3w    360 mg 
3 0.006 mg/kg q2w  240 mg  
4 0.009 mg/kg q3w    360 mg 
For dose escalation cohorts the Safety Review Committee will jointly decide the 
following:  
• Dose escalation to the next cohort and/or dose schedule  
• RP2D 
• Dose levels of NKTR -214 for a given cohort may be red uced depending on the 
severity, duration, and frequency  of toxicities observed at the previous dose level 
tested. 
• Decision to evaluate NKTR -214 and nivolumab in additional patients at lower 
NKTR-214 doses and different dose schedules to assess the benefit/ risk profile 
within the anticipated total number of pat ients. 
DLT evaluation will be based on the study dose schedule as detailed in Section  5.11. 
The Sponsor may choose to concurrently enroll patients a nd dose NKTR-214 at lower 
dose levels and/or different dose schedules to assess the benefit/risk profile within the 
anticipated 50  patients.  The Sponsor may also evaluate other doses and dose schedules 
based on the safety findings from ongoing clinical tr ials. 
 
Determination of the Recommended Phase 2 Dose:  
As of October 05, 2017, the safety of NKTR -214 in combination with nivolumab has 
been established in 38 patients across 5  dose cohorts.  In the highest dose tested, 
NKTR-214, 0.009 mg/kg + 360 mg nivolumab, two  patients experienced a DLT.  One 
patient had Grade  3 hypotension and a second patient experienced Grade  4 metabolic 
acidosis, each of which resolved within 5 days and the patients continued on treatment 
at a lower d ose of NKTR -214.  There were no Grade 3 TRAEs in the 25  patients 
treated at 0.006 mg/kg NKTR -214 with nivolumab 360  mg flat dose q3w .  At the data 
cut of October 05, 2017, there were 34  patients with at least 1  post-treatment tumor 
scan, including 10 with metastatic melanoma, 19 with renal cell carcinoma (RCC), and 
5 with non-small cell lung cancer (NSCLC).  Of these 34  response-evaluable patients, 
21 were treated at 0.006  mg/kg NKTR -214 with nivolumab 360  mg flat dose q3w; 17 
patients had partial or comple te responses and 13  had stable disease.  The dose 
escalation portion for NKTR -214 and nivolumab (Part  1) is complete, with the RP2D 
established at 0.006  mg/kg NKTR -214 with nivolumab 360  mg flat dose q3w.  
 
Part 2:  Dose Expansion (NKTR -214 plus nivolumab ± other anti -cancer 
therapies)  
Approximat ely 936 patients will be enrolled in the cohorts  specified in the table below.  
Part 2 is closed to patient screening and enrollment under Amendment 7.  
Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 20 of 178 
Confidential and Proprietary   11 Febru ary 2020  Part 2 Cohorts:  All Patients Receive NKTR -214 plus Nivolumaba 
Indication  Cohort Description  
Melanoma  1ab 1L 
1bb 2-3L, anti-PD-1 or anti-PD-L1 relapse/refractory  
1cc 2L, BRAF wild type anti -PD-1 or anti-PD-L1 relapse/refractory  
1dc 1L, following prior adjuvant therapy  
1e Patients enrolled under an earlier protocol version who are no longer 
eligible for Cohorts 1a to 1d  
RCC   2ab 1L 
2bc 2-3L, anti-PD-1 or anti-PD-L1 relapse/refractory  
2c Patients enrolled under an earlier protocol version who are no longer 
eligible for Cohorts 2a or 2b  
NSCLC 3a.1f 1L, PD-L1< 1%  
3a.2f 1L, PD-L1 ≥ 1% - < 50%  
3a.3f 1L, PD-L1 ≥ 50% 
3a.4f 1L, PD-L1 status unknown  
3bd 2L, I-O therapy -naive following platinum -based therapy  
3cc 2L-3L, anti-PD-1 or anti-PD-L1 relapse/refractory  
3d.1f 1L, nonsquamous in combination with platinum/pemet rexed 
(+ maintenance pemetrexed)  
3d.2f 1L, nonsquamous in combination with platinum/pemetrexed 
(no maintenance pemetrexed)  
3ef 1L squamous in combination with platinum/taxane  
3fe 3L+, ALK -translocation/RO S1 rearrangement positive  
3ge 3L+, EGFR muta tion/deletion  
3hf 2L, following platinum -based doublet cytotoxic chemotherapy 
combined with anti -PD-1 
3i Patients enrolled under an earlier protocol version who are no longer 
eligible for Cohorts 3a.1 to 3h 
Urothelial  4ad 1L, cisplatin ineligible  
4ad,g 1L, refused standard of care  
4bc 2-3L, anti-PD-1 or anti-PD-L1 relapse/refractory  
4c Patients enrolled under an earlier protocol version who are no longer 
eligible for Cohorts 4a and 4b  
TNBC 5ab 1-2L, I-O therapy na ive 
5bc 1-2L, I-O therapy naiv e in combination with nab -paclitaxel  
5cc 1-2L, I-O therapy naive in combination with eribulin  
5d Patients enrolled under an earlier protocol version who are no longer 
eligible for Cohorts 5a to 5c  
HR+ 
HER2- 
BC 6ac I-O therapy naive following hormonal therapy 
6bc I-O therapy naive following hormonal and cytotoxic therapy  
Gastric 7d 2-3L, I-O therapy naïve  
CRC 8ac 2-3L, I-O therapy naive; MSI -high 
8bc 3-4L, I-O therapy naive; MSI -non-high 
SCLC 9e  2L, I-O therapy na ive 
Abbreviations: CRC  = colorectal carcinoma; HR+  HER2- BC = hormone-receptor positive, HER2 -negative 
breast cancer; I -O = immuno-oncology; MSI  = microsatellite  instability; NSCLC  = non-small cell lung 
cancer; RCC  = renal cell carcinoma; RP2D  = recommended Phase  2 dose; SCLC = small cell lung 
cancer; TNBC = triple-negative breast cancer  
a.   All patients receive the RP2D:  NKTR -214 0.006 mg/kg q3w with nivolumab 360  mg q3w 
b.   Cohorts closed under Amendment 5.1.  
c.   Cohorts c losed with an administrative letter dated  29 March 2019.  
d.   Cohorts closed under Amendment 6.  
e.   Cohorts never opened for screening.  
f.   Cohorts closed  with an administrative letter dated  22 January 2020 . 
Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 22 of 178 
Confidential and Proprietary   11 Febru ary 2020  Melanomad 1 mg/kg 
× 4 doses 3 mg/kg  
q3w × 4 doses NKTR-214 
0.006 mg/kg 
+ nivolumab  
360 mg  3 RCCd 
12 0.006 mg/kg 3 mg/kg 
× 4 doses 1 mg/kg q3w  × 4 doses 
Melanomad 
a  Enrollment w ill be up to 12 patients.  
b  NKTR-214 at 0.006  mg/kg and nivolumab at 360  mg will be dosed continuously q3w after the last dose of 
ipilimumab for dosing schedules 2 and 3 following the 4 doses of nivolumab and ipilimumab and 
NKTR-214. 
c  This cohort is a h istorical cohort and was closed to patient  enrollment under Amendment 6. 
d  Cohorts closed  with an administrative letter dated  22 January 2020 . 
 
The Safety Review Committee will jointly decide the following:  
• Dose and schedule for the next cohort  
• RP2D 
• Dose levels of NKTR -214, for a given dosing schedule, may be reduced 
depending on the severity, duration, and frequency of toxicities observed at the 
previous dose level tested.  
• Decision for a recommended phase 2 dose schedule will be determined by both 
safety and pharmacological parameters.  
• Decision to evaluate the  triplet in additional patients at lower doses and/or 
different dose schedules within the anticipated 36 patients to better assess the 
benefit/risk profile.  
The Sponsor may choose to concurrently enro ll patients at lower dose levels and/or 
different dose s chedules to assess the benefit/risk profile within the anticipated 
36 patients.  In Part  3, the RP2Ds will be established for each of the 3  dosing schedules 
(it may be necessary for a separate RP2D be  established for patients with melanoma 
and urothelial c ancers, if the tolerability is different between these 2  groups).  When an 
RP2D is established in Part  3, enrollment for that dosing schedule will begin in Part  4.  
The sponsor will decide which dosin g schedules will be opened in Part  4. 
Part 4:  Dose Expa nsion of Triplet (NKTR -214 plus nivolumab plus ipilimumab)  
Enrollment into the dose expansion cohorts will commence once the RP2D for the 
triplet has been established in Part 3 for each respective tum or type.  The maximum of 
patients in each cohort is list ed in Section 9.2 Table 25 (based on a Historical and 
Target ORR); the total will include any patients from each of the 6  cohorts in Part  3, 
thus approximatel y 106 additional patients may  be enrolled into Part 4 (below).   
Patients will be enrolled simultaneously to each indication; for patients with 
melanoma, enrollment will occur simultaneously with dose schedule assigned 
alternately based on  date of screenin g until one of the respective dosing schedule’s 
enrollment is fulfilled.    
Part 4 is closed to patient screening and enrollment under Amendment 7.  
Part 4 Indications and Dosing Schedules  
Indication  Cohort  Concurrent Dosing Schedulea 
RCC 10a.1b 1 
10a.3d 3 
NSCLC 11a.1d 1 
Melanoma  12a.2d 2 
12a.3c 3 
Urothelial  13a.2d 2 
Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 23 of 178 
Confidential and Proprietary   11 Febru ary 2020  a  If staggered dosing is to be tested, matching cohorts will be named as follows:  the letter ‘a’ will be 
substituted with ‘b’ (e.g., for the urothelial indication, concurrent dosing Co hort 13a.2 will be named 
staggered dosing Cohort  13b.2). 
b  This cohort is a historical cohort for both concurrent and staggered dosing and was closed to enrollment 
under Amendment 6.  
c  This cohort was closed  with an administrative letter dated  29 March 2 019. 
d  Cohorts closed  with an administrative letter dated  22 January 2020 .  
 
If multiple cohorts in the same tumor type are open for enrollment, the sponsor  will 
assign the appropriate cohort (whether this is a Part  2 NKTR-214/nivolumab doublet 
cohort [wi th or without other an ti-cancer therapies] or one of the dosing schedules 
investigating the NKTR -214/nivolumab/ipilimumab triplet in Parts  3 and 4).  
Key Eligibility Criteria:  Under Amendment 7 , the study is closed to patient screening and enrollment.  
For the purposes of patient eligibility determination, note the following definitions:  
• For the purposes of eligibility, “neoadjuvant therapy” is defined as systemic 
chemotherapy administered prior to definitive local surgery in a patient without 
distant metast ases; “adjuvant therapy” is defined as systemic therapy administered 
following definitive local therapy (surgery or radiation) in a patient without distant 
metastases (with no evidence of disease).  
• A “line of therapy” is defined as any regimen – single-agent or combinatio n 
therapy, cytotoxic therapy, immuno -oncology therapy separately or in 
combination – that is given for patients with advanced disease, and that is stopped 
for any reason, including progression of disease, toxicity, physician decision, or 
patient withdrawal  of consent.  
 
For Parts 1 -4 
Under Amendment 7 , the study is closed to patient screening and enrollment.  
• Provide written, informed consent to participate in the study and follow the study 
procedures  
• Male or female patients, age 18  years or o lder at the time  of signing the informed 
consent form (ICF)  
• Life expectancy >  12 weeks 
• Patients must not have received prior interleukin -2 (IL-2) therapy.  
• Eastern Cooperative Oncology Group (ECOG) performance status  0 or 1 
• Measurable disease per RECIST  1.1 
• Fresh biopsy or recently obtained biopsy within the past 6  months without 
intervening treatment, and archival tumor tissue available  
 
For Parts 1 and 2 ( NKTR -214 plus nivolumab ± other anti -cancer therapies)  
Under Amendment 7 , the study is closed to patient screening and enrollment.  
For Disease -Specific  Tumor Types  
Melanoma  
• Histologically confirmed stage  III (unresectable) or stage  IV melanoma, as per 
American Joint Committee on Cancer (AJCC) staging system.  
• Patients must consent to BRAF testing or ha ve documented BRAF status as per 
regionally acceptable V600 mutational status testing.  
• Uveal melanoma will be excluded.  
• “Isolated limb perfusion” is not considered systemic chemotherapy.  
Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 24 of 178 
Confidential and Proprietary   11 Febru ary 2020  Cohort 1a −  Melanoma (1L)  
• Have not received prior anti -cancer therap y for advanced or metastatic melanoma.  
For Part 2:   
• Prior to disease  metastasis , patients must not have received neoadjuvant or 
adjuvant therapy with any immuno -oncology regimens, includ ing, but not limited 
to, checkpoint inhibitors such as anti -PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, 
or anti-cytotoxic T -lymphocyte antigen  4 (anti-CTLA-4) antibody, or any other 
antibody or drug specifically targeting T  cell co-stimulation or checkpoint 
pathways, indoleamine 2,3 -dioxygenase pathway inhibitors, cancer vacc ines, 
adoptive cell therapies, or other cytokine therapies.  
• Patients must not have received any prior therapy for melanoma (including 
therapy for neoadjuvant, adjuvant, locally advanced o r metastatic disease, 
including all systemic therapy including tyrosine kinase inhibitors [BRAF, MEK, 
mTOR], bevacizumab, I -O therapy, cytotoxic chemotherapy, and/or isolated limb 
perfusion ). 
Cohort 1b −  Melanoma (2 -3L, anti-PD-1 or anti -PD-L1 relapse/ refractory ) 
• Patients must have received only 1 prior line of therapy with an anti -PD-1 or 
anti-PD-L1 containing regimen (doublet -based therapy), which must be their most 
recent anti -cancer treatment.  Patients must not have received neoadjuvant or 
adjuvant the rapy with any immuno -oncology regimens.   
• Patients must have confirmed radiographic or biopsy -proven disease progression 
at least 4 weeks after initial disease progression, or unequivocal radiographic 
progression as per the Investigator based on a single i maging assessment; this 
assessment must be within 90 days from last dose of anti -PD-1 or anti-PD-L1 
containing regimen.  Patients  must consent to providing pre -study scans (if 
available) to confirm radiographic progression.  
• Patients may have received only 1 prior line of therapy with molecular -targeted 
therapy. 
• Patients who have received only 1 prior regimen of cytotoxic chemotherap y, but 
have not received prior molecular targeted therapy, are eligible.  
• Patients may not have primary  refractory disease  to prior anti-PD-1 therapy 
(radiographic or clinical progression within 120 days of initiation of immun o-
oncology therapy).  
Cohort 1c – Melanoma BRAF wild type (2L, anti -PD-1 or anti -PD-L1 
relapse/refractory)  
• Patients must be BRAF wild type.  
• Patients must have  received only 1 prior line of therapy with single -agent 
anti-PD-1 or anti-PD-L1 therapy, which must be their most recen t anti-cancer 
treatment.  Patients must not have received anti -CTLA-4 alone or in combination 
with anti-PD-1 or anti-PD-L1.  Patients mu st not have received neoadjuvant or 
adjuvant therapy with any immuno -oncology regimens.  
• Patients are not eligible who re ceived adjuvant or first -line therapy for 
advanced/metastatic disease consisting of molecular target therapies including, but 
not limite d to, BRAF, MEK, or C -KIT targeted therapies (single agent or in any 
combination), or intralesional therapy.  
• Patients ar e not eligible who received doublet immuno -oncology therapy, 
including checkpoint inhibitors combined with either systemic or intralesio nal 
therapy.  Patients are not eligible who received cytotoxic chemotherapy such as 
dacarbazine, paclitaxel or others.  
Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 25 of 178 
Confidential and Proprietary   11 Febru ary 2020  • Patients must have confirmed radiographic or biopsy -proven disease progression 
at least 4 weeks after initial disease progression, or une quivocal radiographic 
progression as per the Investigator based on a single imaging assessment; this 
assessment must be within 90 days from last dose of anti -PD-1 or anti-PD-L1 
therapy.   
• Patients must consent to providing pre -study scans (if available) to  confirm 
radiographic progression.  
Cohort 1d – Melanoma (1L following prior adjuvant therapy)  
• Have not received prior an ti-cancer therapy for advanced or metastatic melanoma  
• Patient must have received prior adjuvant therapy for melanoma; adjuvant therapy 
may consist of any immuno -oncology regimens (single -agent or combination 
therapy) or molecularly targeted therapy(such as  tyrosine kinase inhibitors). The 
disease-free interval from last dose of adjuvant therapy to a diagnosis of advanced 
or metastatic mela noma must be less than 180  days.  
Cohort 1e − Melanoma  
• Patients who were enrolled under an earlier version of the protocol who are no 
longer eligible for Cohorts 1a through 1d.  
 
Renal Cell Carcinoma (RCC)  
• Advanced (not amenable to curative surgery or radia tion therapy) or metastatic 
(AJCC stage  IV) RCC.  
• Histologically confirmed RCC with a clear -cell component.  
Cohort 2a − RCC (1L)  
• Have not received prior anti -cancer therapy for advanced or metastatic RCC.  
• Prior to disease metastasis, patients must not have received neoadjuvant or 
adjuvant therapy with any immuno -oncology regimens, including, but not limited 
to, checkpo int inhibitors such as anti -PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, 
or anti-cytotoxic T -lymphocyte antigen  4 (anti-CTLA-4) antibody, or any other 
antibody or drug specifically targeting T  cell co-stimulation or checkpoint 
pathways, indoleamine 2,3 -dioxygenase pathway inhibitors, cancer vaccines, 
adoptive cell therapies, or other cytokine therapies.  
Cohort 2b  − RCC (2 -3L, anti -PD-1 or anti -PD-L1 relapse/refractory)  
• Patients must have received only 1 prior line of therapy with an anti -PD-1 or 
anti-PD-L1 containing regimen, which must be their most recent anti -cancer 
treatment.  Patients must not have received n eoadjuvant or adjuvant therapy with 
any immuno -oncology regimens.  
• Patients must have confirmed radiographic disease progression at least 4  weeks 
after initial disease progression, or unequivocal radiographic progression as per 
the Investigator based on a s ingle imaging assessment; this assessment must be 
within 90  days from last dose of anti -PD-1 or anti-PD-L1 containing regimen.  
Patients must consent  to providing pre -study scans (if available) to confirm 
radiographic progression.  
Cohort 2c – Renal Cell Ca rcinoma  
• Patients who were enrolled under an earlier version of the protocol who are no 
longer eligible for Cohorts 2a or 2b.  
 
Non-Small Cell Lung Can cer (NSCLC)  
• Histologically confirmed or cytologically confirmed diagnosis of stage IV NSCLC 
(unless otherwi se noted) 
Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 26 of 178 
Confidential and Proprietary   11 Febru ary 2020  • Patients with nonsquamous  NSCLC must lack both epidermal growth factor 
receptor (EGFR) -sensitizing mutation/deletion and anaplastic lymphoma kinase 
(ALK) translocation by local testing (assessment of ROS1 mutation status is not 
required, unless o therwise noted).  For ALK or EGFR t esting, an FDA-approved 
test or validated assay should be used as applicable for selection of patients.  For 
patients with squamous NSCLC, testing for EGFR, ALK, or ROS1 is not required.  
Cohorts 3a.1, 3a.2, 3a.3 , and 3a.4  − NSCLC (1L)  
• Patients must have known PD -L1 status as per validated immunohistochemistry 
testing.  Up to 20 efficacy-evaluable patients will be enrolled in each subgroup of 
PD-L1 negative (PD -L1 < 1%; Cohort 3a.1), PD-L1 highly positive 
(PD-L1 ≥ 50%; Cohort 3a.3), or PD-L1 low/inter mediate (PD -L1 ≥ 1% - < 50%; 
Cohort 3a.2 ).  For patients who do not have known PD-L1 status, testing must be 
done using an FDA -approved PD -L1 test.  An abbreviated consent may be 
presented to the patient prior to the Screening period to permit early assess ment of 
the PD-L1 status of the tissue sample .  Patients enrolled in Cohort 3a who do not 
have a PD -L1 status assessed by central testing will be assigned to Cohort 3a.4.  
• Patients must not have received prior anti -cancer therapy  for advanced or 
metastatic NSCLC; patients must not have received prior immuno -oncology in 
any setting (including neoadjuvant, adjuvant, locally advanced or metastatic 
disease). 
Cohort 3b − NSCLC (2L, I -O therapy naive) following platinum -based therapy  
• Patients must have experienced disease recurrence or progression during or after 
one prior platinum doublet -based chemotherapy regimen for advanced or 
metastatic disease.  Patients are not eligible who refused prior platinum -based 
therapy.  
• Patients who received platinum -containing adjuvant, neoadjuvant, or definitive 
chemoradiation therapy given for locally advanced disease and developed 
recurrent (local or metastatic) disease withi n 6 months of completing therapy are 
eligible. 
• Patients must not have received any prior immun o-oncology in any setting  
regimens, including, but not limited to, checkpoint inhibitors such as anti -PD-1, 
anti-PD-L1, anti-PD-L2, anti-CD137, or anti -cytotoxic T-lymphocyte antigen 4 
(anti-CTLA-4)  antibody, or any other antibody or drug specifically tar geting 
T cell co-stimulation or checkpoint pathways, indoleamine 2,3 -dioxygenase 
pathway inhibitors, cancer vaccines, adoptive cell therapies, or other cytokine 
therapies. 
Cohort 3c − NSCLC (2 -3L, anti -PD-1 or anti -PD-L1 relapse/refractory)  
• Patients must h ave received only 1 prior line of therapy with anti -PD-1 or 
anti-PD-L1 therapy. Patients are eligible if they received sequential therapy (e.g., 
cytotoxic chemotherapy foll owed by anti PD -1 or anti PD -L1 therapy, or vice 
versa). Patients must not have rece ived neoadjuvant or adjuvant therapy with any 
immuno-oncology regimens.  
• Patients must not have received anti -CTLA-4 alone or in combination with 
anti-PD-1 or anti-PD-L1, unless the anti -CTLA-4 therapy stopped >  1 year prior 
to Cycle 1 Day 1. 
• Prior to the anti-PD-1 or anti-PD-L1 therapy regimen, patients must have received 
zero or 1 prior line of cytotoxic chemotherapy for metastatic disease.  
• Patients must have confirmed rad iographic disease progression at least 4 weeks 
after initial disease progression, or  unequivocal radiographic progression as per 
the Investigator based on a single imaging assessment; this assessment must be 
within 90  days from last dose of anti -PD-1 or anti-PD-L1 containing regimen. 
Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 27 of 178 
Confidential and Proprietary   11 Febru ary 2020  Patients must consent to providing pre study scans (if available) to confirm 
radiographic progression.  
• Patients may not have primary immun o-oncology refractory disease (radiographic 
or clinical progression within 120 days of in itiation of immun o-oncology therapy).  
Cohorts 3d.1 and 3d.2 − NSCLC (1L nonsquamous)  (in combination with 
platinum/pemetrexed and maintenance pemetrexed [Cohort  3d.1] or without 
maintenance pemetrexed [Cohort  3d.2])  
• Patients must have nonsquamous NSCLC.  T he patient will be excluded if the 
histology is considered predominantly squamous ce ll NSCLC.  Mixed tumors will 
be categorized by the predominant cell type; if small cell elements are present, the 
patient is ineligible.  
• Patients must not have received pri or anti-cancer therapy for advanced or 
metastatic NSCLC; patients who received adjuv ant or neoadjuvant therapy are 
eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months 
prior to the development of metastatic disease.  Patients must not have received 
prior immuno -oncology therapy in any setting (including neoadjuvan t, adjuvant, 
locally advanced or metastatic disease).  
• Patients must be candidates for platinum/pemetrexed chemotherapy and willing to 
take folic acid and vitamin B12 supple mentation.  
• Patients must not have received radiation therapy to the lung that is >  30 Gy 
within 6 months of the first dose of study medication.  
Cohort 3e − NSCLC (1L squamous) (in combination with platinum/taxane)  
• Patients must have squamous NSCLC.  
• Patients must not have received prior anti -cancer therapy for advanced or 
metastatic NSCLC; patients who received adjuvant or neoadjuvant chemotherapy 
(after surgery and/or radiation therapy) and developed recurrent or metastatic 
disease within 6  months of completing therapy are eligible. Patients must not have 
received prior im muno-oncology therapy in any setting (including neoadjuvant, 
adjuvant, locall y advanced or metastatic disease).  
• Patients must be candidates for platinum/taxane chemotherapy.  
• Patients must not have received radiation therapy to the lung that is >  30 Gy 
within 6 months of the first dose of study medication.  
• Known hypersensitivity to the selected cytotoxic chemotherapy study drugs.  
Cohort 3f − NSCLC (3L+, ALK -translocation/ROS1 rearrangement positive)  
• Patients must have ALK -translocation positive or ROS1 rear rangement NSCLC 
by local pathology report (assessment of ROS1 mutation status  is not required).  
For ALK testing, an FDA -approved test or validated assay must be used.  
• Patients must have received at least two prior anti -cancer therapies for advanced 
or metastatic NSCLC (these may have included chemotherapy and must have 
included at  least one ALK -directed and/or ROS -1-directed therapy), be ineligible 
to receive these therapies due to toxicity, or no longer be considered a candidate 
for additional tyrosine ki nase inhibitor therapy; patients must not have received 
prior immuno -oncology therapy in any setting (including neoadjuvant, adjuvant, 
locally advanced or metastatic disease).  
• Patients may not have received more than one prior cytotoxic -based regimen (e.g. , 
carboplatin with paclitaxel).  
Cohort 3g − NSCLC ( 3L+, EGFR mutation/deletio n) 
• Patients must have EGFR mutation or relevant deletion NSCLC by local 
pathology report.  For EGFR testing, an FDA -approved test or validated assay 
should be used.  
Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 28 of 178 
Confidential and Proprietary   11 Febru ary 2020  • Patients must have received at least two prior anti -cancer therapies for advanced 
or metastatic NSCLC (these may have included chemotherapy and must have 
included at least one EGFR -directed small molecule therapy), be ineligible to 
receive these therapies due to toxicity or no longer be considered a candidate for 
additional tyrosine kinase inhib itor therapy; patients must not have received prior 
I-O therapy in any setting (including neoadjuvant, adjuvant, locally advanced or 
metastatic disease).  
• Patients ma y not have received more than one prior cytotoxic -based regimen (e.g., 
carboplatin with pac litaxel). 
Cohort 3h − NSCLC (2L, anti PD 1 or anti PD L1 relapse/refractory)  
• Patients must have received only 1 prior line of therapy with anti PD -1 or anti 
PD-L1 therapy in combination with doublet platinum -containing cytotoxic 
chemotherapy , which must be their mos t recent anti -cancer treatment. Patients are 
not eligible if they received sequential therapy (e.g., cytotoxic chemotherapy 
doublet therapy followed by ant i PD-1 or anti PD -L1 therapy or vice versa). 
Patients must not have received neoadjuvant or adjuvant therapy with any 
immuno-oncology regimens.  
• Patients must not have received more than 1 prior line of cytotoxic chemotherapy 
for metastatic disease.  
• Patients must have confirmed radiographic disease progression at least 4 weeks 
after initial disease progres sion, or unequivocal radiographic progression as per 
the Investigator based on a single imaging assessment; this assessment must be 
within 90  days from las t dose of anti -PD-1 or anti-PD-L1 containing regimen.  
Patients must consent to providing pre study s cans (if available) to confirm 
radiographic progression.  
• Patients may not have primary immun o-oncology refractory disease (radiographic 
or clinical progres sion within 120 days of initiation of immuno -oncology therapy).  
Cohort 3i – NSCLC  
• Patients who were e nrolled under an earlier version of the protocol who are no 
longer eligible for Cohorts 3a.1 to 3h.  
 
Urothelial Carcinoma  
• Histologically or cytologically documented locally advanced or transitional cell 
carcinoma of the urothelium including renal pelvis, u reters, urinary bladder, or 
urethra.  Patients with mixed histologies are required to have a dominant 
transitional cell pa ttern. 
Cohort 4a – Urothelial Carcinoma (1L)  
• Enrollment of urothelial carcinoma 1L patients will target accrual of up to 
20 patients w ho are cisplatin -ineligible and up to 20 patients, who, after 
consultation with the Investigator, choose to forego front -line chemotherapy.  
• Treatment naive patients who refuse chemotherapy standard of care or treatment 
naive, cisplatin -ineligible patients who meet at least one of the following criteria:  
• Creatinine clearance (calculated or measured) < 60 mL/min.  Cisplatin-ineligible 
patients must have a creatinine clearance <  60 mL/min and GFR ≥ 30 mL/min.  
• Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade  ≥ 2 
audiometric hearing loss  
• CTCAE v4.03 Grade ≥  2 peripheral neuropathy  
• No prior chemotherapy for inopera ble locally advanced or metastatic urothelial 
carcinoma.  Prior local  intravesical chemotherapy is allowed if completed at least 
4 weeks prior to the initiation of study treatment.  
Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 29 of 178 
Confidential and Proprietary   11 Febru ary 2020  • For patients who received prior adjuvant/neoadjuvant chemotherapy or 
chemo-radiation for urothelial carcinoma, a treatment -free interval of more  than 
12 months between the last treatment administration and the date of recurrence is 
required to be considered treatment naive in the metastatic setting.  Patients must 
not have receiv ed neoadjuvant or adjuvant therapy with any immuno -oncology 
regimens.  
Cohort 4b – Urothelial Carcinoma (2 -3L, anti -PD-1 or anti -PD-L1 
relapse/refractory)  
• Patients must have progressed on only one prior line of therapy that contains 
platinum-based chemother apy in the metastatic setting or post platinum -based 
chemotherapy in an adjuvant setting with progression <  6 months.   
• Patients must have received only one prior line of therapy with single -agent 
anti-PD-1 or anti-PD-L1 therapy, which must be their most r ecent anti -cancer 
treatment.  Patients must not have received anti -CTLA-4 alone or in combination 
with anti-PD-1 or anti-PD-L1. Patients must not have received neoadjuvant or 
adjuvant therapy with any immuno -oncology regimens.  
• Patients must have confirmed radiographic disease progression at least 4 weeks 
after initial disea se progression, or unequivocal radiographic progression as per 
the Investigator based on a single imaging assessment; this assessment must be 
within 90  days from last dose of anti -PD-1 or anti-PD-L1 therapy.  Patients must 
consent to providing pre -study scans (if available) to confirm radiographic 
progression.  
Patients may not have primary immuno -oncology refractory disease (radiographic 
or clinical progression within 120 days of initiatio n of immuno -oncology therapy).  
Cohort 4c − Urothelial  
• Patients who we re enrolled under an earlier version of the protocol who are no 
longer eligible for Cohorts 4a or 4b.  
 
Cohort 5 −  Triple -Negative Breast Cancer (1 -2L, I -O therapy naive)  
• Patients must have diagnosis of advanced triple -negative breast cancer (TNBC) 
(“advanced” is defined either locally advanced breast cancer not amenable to 
curative surgery or radiotherapy or distant metastases).  
• Less than 1% of tumor cell nuclei test positive for estrogen and progesterone 
receptors determined by using standard immunohistoch emistry (IHC).  
• Human epidermal growth factor receptor 2 (HER2) negative as determined by 
local pathologist, using  IHC or in situ hybridization.  
• Patients must have had triple negative phenotype of breast cancer in all available 
biopsies that have been exami ned during the course of the disease.  
• Patients must have received 0 or 1  prior line of therapy with systemic cyt otoxic 
chemotherapy for advanced TNBC or patient refuses standard of 
care.  Substitution within a class of anti -cancer therapy (e.g., nab -paclitaxel for 
paclitaxel; carboplatin for cisplatin) is permitted; otherwise patients who 
discontinued therapy for re asons other than progressive disease are still considered 
to have received 1  prior line of therapy.  
• Patients are excluded whose disease -free interval (for patients with prior 
neoadjuvant or adjuvant chemotherapy: the interval between the last dose of 
neoadjuvant or adjuvant chemotherapy to the diagnosis of advanced breast cancer; 
for patients originally diagnosed with Stage I/II/III breast cancer  who did not 
receive prior neoadjuvant or adjuvant chemotherapy: the interval between date of 
original diagnosis of breast cancer and date of diagnosis of advanced breast 
cancer) is less than 6 months and no clinically significant tumor -related symptoms 
Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 30 of 178 
Confidential and Proprietary   11 Febru ary 2020  in the judgment of the investigator.  Patients with a diagnosis of de novo Stage IV 
breast are eligible.  
• Patients a re excluded if the screening LDH >  2 × ULN (based on the central 
laboratory).  
• Must not have received any prior immuno -oncology regimens, includ ing, but not 
limited to, checkpoint inhibitors such as anti -PD-1, anti-PD-L1, anti-PD-L2, 
anti-CD137, or anti -CTLA-4 antibody, or any other antibody or drug specifically 
targeting T  cell co-stimulation or checkpoint pathways, indoleamine 
2,3-dioxygenase pa thway inhibitors, cancer vaccines, adoptive cell therapies, or 
other cytokine therapies.  
Cohort 5a – Triple -Negat ive Breast Cancer (1 -2L, I -O therapy naive)  
• Patients must be a candidate for NKTR -214 in combination with nivolumab.  
Cohort 5b – Triple -Negativ e Breast Cancer (1 -2L, I -O therapy naive) in 
combination with nab -paclitaxe l 
• Patients must be a candidate for sin gle-agent nab -paclitaxel; patients may not have 
received paclitaxel or docetaxel for metastatic carcinoma and may not have 
relapsed with metast atic disease within 1 year of adjuvant paclitaxel or docetaxel 
treatment.  
• Patients may not have received prior na b-paclitaxel in any setting.  
Cohort 5c – Triple -Negative Breast Cancer (1 -2L, I -O therapy naive) in 
combination with eribulin  
• Patients must be a candidate for single -agent eribulin; patients may not have 
relapsed with metastatic disease within 1 year of ad juvant taxane -based treatment.  
• Patients may not have received prior eribulin in any setting.  
 
Cohort 6 − Hormone -Receptor Positive, HER2 Negati ve Breast Cancer  
• Patients must have diagnosis of advanced hormone -receptor positive breast 
carcinoma (“advanced” is defined either locally advanced breast cancer not 
amenable to curative surgery or radiother apy or metastatic disease).  
• ≥ 1% of tumor cell nuclei test positive for estrogen or progesterone receptors 
determined by using standard IHC  
• HER2 nega tive as determined by local pathologist, using IHC or in situ 
hybridization  
• For patients whose primary tum or was HER2 -positive or hormone -receptor 
positive, eligibility will be based on the first biopsy for advanced disease.   
• Patients must have either arch ival or fresh tumor biopsy that demonstrates 
≥ 1% positive PD -L1 staining by the central pathology laborat ory.  An abbreviated 
consent may be presented to the patient prior to the Screening period to permit 
early assessment of the PD -L1 status of the tissu e sample.  
• Patients must have received prior aromatase and fulvestrant therapy for advanced 
breast cancer.  (Progression after prior adjuvant therapy with an aromatase 
inhibitor within 12  months will count as a line of therapy).  Hormonal therapy 
may have b een administered as single -agent or in combination with CDK4 -6 
inhibitors (such as palbociclib and others) , mTOR inhibitors (everolimus and 
others), PI3K inhibitors (buparlisib and others), or other agents used in 
combination with hormonal agents (AKT inhi bitors, WNT inhibitors, or others).  
• Must not have received any prior immuno -oncology regimens, including, but not 
limited to, checkpoint inhibitors such as anti -PD-1, anti-PD-L1, anti-PD-L2, 
anti-CD137, or anti -CTLA-4 antibody, or any other antibody or dru g specifically 
targeting T  cell co-stimulation or checkpoint pathways, indoleamine 
Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 31 of 178 
Confidential and Proprietary   11 Febru ary 2020  2,3-dioxygenase pathway  inhibitors, cancer vaccines, adoptive cell therapies, or 
other cytokine therapies.  
Cohort 6a – Hormone -Receptor Positive, HER2 -Negative Breast Cancer  
(I-O therapy naive following hormonal therapy)  
• Patients must not have received prior cytotoxic chemothera py (such as tubulin -
targeting agents (paclitaxel, docetaxel, nab -paclitaxel, eribulin, vinca alkaloids, 
epothilones, and others), anti -metabolites (5 -fluorouracil, capecitabine, 
gemcitabine, and others), platinum agents (carboplatin, cisplatin, and others) , 
alkylating agents (cyclophosphamide and others), topoisomerase 1 or 2 inhibitors 
(irinotecan, doxorubicin, epirubicin, etoposide, and others) or VEG F-targeted 
monoclonal antibodies (bevacizumab and others).  Prior systemic therapy must be 
reviewed by the  Medical Monitor prior to registration for the trial.  
Cohort 6b – Hormone -Receptor Positive, HER2 -Negative Breast Cancer 
(I-O therapy naive following hormonal and cytotoxic therapy)  
• Patients must have received at least one and up to 2  prior lines of cytoto xic 
chemotherapy (such as tubulin -targeting agents (paclitaxel, docetaxel, nab -
paclitaxel, eribulin, vinca alkaloids, epothilones, and others), anti -metabolites 
(5-fluorouracil, capecitabine, gemcitabine, and others), platinum agents 
(carboplatin, cisplati n, and others), alkylating agents (cyclophosphamide and 
others), topoisomerase 1 or 2 inhibitors (irinotecan, doxorubicin, epirubicin, 
etoposide, and others).  Substitution within a class of anti -cancer therapy (e.g., 
carboplatin for cisplatin) is permitte d; otherwise patients who discontinued 
therapy for reasons other than progressive disease are still considered to have 
received a prior line of therap y.  Prior systemic therapy must be reviewed by the 
Medical Monitor prior to registration for the trial.  
Cohort 7 − Gastric Carcinoma (2 -3L, I -O therapy naive)  
• Patients must have diagnosis of advanced gastric adenocarcinoma or 
gastroesophageal carcinoma (GC ) (“advanced” is defined either locally recurrent 
surgically unresectable advanced cancer or metastatic di sease). 
• Patients must have either archival or fresh tumor biopsy that demonstrates PD -L1 
staining (Combined Positive Sc ore ≥ 1 as determined by an FDA-approved test or 
validated assay).   An abbreviated consent may be presented to the patient prior to 
the Screening period to permit early assessment of the PD -L1 status of the tissue 
sample. 
• Patients must have received no more than two prior lines of therapy including 
fluoropyrimidine - and platinum -containing chemotherapy, and (if appropriate) 
HER2-targeted sy stemic therapy for gastric cancer. These drugs may have been 
administered in the neoadjuvant, adjuvant, locally advance d or metastatic setting. 
Patients may have progressed or been intolerant to these therapies. (“Systemic 
therapy” includes all agents, inc luding cytotoxic, molecularly targeted or 
other).  Substitution within a class of anti -cancer therapy (e.g., capecitabi ne for 
fluorouracil [5 -FU]; carboplatin for cisplatin) is permitted; otherwise patients who 
discontinued therapy for reasons other than p rogressive disease are still considered 
to have received a  prior line of therapy.  
• Must not have received any prior immu no-oncology regimens, including, but not 
limited to, checkpoint inhibitors such as anti -PD-1, anti-PD-L1, anti-PD-L2, 
anti-CD137, or anti -CTLA-4 antibody, or any other antibody or drug specifically 
targeting T  cell co-stimulation or checkpoint pathways, in doleamine 
2,3-dioxygenase pathway inhibitors, cancer vaccines, adoptive cell therapies, or 
other cytokine therapies.   
 
Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 32 of 178 
Confidential and Proprietary   11 Febru ary 2020  Cohort 8a − Colore ctal Carcinoma (2 -3L, I-O therapy naive); 
microsatellite  instability (MSI) -high  
• Patients must have diagnosis of advanced colorectal carcinoma ( CRC) 
(“advanced” is defined either locally advanced unresectable cancer or metastatic 
disease).   
• Patients must have either archival or fresh tumor biopsy that demonstrates 
microsatellite insta bility high or mismatch repair deficient disease.  An 
abbreviated consent may be presented to the patient prior to the Screening period 
to permit early assessment of the CD8+ TIL status of the tissue sample.  
• Patients who had disease progression during, aft er, or were intolerant to, prior 
treatment with fluoropyrimidine -, oxaliplatin -, or irinotecan -based chemotherapy 
(patients must have received either fluoropyrimidine and oxal iplatin-containing 
chemotherapy OR fluoropyrimidine and irinotecan -containing che motherapy for 
colorectal carcinoma (“FOLFOX” [fluorouracil, leucovorin, and oxaliplatin] or 
“FOLFIRI” [5 -fluorouracil, leucovorin, and irinotecan]); and (if appropriate) 
EGFR-targeted and/or VEGF -targeted systemic therapy. These drugs may have 
been adminis tered in the neoadjuvant, adjuvant, locally advanced or metastatic 
setting.  (“Systemic therapy” includes all agents, including cytotoxic, molecularly 
targeted or other).  Substitution within a class of anti -cancer therapy (e.g., 
capecitabine for 5 -FU) is permitted; otherwise patients who discontinued therapy 
for reasons other than progressive disease are still considered to have received 
a prior line of therapy.  
• Must not have received any prior immuno -oncology regimens, including, but not 
limited to, check point inhibitors such as anti -PD-1, anti-PD-L1, anti-PD-L2, 
anti-CD137, or anti -CTLA-4 antibody, or any other antibody or drug specifically 
targeting T  cell co-stimulation or checkpoint pathways, indoleamine 
2,3-dioxygenase pathway inhibitors, cancer vacci nes, adoptive cell therapies, or 
other cytokine therapies.  
Cohort 8b − Colorectal Carcinoma ( 3-4L, I-O therapy naive); MSI -non-high  
• Patients must have diagnosis of advanced co lorectal carcinoma (CRC) 
(“advanced” is defined either locally advanced unresecta ble cancer or metastatic 
disease). 
• Patients must have either archival or fresh tumor biopsy that demonstrates MSI 
not high (MSI -stable or MSI -low) or mismatch repair proficien t (pMMR) disease.  
In addition, tumor tissue must demonstrate CD8+ tumor infiltra ting lymphocytes 
(≥ 10% by IHC) by central laboratory .  An abbreviated consent may be presented 
to the patient prior to the Screening period to permit early assessment of the CD8+ 
TIL status of the tissue sample.  
• Patients must have received at least two bu t no more than 3 prior lines of therapy 
including fluoropyrimidine -, oxaliplatin and irinotecan -containing chemotherapy 
colorectal cancer; and (if appropriate) EGFR -targeted and/or VEGF -targeted 
systemic therapy. These drugs may have been administered in t he neoadjuvant, 
adjuvant, locally advanced or metastatic setting.   (“Systemic therapy” includes all 
agents, including cytotoxic, molecularly targeted or other).  Substitution within a 
class of anti -cancer therapy (e.g., capecitabine for 5 -FU) is permitted;  otherwise 
patients who discontinued therapy for reasons other than progressive disease are 
still considered to have received a  prior line of therapy.  
• Must not have received any prior immuno -oncology regimens, including, but not 
limited to checkpoint inhib itors such as ant i-PD-1, anti-PD-L1, anti-PD-L2, 
anti-CD137, or anti -CTLA-4 antibody, or any other antibody or drug specifically 
targeting T  cell co-stimulation or checkpoint pathways, indoleamine 
Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 33 of 178 
Confidential and Proprietary   11 Febru ary 2020  2,3-dioxygenase pathway inhibitors, cancer vaccines, adopti ve cell therapies , or 
other cytokine therapies.  
Cohort 9 − Small Cell Lung Cancer (2L, I -O therapy naive)  
• Patients must have diagnosis of limited -stage or extensive -stage SCLC.    
• Patients must have received no more than 1  prior line of platinum -based therapy.  
Substitution  within a class of anti -cancer therapy (e.g., carboplatin for cisplatin) is 
permitted; otherwise patients who discontinued therapy for reasons other than 
progressive disease are still considered to have received a  prior line of therap y.   
• Must not have rec eived any prior immuno -oncology regimens, including , but not 
limited to , checkpoint inhibitors such as anti -PD-1, anti-PD-L1, anti-PD-L2, 
anti-CD137, or anti -CTLA-4 antibody, or any other antibody or drug specifically 
targeting T  cell co-stimulation or che ckpoint pathways, indoleamine 
2,3-dioxygenase pathway inhibitors, cancer vaccines, adoptive cell therapies, or 
other cytokine therapies.  
 
For Parts 3 and 4 (NKTR -214/nivolumab/ipilimumab)  
Parts 3 and 4 are closed to patient screening and enrollment under A mendment 7.  
For Disease -Specific  Tumor Types  
Cohorts  10a.1 and 10a.3  − Renal Cell Carcinoma (1L), as follows:  
Cohort 10a.1 concurrent dosing schedule 1 (this cohort was closed to 
enrollment  under Amendment 6.0 ) 
Cohort 10a.3 concurrent dosing schedule 3  
• Advanced (not amenable to curative surgery or radiation therapy) or met astatic 
(AJCC stage  IV) RCC.  
• Histologically confirmed RCC with a clear -cell component.  
• Patients must not have received prior anti -cancer therapy for advance d or 
metastatic RCC.  
• Prior to disease metastasis, patients must not have received neoadjuvant or 
adjuvant therapy with any immuno -oncology regimens, including, but not limited 
to, checkpoint inhibitors such as anti -PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, 
or anti-cytotoxic T -lymphocyte antigen  4 (anti-CTLA-4) antibody, or any other 
antibody or drug spec ifically targeting T  cell co-stimulation or checkpoint 
pathways, indoleamine 2,3 -dioxygenase pathway inhibitors, cancer vaccines, 
adoptive cell therapies, o r other cytokine therapies.  
Cohort 11a.1 − Non-Small Cell Lung Cancer (1L)  
• Histologically confirmed or cytologically confirmed diagnosis of stage IV NSCLC  
• Patients with nonsquamous NSCLC must lack both EGFR -sensitizing 
mutation/deletion and anaplastic lymphoma kinase (ALK) translocation by local 
testing (assessment of ROS1 mutation status is not require d).  For ALK or EGFR 
testing, an FDA -approved test or validated assay should be used as applicable for 
selection of patients.  For patients wi th squamous NSCLC, testing for EGFR and 
ALK is not required.  
• Patients must not have received prior anti -cancer the rapy for advanced or 
metastatic NSCLC.  
• Patients must not have received neoadjuvant or adjuvant therapy with any 
immuno-oncology regimens.  
Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 34 of 178 
Confidential and Proprietary   11 Febru ary 2020   
Cohorts  12a.2 and 12a.3 − Melanoma (1L), as follows:  
• Cohort 12a.2:  concurrent dosing schedule 2  
• Cohort 12a.3:  conc urrent dosing schedule 3  
• Histologically confirmed stage  III (unresectable) or stage  IV melanoma, as per 
American Joint Committee on Cancer ( AJCC) staging system.  
• Patients must consent to BRAF testing or have documented BRAF status as per 
regionally accepta ble V600 mutational status testing.  
• Uveal melanoma will be excluded.  
• Have not received prior anti -cancer therapy for advanced or metastatic melanoma.  
• Prior to disease metastasis, patients must not have received neoadjuvant or 
adjuvant therapy with any immu no-oncology regimens, including, but not limited 
to, checkpoint inhibitors such as anti -PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, 
or anti-cytotoxic T-lymphocyte antigen  4 (anti-CTLA-4) antibody, or any other 
antibody or drug specifically targeting T  cell co-stimulation or checkpoint 
pathways, indoleamine 2,3 -dioxygenase pathway inhibitors, cancer vaccines, 
adoptive cell therapies, or other cyt okine therapies.  
• Prior to disease metastasis, patients must not have  received neoadjuvant or 
adjuvant tyrosine kinas e (BRAF, MEK, mTOR), bevacizumab or intralesional 
therapy.   
 
Cohort  13a.2  – Urothelial Carcinoma  (1L) 
• Histologically or cytologically docum ented locally advanced or transitional cell 
carcinoma of the urothelium including renal pelvis, ureters, urinary bla dder, or 
urethra.  Patients with mixed histologies are required to have a dominant 
transitional cell pattern.  
• Treatment naive patients who r efuse chemotherapy standard of care or treatment 
naive, cisplatin -ineligible patients who meet at least one of the f ollowing criteria:  
• Creatinine clearance (calculated or measured) < 60 mL/min.  
Cisplatin -ineligible patients must have a creatinine clearance  < 60 mL/min 
and GFR ≥ 30 mL/min.   
• Common Terminology Criteria for Adverse Events (CTCAE) v4.03 
Grade  ≥ 2 audiometri c hearing loss  
• CTCAE v4.03 Grade ≥  2 peripheral neuropathy  
• No prior chemotherapy for inoperable locally advanced or metastatic urothelial 
carcinoma.  Prior local intravesical chemotherapy is allowed if completed at least 
4 weeks prior to the initiation of study treatment.  
• For patients who received prior adjuvant/neoadjuvant chemotherapy or 
chemo-radiation for urothelial carcinoma,  a treatment -free interval of more than 
12 months between the last treatment administration and the date of recurrence is 
required to be considered treatment naive in the metastatic setting.  Patients must 
not have received neoadjuvant or adjuvant therapy with any immuno -oncology 
regimens.   
Test Product, Dose and 
Mode of Administration:   NKTR-214 administered IV over 30  (± 5) minutes at a starting dose of 0.006  mg/kg 
q3w (Parts 2, 3 , and 4) 
Nivolumab (anti -PD-1) administered IV over 30 (±  5) minutes at either a 360  mg flat 
dose q3w (Parts  2, 3, and 4), 1  mg/kg q3w × 4 doses or  3  mg/kg q3w × 4 doses 
(Parts 3 and 4) 
Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 35 of 178 
Confidential and Proprietary   11 Febru ary 2020  Ipilimumab admi nistered IV over 30 (±  5)  minutes at  1 mg/kg q6w, 3  mg/kg q3w 
× 4 doses or 1  mg/kg q3w × 4 doses (Parts  3 and 4) 
 
Part 2 
Institutional guidelines for administration of other anti -cancer therapies should be 
followed in Part  2.  
• Cohort 3d.1 NSCLC (1L nonsqu amous): NKTR -214 followed by nivolumab 
(q3w) followed by investigator’s choice of cisplatin 75  mg/m2 administered IV or 
carboplatin AUC  5 followed by pemetrexed 500  mg/m2 q3w by IV administration 
for 4 cycles followed by maintenance NKTR -214, nivolumab, an d pemetrexed 
q3w 
• Cohort 3d.2 NSCLC (1L nonsquamous): NKTR -214 followed by nivoluma b 
(q3w) followed by investigator’s choice of cisplatin 75  mg/m2 administered IV or 
carboplatin AUC  5 followed by pemetrexed 500  mg/m2 q3w by IV administration 
for 4 cycles followed by maintenance NKTR -214 and nivolumab q3w  
• Cohort 3e NSCLC (1L squamous): NK TR-214 followed by nivolumab (q3w) 
followed by either Cremophor -based paclitaxel 200  mg/m2 on Day 1 of each 
21-day cycle or nab -paclitaxel 100  mg/m2 by IV administration on D ays 1, 8, and 
15 of each 21 -day cycle with investigator’s choice of either carbopl atin AUC 6 by 
IV administration on cycle Day  1 q3w for 4  cycles or cisplatin 75  mg/m2 q3w by 
IV administration for 4  cycles followed by maintenance NKTR -214 and 
nivolumab q3w . 
• Cohort 5b TNBC (1 -2L): NKTR -214 followed by nivolumab (q3w) followed by 
nab-paclitaxel 260  mg/m2 by IV administration q3w.  
• Cohort 5c TNBC (1 -2L): NKTR -214 followed by nivolumab (q3w) followed by 
eribulin mesylate 1.4 mg/m2 (equivalent to eribulin  1.23 mg/m2) by IV 
administration on Days 1 and 8 q3w.  
Safety:  Assessment of safety will be determined by an ongoing review of the following:  
• incidence of adverse events (AEs), including serious AEs (SAEs)  
• clinical laboratory tests (blood and urine sampling)  
• vital signs 
• electrocardiograms (ECG) and echocardiograms (ECHO)  
• physical examinat ion 
Pharmacokinetics:  Blood samples for PK analyses will be collected from all patients.  Serial PK samples 
will be collected at multiple scheduled sampling times.  Plasma concen trations of 
NKTR-214 and its metabolites will be measured for each PK sample using validated 
method(s).  Serum concentrations of nivolumab and ipilimumab will be measured 
using validated methods.  Pharmacokinetic parameters such as maximum 
concentration (C max), time to C max (Tmax), area under the curve (AUC), clearance (CL), 
volume of distribution (V d), and half -life (t1/2) will be estimated from plasma or serum 
concentration -time data where possible.  
Pharmacodynamics:  Systemic and tumor tissue -based pharm acodynamic effects of NKTR -214 in 
combination with nivolumab and in com bination with nivolumab and other anti -cancer 
therapies will be examined.  
Blood samples for systemic pharmacodynamic analyses will be collected pre - and 
post-combination treatment from all patients enrolled to assess the effects of the 
combination treatmen t on markers of immune system activation, and immune cell 
populations.  
Protocol No. 16 -214-02 Amendment 7.0    Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 37 of 178 
Confidential and Proprietary   11 February 2020  1.1 Study Schematics  
Figure  1: Study Schematic for Parts 1 and 2  
 
Abbreviations:  HR+  = hormone-receptor positive; I -O = immuno-oncology; L = line; MSI  = microsatellite  instability; MTD = maximum tolerated dose; NSCLC = non -small cell lung cancer; 
RCC = renal cell carcinoma; RP2D  = recommended Phase 2 dose; SOC  = standard of care; TNBC  = triple-negative breast cancer  
a. Up to 20 efficacy-evaluable NSCLC patie nts will be enrolled in each cohort of PD -L1 negative, PD -L1 low/intermediate, or PD -L1 positive.   Patients enrolled in Cohort 3a who do not have a 
PD-L1 status assessed by central testing will be assigned to Cohort 3a.4.  
b. Up to 20 urothelial carcinoma 1L p atients who are cisplatin -ineligible and (for countries other than Italy) up to 20 patients who choose to forego standard of care.  

Protocol No. 16 -214-02 Amendment 7.0    Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 39 of 178 
Confidential and Proprietary   11 February 2020  1.2 Schedule of Events  
Table  1: Schedule of Events for Part 1  
Assessment Period  Screening  Cycle 1 Only  Cycle 2 and Beyond  Post-treatment  
Study  Daysa Day 
-28 to -1 Day 1  Day 2  Day 3  Day 4  Day 5  Day 8  Day 11  Day 1  Day 8 End of 
Treatmentu Follow 
up 
3 mot 
Physical examinationb X X X X   X  X   X  
Vital signsc X  Xc Xc Xc   X X Xc X X  
ECOG performance status  X        X    
ECGd X X  X  X X X     
ECHO/MUGA Xe          X  
Pregnancy testf X X       X  X  
Hematologyg X X X X X X X X X X X  
Serum chemistryh X X   X  X X X X X  
Coagulationh X X   X  X X X X X  
Additional labsi X       X Xi  X  
Urinalysis (dipstick)j X X       X  X  
Serologyh X            
Archival tumor tissuek X            
Tumor biopsyl X Refer to Section 5.10.2 
 
Protocol No. 16-214-02 Amendment 7.0   Bempegaldesleukin (NKTR- 214) 
Nektar Therapeutics  Page 40 of 178 
Confidential and Proprietary  11 February 2020 Table 1: Schedule of Events for Part 1 (Contd) 
Assessment Period Screening Cycle 1 Only Cycle 2 and Beyond Pos t-treatment 
Study Daysa Day 
-28 to -1 Day 1 Day 2 Day 3 Day 4 Day 5 Day 8 Day 11 Day 1 Day 8 End of 
TreatmentuFollow 
up 
3 mot 
Immunogenicity serum 
samplem  X        Xm  X  Xm 
Tumor assessmentn X        Every 8 weeks (± 7d)   X 
             
NKTR-214 PK blood sample
q  X  X  X  X  X  X  X  X  X    
Nivolumab PK blood sampleq  X        Xq    
Administer IV fluidsr  X       X    
Drug administrations  X        X     
Long-term follow-upt            X  
Footnotes: 
Abbreviations: d = day;  ECG = electrocardiogram; ECHO = echocardiogram; ECOG = Eastern Cooperative Oncology Group ; IV = intravenous; MUGA = multigated acquisition; 
PK = pharmacokinetic . 
a. The acceptable visit window is ± 3 days for Day 1.  Cycle inter vals less than 21 days (e.g., 21 days minus-3 days) should only  occur if the investigator  believes there are no 
safety concerns with dosing the patient 1 to 3 days prior to a 21-day cycle.  Additional visit windows are:  ± 2 days for Day 8 in Cycle 2 and beyond; ± 7 days for the 
follow-up visits post-treatment a nd + 10 days for End of Treatm ent (EOT) visit at 30 days.  Visits may be skipped or postponed  if prospectively identified by the Investigator 
(e.g., national holidays, patient holidays).  If Day 4 visit is  missed, then Day 4 assessments must be done at the next in-cli nic visit.  All procedures and examinations should be 
performed before the administration of study drug(s), except as  indicated. 
b. See Section 7.15. 
c. Some clinic visits will have more frequent vital sign measureme nts.  See Sections 5.3.7.1 and 7.16. 
d. In Cycle 1 only, ECGs are performed prior to each NKTR-214 PK sampling time.  The frequency of E CGs may be increased if clinic ally indicated. 
e. A standard echocardiog ram or MUGA will be p erformed for all patients within 60 days prior to dosing Cycle 1 Day 1.  See Sectio n 7.18. 
f. See Section 7.19. 
g. Hematology assessments scheduled  for the day of study drug(s) d osing must be available and assessed before dosing.  The sampli ng for hematology assessments can be drawn 
within 72 hours prior to dosing.  See  Appendix 1 . 
h. The sampling for laboratory tests can be drawn within 72 hours prior to dosing.  See Appendix 1. 

Protocol No. 16 -214-02 Amendment 7.0    Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 42 of 178 
Confidential and Proprietary   11 February 2020  Table  2: Schedule of Events for Part 2  
Assessment Peri od Screening  Cycle 1 Only  Cycle 2 and Beyond  Post-treatment  
Study Daysa Day 
-28 to -1 Day 1  Day 2  Day 3  Day 8  Day 1  Day 3  Day 8 End of 
Treatmentw Follow up  
3 mov 
Physical examinationb X X   X X   X  
Vital signsc X Xc Xc Xc X Xc  Xc X  
ECOG performance status X     X     
ECGd X X  X X      
ECHO/MUGAe X        X  
Pregnancy testf X X    X   X  
Hematologyg X X X X X X  X X  
Serum chemistryh X X   X X  X X  
Coagulationh X X   X X  X X  
Additional labs h X     Xh    X  
Local labs prior to dosing i  Xi    Xi      
Urinalysis (dipstick)j X X    X   X  
Serologyh X          
Archival tumor tissuek X          
Tumor biopsyl X Refer to Section 5.10.2 
 
Protocol No. 16 -214-02 Amendment 7.0    Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 43 of 178 
Confidential and Proprietary   11 February 2020  Table 2:   Schedule of Events for Part 2 (Cont’d)  
Assessment Period  Screening  Cycle 1 Only  Cycle 2 and Beyond  Post-treatment  
Study Daysa Day 
-28 to -1 Day 1  Day 2  Day 3  Day 8  Day 1  Day 3  Day 8 End of 
Treatmentw Follow up  
3 mov 
Immunogenicity serum 
samplem  X    X   X X 
Tumor assessmentn X     Every 8 weeks (±  7d)  X 
           
Stool sample collectionp X     Xp     
NKTR-214 PK blood 
sampleq  X  X X X     
Nivolumab PK blood sampleq  X    X     
BRAF mutation testingr X          
Administer IV fluidss  X    X     
Drug administrationt  X    X     
Oral hydration follow -upu    Xv   Xv    
Long-term follow -upv          X 
Footnotes:  
Abbreviations: d  = day; ECG = electrocardiogram; ECHO  = echocardiogram; ECOG = Eastern Cooperative Oncology Group ; IV = intravenous; MUGA  = multigated acquisition; 
PK = pharmacokinetic . 
a. The acceptable visit window is ± 3 days for Day  1.  Cycle intervals less than 21 days (e.g., 21  days minus -3 days) should only occur if the investigator believes there are no 
safety concerns with dosing the patient 1  to 3 days prior to a 21 -day cycle.  Additional visit windows are:  ± 2 days for Day 8 in Cycle  2 and beyond; ±  7 days for the 
follow-up visits post -treatment and +  10 days for End of Treatment (EOT) visit at 30  days.  Study assessments, including imaging, may be delayed or moved ahea d of the 
window to accommodate holidays, vacations, and unforeseen de lays after permission from the medical monitor.   If Day 4 visit is missed, then Day  4 assessments must be done 
at the next in -clinic visit.  All procedures and examinations should be perf ormed before the administration of study drug(s), except as indicated . 
b. See Section 7.15. 
c. Some clinic visits will have more frequent vital sign measurements.  See Appendix 2 Schedule of Assessments and Sections  5.3.7.1 and 7.16.  Beginning on Day 8 of Cycle 3 
and beyond, vital signs should be collected according to the Investigato r’s discretion based on the clinical status of the patient.  

Protocol No. 16 -214-02 Amendment 7.0    Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 45 of 178 
Confidential and Proprietary   11 February 2020  Table  3: Schedule of Events for Parts 3 and 4  
Assessment Period  Screening  Cycle 1 Only  Cycle 2 and Beyond  Post-treatment  
Study Daysa Day 
-28 to -1 Day 1  Day 2  Day 3  Day 8  Day 11  Day 1 Day 3  Day 8 End of 
Treatmentw Follow up  
3 mov 
Physical examinationb X X X X X  X    X  
Vital signsc X  Xc Xc Xc X X Xc  Xc X  
ECOG performance status  X      X     
ECGd X X  X X       
ECHO/MUGAe X         X  
Pregnancy testf X X     X   X  
Hematolo gyg X X X X X X X  X X  
Serum chemistryh X X   X X X  X X  
Coagulationh X X   X X X  X X  
Additional labs h X     X Xh   X  
Local labs prior to dosing i  Xi     Xi     
Urinalysis (dipstick)j X X     X   X  
Serologyh X           
Archival tumor tissuek X           
Tumor biopsyl X Refer to Section 5.10.2 
Immunogenicity serum samplem  X     X   X X 
Tumor assessmentn X      Every 8 weeks (±  7d)   X 
 
Protocol No. 16 -214-02 Amendment 7.0    Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 46 of 178 
Confidential and Proprietary   11 February 2020  Table 3:  Schedule of Events for Parts 3 and 4 (Cont’d)  
Assessment Period  Screening  Cycle 1 Only  Cycle 2 and Beyond  Post-treatment  
Study Daysa Day 
-28 to -1 Day 1  Day 2  Day 3  Day 8  Day 11  Day 1  Day 3  Day 8 End of 
Treatmentw Follow up  
3 mov 
             
Stool sample collectionp X      X     
NKTR-214 PK blood sampleq  X  X X  X     
Nivolumab or ipilimumab PK 
blood sampleq  X     X     
BRAF mutation testingr Part 3 only            
Administer IV fluidss  X     X     
Drug administrationt  X     X     
Oral hydration follow -upu    Xv    Xv   X 
Long-term follow -upv           X 
Abbreviations: d  = day; ECG = electrocardiogram; ECHO  = echocardiogram; ECOG = Eastern Cooperative Oncology Group ; IV = intravenous; MUGA  = multigated acquisition; 
PK = pharmacokinetic . 
a. The acceptable visit window is ± 3 days for Day 1.  Cycle intervals less than 21 days (e.g., 21  days minus -3 days) should only occur if the investigator believes there are no 
safety concerns with dosing the patient 1  to 3 days prior to a 21 -day cycle.  Add itional visit windows are:  ± 2 days for Da y 8 in Cycle  2 and beyond; ±  7 days for the 
follow-up visits post -treatment and +  10 days for End of Treatment (EOT) visit at 30  days.  Study assessments, including imaging, may be delayed or moved ahead of the 
window to accommodate holidays, vacations, an d unforeseen delays after permission from the medical monitor.   If Day 4 visit is missed, then Day  4 assessments must be done 
at the next in -clinic visit.  All procedures and examinations should be performed befor e the administration of study drug(s), exce pt as indicated.  Samples for hematology, 
chemistry, coagulation, and pregnancy are drawn at the same time points in Parts 3 and 4. Local laboratories will be used for  Parts 1 and 3; a central laboratory will be us ed for 
Part 2 and Part 4. 
b. See Section 7.15. 
c. Some clinic visits will have more frequent vital sign measurements.  See Appendix  2 Schedule of Assessments and Sections  5.3.7.1 and 7.16.  Beginning on Day 8 of Cycle 3 
and beyond, vital signs should be collected according to the Investigator’s dis cretion based on the clinical status of the patient.  
d. See Section  7.17.  In Cycle 1 only, ECGs are performed prior to each NKTR -214 PK sampling time  (see Appendix  2 Schedule of Assessments for PK and ECG sampling 
times).  The frequency of ECGs may  be increased if clinically indicated.  
e. A standard echocardiogram or MUGA will be performed for all patients wi thin 60 days prior to dosing Cycle  1 Day 1.  See Section  7.18. 
f. See Section  7.19. 

Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 48 of 178 
Confidential and Proprietary   11 February 2020  2.0 INTRODUCTION  
2.1 Background  
2.1.1 NKTR -214 Mechanism of Action  
Aldesleukin (recombinant human interleukin -2 [rhIL-2]) directly stimulates the immune syst em 
and has been shown to lead to durable responses in ~10% of people with metastatic melanoma 
and renal cancer ( Payne, 2014).  However, in addition to aldesleukin acti ng as a stimulator of the 
immune system by activating tumor  killing CD8+ T cells, it also suppresses the immune system 
by activating regulatory T  (Treg) cells ( Boyman, 2012).  Despite favorable clinical outcomes 
associated wi th aldesleukin, it has several therapeutic limitations incl uding the need for inpatient 
hospital administration, 5  consecutive days of dosing, and the potential for serious toxicities, 
comprising capillary leak syndrome, hypotension, and pulmonary edema re quiring medical 
management in the intensive care unit.  In contrast to aldesleukin, NKTR -214 was designed as an 
outpatient therapy.  In addition, NKTR -214 was designed to mitigate the serious toxicities 
associated with rapid systemic immune activation seen  with administration of high -dose 
interleukin -2 (i.e., rhIL-2 also referred to as IL-2). 
Bempegaldesleukin  (NKTR-214), a novel cytokine with enhanced immune system activation and 
the targeted profile of NKTR -214 (i.e., a superior safety profile allowing fo r outpatient 
administration and a longer duration of action  requiring less frequent dosing) has the potential to 
be an important advancement for the treatment of patients with cancer.  NKTR -214 consists of 
IL-2, which has the same amino acid sequence as al desleukin, conjugated at a defined region 
within the protei n to releasable polyethylene glycol (PEG) chains.  The PEG chains render the 
molecule inactive.  After administration in vivo, the PEG chains are slowly hydrolyzed to 
generate active cytokine conju gates.  The most active IL -2 conjugates are 2 -PEG-IL2 and 
1-PEG-IL2.  The location of the PEG chains on the active conjugated -IL-2 reduces its affinity to 
the IL-2 receptor alpha subunit (IL2R ), responsible for activating undesirable Treg cells to a 
greater extent than affinity to the IL -2-receptor beta subunit ( IL2R).  In the tumor, NKTR -214 
preferentially activates CD8+ T  cells and natural killer (NK) cells over Treg cells and provides 
sustained exposure to active 1 -PEG and 2 -PEG-IL2. 
2.1.2 Rationale for the Combination of NKTR -214 and Immune Checkpoint 
Inhibitors  
Accumulating evidence suggests that patients with low baseline CD8+ T  cells within the tumor 
microenvironment (tumor infiltrating lymphocytes [TILs]) predict poor response to checkpoint 
inhibitor imm unotherapies ( Daud, 2016a; Daud, 2016b); thus, agents designed to specifically 
activate and expand CD8+ T  cells may improve clinical outcomes in patients with low TILs.  
NKTR-214 targets the IL -2 pathway and is designed to provide biased sustained signali ng 
through the heterodimeric IL -2 receptor pathway (IL -2Rβɣ) to preferentially activate and expand 
NK and effector CD8+ T  cells over Treg cells.  Preliminary analyses of patients’ blood and 
tumor by flow cytometry and immunohistochemistry (IHC)  demonstrate  that NKTR -214, as a 
single agent, increases activated CD4+ and CD8+ T  cells in peripheral blood, with an increase in 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 49 of 178 
Confidential and Proprietary   11 February 2020  T cell infiltrates within the tumor tissue after 1  dose of NKTR -214.  In addition, there is an 
increase in programmed cell death receptor -1 (PD-1) expression on T  cells in the b lood and 
tumor after treatment with NKTR -214.  The ability to alter the immune environment and 
increase PD -1 expression on effector T  cells may improve the effectiveness of anti -PD-1 
blockade.  
2.1.3 Clinical Experience with  IL-2 and Checkpoint Inhibitors  
Simultaneous administration of IL -2 with immune checkpoint inhibitors directed against PD -1 
(nivolumab and pembrolizumab) or its ligand has not been reported as of the date of this 
protocol, although several studies are ongo ing in which IL -2 and an anti -PD-1 antibody are 
co-administered following an infusion of either adoptive CD8+ T  cells or tumor -infiltrating 
lymphocytes ([STUDY_ID_REMOVED], [STUDY_ID_REMOVED]) . 
Published data on the sequential administration of IL -2 with an anti -PD-1 inhibitor have been 
reported recently.  A  case report noted a near -complete response (near -CR) with extended 
duration of response when a patient with renal cell carcinoma ( RCC; non-responsive to 
nivolumab) was treated with high -dose IL-2 (Brayer, 2014).  A larger ex perience from an 
observational clinical trial reported that patients with metastatic melanoma who received 
high-dose IL-2 and received either ipilimumab or an anti -PD-1 inhibitor experienced a 
differential increase in  median overall survival  (OS), 15.8 vs 28.7 months, respectively.  The 
12-month survival rate was 64% for patients receiving ipilimumab post high -dose IL-2 compared 
with 97% for patients receiving an anti -PD-1 inhibitor, suggesting that these two checkpoin t 
inhibitors do not have overlapping me chanisms of action and that IL -2 may enhance the curative 
potential of the anti -PD-1 inhibitor ( Wong, 2015).  In support of the hypothesis that IL -2 may 
have enhanced the curative potentia l of nivolumab/pembrolizumab, a recent report demonstrated 
that IL-12, which has been shown to induce tumor infiltrating lymphocytes and anti -tumor 
immunity similar to IL -2, appeared to prime response to anti -PD-1/PD-L1 inhibitors and 
demonstrated a clinic al benefit rate of 75% (50% CR and 25%  partial response [PR])  
(Algazi, 2016). 
2.1.4 Clinical Experience with NKTR -214 
Study 15-214-01 ([STUDY_ID_REMOVED]) is a Phase  1/2 open-label, multicenter, dose escalation and 
dose expansion monothe rapy study of NKTR -214 in patients with  locally advanced or metastatic 
solid tumors.  The objectives of the study are to evaluate the safety and tolerability of NKTR -214 
to determine the maximum tolerated dose (MTD) as well as to assess the objective respo nse rate 
(ORR) at or below the MTD, or to identify the recommended Phase  2 dose (RP2D).  
In Study 15 -214-01, hypotension has been identified as a principal toxicity.  Hypotension is a 
known adverse event (AE) associated with both IL -2 and engineered cytokin es.  Instances of 
hypotension most comm only appeared 2 -3 days following the first infusion, coinciding with the 
peak plasma concentration of the active metabolites formed after administration of NKTR -214.  
Patients for whom intravenous (IV) fluid administr ation was clinically indicated responde d 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 50 of 178 
Confidential and Proprietary   11 February 2020  rapidly (in less than 24  hours) to IV hydration.  To mitigate the risk of hypotension, management 
guidelines were implemented and included the following recommendations:  
• Withholding  antihypertensive therapy and drug s with hypotensive properties, prior to  
administration of NKTR -214. 
• Maintaining adequate oral fluid intake, particularly during the first 5  days post-dose. 
• Avoiding activities that could lead to dehydration (e.g.,  physically strenuous activity) or 
vasodilation (e.g.,  hot showers, sauna).  
• Providing additional corticosteroid support for patients with adrenal insufficiency on 
corticosteroid replacement therapy.  
Since the implementation of these mitigation measures, the frequency of hypotension, 
particularly Gr ade 3 hypotension, has been reduced. 
In contrast to aldesleukin, none of the 28  patients treated to date with NKTR -214 monotherapy 
have experienced capillary leak syndrome.  In addition, the severity and duration of any 
temporally associated hypotension is  markedly reduced.  The most  common Grade  1-2 
treatment -related AEs were fatigue, pruritus, chills, and decreased appetite.  Grade  3 
treatment -related AEs included hypotension, abdominal pain, and infusion -related reaction.  For 
the every 3  weeks (q3w) dos ing frequency, NKTR -214 mono therapy doses up to 0.009  mg/kg 
were well tolerated.  At 0.012  mg/kg NKTR -214 monotherapy dose, one patient experienced 
DLTs of Grade  3 hypotension and syncope, which was rapidly reversed with fluids; this patient 
received anoth er 2 doses at a lower dose o f 0.006 mg/kg and tolerated treatment well.  Dosing at 
0.006 mg/kg q2w and q3w, as well as dosing at 0.003 and 0.009 mg/kg at q3w of NKTR -214 
monotherapy have been deemed safe per the Safety Review Committee.  No Grade  4 
treatment-related AEs were reported .  One patient dosed at 0.009  mg/kg discontinued the study 
due to a treatment -related AE of infusion -related reaction.  The pattern of AEs attributable to 
NKTR-214 observed in Study 15 -214-01 is dissimilar from the immune -mediated AEs (imAEs) 
that commonly  develop with the use of checkpoint inhibitors.  Neither clinical nor nonclinical 
data predict “immune -mediated inflammatory events,” such as endocrinopathies, colitis, 
nephritis, pneumonitis, dermatitis, or hepatitis to occur w ith NKTR -214.  The non -overlapping 
toxicities observed with NKTR -214 and nivolumab may therefore result in a reasonably well -
tolerated immuno -oncology combination.  
2.1.4.1  Observed Events of Cerebrovascular Accident in Study 16 -214-02 
Following the occurrence of t hree SAEs (one of which was fatal) of cerebrovascular accident 
(CVA) in the first 43  patients treated with NKTR -214, nivolumab, and ipilimumab (“triplet 
immunotherapy” cohort) in Study 16 -214-02, a comprehensive review of CVA -related safety 
information for  the entire clinical pro gram for NKTR -214 (N=721) was performed.  The 
assessment included a broad search to identify any potential CVA cases among all NKTR -214 
studies; case reviews by independent neurology, cardiology, and coagulation expert consultants; 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 51 of 178 
Confidential and Proprietary   11 February 2020  and an analysis of patie nt demographics, medical histories, drug exposure, laboratory values, 
vital signs, and PK/pharmacodynamic parameters.  
Table 4 summarizes the results of the comprehensive search, which utilize d a data cut -off date of 
21 June 2019.  A total of 3 of 43 patients (7.0%) who received triplet immunotherapy and 8 of 
478 patients (1.7%) who received NKTR-214 and nivolumab (“ doublet immunotherapy ”) in 
Study 16-214-02 were determined to have CVA events t hat were confirmed by the neurology 
consultants.  No confirmed CVA events occurred in any patients in any other studies of 
NKTR-214 and nivolumab (n=115) , in studies of  NKTR-214 monotherapy (n=28) , or in studies 
of NKTR-214 in combination  with any other se cond agent (including pembrolizumab [n=12], 
atezolizumab [n=23], or NKTR -262 [n=22]).  The incidence of CVA, combining all clinical 
trials in which the doublet of NKTR-214 plus nivolumab was administered was 8 out of 
593 patients (1.3%).  
Sections 2.1.4.1.1 and 2.1.4.1.2 summarize the CVA events observed in Study 16 -214-02 for 
patients who received triplet immunotherapy and doublet immunotherapy, respectively, and 
Section 2.1.4.2 summarizes the protocol sections with additional safety measures that were 
implemented to mitigate the risk of CVA events and to expedite reporting of CVA events.  
Table 4. CVA Adv erse Events in Study 16 -214-02 
Regimen  Study  Patients Treated with 
NKTR -214 
(N) Patients with  
CVAa 
(n [%])  
Triplet  
NKTR-214 + nivolumab + ipilimumab  16-214-02 (PIVOT -02) 43 3 (7.0) 
Doublet  
NKTR-214 + nivolumab  16-214-02 (PIVOT -02) 478 8 (1.7) 
a. Neurologist-confirmed CVA based on review of local magnetic resonance imaging (MRI) readings and images 
and other patient -related data (utilizing a data cut -off date of 21  June 2019). 
 
2.1.4.1.1  Observed Events of Cerebrovascular Accident Following Triplet 
Immunotherap y 
A total of 3 patients treated with triplet immunotherapy (NKTR -214 in combination with 
nivolumab and ipilimumab) in Study 16 -214-02 were confirmed to have had a CVA by 
independent neurologist review.  
All 3 patients (2  male, 1 female) experienced events w ith the preferred term of cerebrovascular 
accident and had the underlying malignancy of RCC.  These patients had various risk factors for 
stroke, such as hypertension, diabetes, hyperlipidemia, and ven ous thrombosis.  At the time of 
the CVA event, these pa tients were aged 64  years or older.   
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 52 of 178 
Confidential and Proprietary   11 February 2020  Two of the events were Grade  2 in severity and one was Grade 5.  The time to onset of the events 
from the initial dose ranged from 33  to 222 days.  All events were  assessed by the investigator as 
related to NKTR -214, nivolumab, and ipilimumab.  Two patients recovered from the CVA 
events; neither patient received additional NKTR -214, nivolumab, or ipilimumab on study.  One 
patient experienced a fatal outcome.   
There were 2 types of stroke patterns described in imaging o f these 3 patients.  The magnetic 
resonance imaging (MRI) of two patients included infarcts involving multiple vascular territories 
with border -zone appearance.  The MRI of the third patient revealed a  subacute infarct involving 
a single vascular territory  in the right midbrain lateral crus cerebri.  
2.1.4.1.2  Observed Events of Cerebrovascular Accident Following Doublet 
Immunotherapy  
A total of 8 patients treated with doublet immunotherapy (NKTR -214 in combinatio n with 
nivolumab) in Study 16 -214-02 were confirmed to have had a CVA by independent neurologist 
review. 
Of the 8 events that occurred in the 478  patients (1.7%) treated with the doublet immunotherapy, 
4 patients experienced events with the preferred term of cerebrovascular accident, 2 with embolic 
stroke, one  with subacute infarct, and one with encephalopathy.  
The underlying malignancy was melanoma (2 patients), NSCLC (2 patients), RCC (1 patient), 
urothelial carcinoma (2 patients) and TNBC (1 patient).  T hese patients had various risk factors 
for stroke, such  as hypertension, peripheral vascular disease, hyperlipidemia, and venous 
thrombosis.  The patients (5 male, 3 female) ranged in age from 55 to 82 years old.  
All events were SAEs; none were fatal.  Two were Grade 4 in severity, 4 were Grade 3, and 
2 were Grade 2.  The time to onset of the events from the initial dose ranged from 13 to 
578 days.  Four events were deemed unrelated to study drug (NKTR -214 and nivolumab) by the 
investigator and 4 were deemed related to study drug by the investigator ( 3 related to the doublet 
immunotherapy and 1 related to nivolumab only).  These events led to discontinuation in 3  cases 
and dose delay in 1 case.  The study treatment was continued in 1 case; 2 cases  had previously 
discontinued both drugs.  Five patients have recov ered or are recovering from the CVA events, 
2 of whom have recovered with sequelae (left sided paralysis in one patient and not reported in 
the other patient) ; one patient had a recurrence o f the same event following rechallenge with only 
nivolumab and the second event was not resolved; one patient died due to progressive disease on 
the same day the toxicity resolved ; and in 1 patient, the event was reported as “not recovered” at 
the time of study drug discontinuation.  
Of these 8 patients:  
• 6 were considered  to have had an infarct involving multiple vascular territories with 
border-zone appearance on diffusion -weighted MRI  
• 2 were considered to have had an infarct involving a single vascular ter ritory 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 53 of 178 
Confidential and Proprietary   11 February 2020  2.1.4.2  Mitigation Measures  
Following the comprehensive review of t he entire NKTR -214 clinical program, additional safety 
measures and analyses were implemented to mitigate the risk of CVA events and to expedite 
reporting of CVA events by identifying CVA as  an AE of special interest (AESI).  These safety 
measures and analyses are reflected in changes to the following protocol sections: hydration 
guidelines (Sections 1.2 and 5.3.7.2), CVA AE management algorithm ( Appendix 3), criteria to 
delay, resume, or permanently di scontinue  study drug  (Sections 5.13.1 to 5.13.3, 5.13.11, and 
5.13.12, respectively),  AESI (Section  7.11), and reporting AESI (Section  7.7). 
Additional details on the clini cal experience with NKTR -214 are provided in the NKTR -214 
Investigator ’s Brochure.  
2.1.5 Flat Dose Regimens with Nivolumab (360 mg q3w and 480 mg q4w)  
Currently nivolumab is being studied at a flat 360 mg q3w and/or 480 mg q4w dose schedule in a 
number of clinic al trials:  
Phase 3: NSCLC, [STUDY_ID_REMOVED] , [STUDY_ID_REMOVED]  
Phase 2: NSCLC, [STUDY_ID_REMOVED], [STUDY_ID_REMOVED], [STUDY_ID_REMOVED]  
Phase 2: RCC, NCT0 2959554 
Population pharmacokinetic (PPK) analyses have shown that the PK of nivolumab is linear with 
proportional exposure over a d ose range of 0.1 to 10 mg/kg, and no differences in PK across 
ethnicities and tumor types were observed.  As the PK of nivolu mab is linear, the corresponding 
flat dose for a every 3  weeks (q3w) dosing regimen is nivolumab 360 mg.  Using the PPK model 
developed, the exposures following administration of several dosing regimens of nivolumab 
administered as a flat dose were simulat ed, including 360 mg administered q3w.  The simulated 
steady-state average concentration (C avgss) following administration of nivol umab 360 mg q3w 
are expected to be similar to those following administration of nivolumab 3 mg/kg every 2  weeks 
(q2w) to pati ents weighing 80 kg, the approximate median weight of  patients used in the PPK 
analyses.  The predicted steady state peak (C maxss) concentrations following nivolumab 360 mg 
q3w are predicted to be less than those following the administration of nivolumab 10 mg/kg q2w 
providing sufficient safety margins.  
Nivolumab 480  mg administered every 4  weeks (q4w) is also currently under investi gation.  The 
less frequent dosing schedule is designed to be more convenient for patients.  The 480  mg dose 
was chosen based on clinical data as well as modeling and simulation approaches using PPK and 
exposure-response analyses of data from studies in mul tiple tumor types (melanoma, non -small 
cell lung cancer [NSCLC], and RCC) to provide an approximately equivalent dose as 3  mg/kg 
q2w.  Exposures with the 480  mg q4w regimen are predicted to be within the exposure ranges 
observed at doses up to 10  mg/kg q2w  assessed in the nivolumab clinical program and, therefore, 
are not considered to cause an increased risk to patients.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 54 of 178 
Confidential and Proprietary   11 February 2020  Based on these supportive data, nivolumab 360 mg q3w will be examined in the current study 
with NKTR -214. 
Additional details are provided  in the nivolumab Investigator’s Brochure.  
2.1.6 Nivolumab Shorter Infusion Duration  
Establishing that nivolumab can be safely admi nistered using a shorter infusion time 
(30 minutes) is under investigation.  Previous clinical studies of nivolumab monotherapy hav e 
used a 60 -minute infusion duration, and nivolumab has been safely administered up to 10  mg/kg 
over long treatment periods.  Infusion reactions including high -grade hypersensitivity reactions 
have been uncommon across the nivolumab clinical program.  In s tudy CA209010, a dose 
association was observed for infusion site reactions and hypersensitivity reactions (1.7% at 
0.3 mg/kg, 3.7% at 2  mg/kg, and 18.5% at 10  mg/kg).  All of the events were Grade  1-2 and 
were manageable.  An infusion duration of 30  minutes for 3 mg/kg nivolumab (30% of the 
10 mg/kg dose) is not expected to present any safety concerns based on the prior experien ce of 
10 mg/kg infused over 60  minutes.  The safety of 3  mg/kg nivolumab administered as a 
30-minute infusion was assessed in CA209 153 in patients (n  = 322) with previously treated 
advanced NSCLC.  Overall, there were no clinically meaningful differences i n the frequency of 
hypersensitivity/infusion -related reactions (of any cause or treatment related) between patients 
infused over 30  minutes versus the frequency reported for 60 -minute infusions.  Thus, nivolumab 
is considered safe to infuse over 30  minutes. 
Additional details are provided in the nivolumab Investigator’s Brochure.  
2.1.7 Nivolumab Safety Summary  
The overall safety experience with nivolumab, as a monotherapy or in combination with other 
therapeutics, is based on experience in approximately 12,300  patients treated to date.  
For monotherapy, the safety profile is similar across tumor types.  In Phase  3 controlled studies, 
the safety profile of nivolumab monotherapy is acceptable in the context of the observed clinical 
efficacy, and is manageable using e stablished safety guidelines.  Clinically relevant AEs typical 
of stimulation of the immune system were infrequent and manageable b y delaying or stopping 
nivolumab treatment and by timely immunosuppressive therapy or other supportive care.  
In several ongoi ng clinical studies, the safety of nivolumab in combination with other 
therapeutics is being explored.  Most studies are ongoing an d, as such, the safety profile of 
nivolumab combinations continues to evolve.  The most advanced combination under 
developmen t is nivolumab + ipilimumab, which is approved in patients with unresectable or 
metastatic melanoma, and is being investigated in m ultiple other tumor types.  Results to date 
suggest that the safety profile of nivolumab + ipilimumab combination therapy is consistent with 
the mechanisms of action of each drug.  The nature of the AEs is similar to that observed with 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 55 of 178 
Confidential and Proprietary   11 February 2020  either agent as a mo notherapy; however, the frequency and severity of most AEs are increased 
with combination therapy.  
Additional details on the safety profile of nivolumab are provided in the nivolumab 
Investigator’s Brochure.  
2.1.8 Ipilimumab Shorter Infusion Duration  
Establishin g that ipilimumab can be safely administered using a shorter infusion time 
(30 minutes) is under investigation.  Previous clinical studies of ipilimumab when administered 
at 3 or 10 mg/kg have used a 90 -minute infusion duration; ipilimumab has been safely 
administered at a dose of 1 mg/kg over 30 minutes for extended treatment periods.  In 
120 patients treated prospe ctively with ipilimumab 3  mg/kg infused over 30  minutes, 7  patients 
(5.8%) had an infusion -related reaction; all infusion -related reactions occ urred with the second 
dose; six were Grade 2, and one was Grade 3 ( Momtaz, 2015).  All 7 patients received 
subsequent doses of ipilimumab safely, the majority with premedication.  For comparison, the 
3-mg/kg dose over 90  minutes in this series (n  = 457) resulted in an incidence of infusion -related 
reactions at 2.2%.  In a second publis hed series in which 46  melanoma patients received 
100 shortened cycles of combined 3  mg/kg ipilimumab and 1  mg/kg nivolumab (each over 
30 minutes), one patient (2.2%; 1  of 46 patients) had a questionable reaction after administration 
of 1 mg/kg nivolumab o ver 30 minutes (Gassenmaier,  2018).  The authors concluded that the 
shortened infusion times for combined ip ilimumab and nivolumab treatment could be safely 
administered.  The shorter duration ipilimumab infusion is bein g currently investigated in larger 
clinical trials.  Given available information comparing the 30 - and 90-minute ipilimumab 
infusion times, ipil imumab is considered safe to infuse over 30  minutes. 
2.1.9 Ipilimumab Safety Summary  
The safety profile of ipilimumab was evaluated in two clinical studies in which 982  melanoma 
patients received ipilimumab either as monotherapy or in combination with other ther apeutics. 
The safety profile of ipilimumab is acceptable in the context of the observed clinical efficacy, 
and is manageable using established safety guidelines.  The most common clinically relevant 
AEs typical of stimulation of the immune system were ente rocolitis and hepatitis, which were 
manageable by delaying or stopping ipilimumab treatment and by timely immuno suppressive 
therapy or other supportive care.  
Additional details on the safety profile of ipilimumab  are provided in the ipilimumab  
Investigator ’s Brochure.  
2.1.10  Safety Summary of Study Regimen in Patients with 1L Nonsquamous NSCLC  
Patients with 1L metastatic n onsquamous NSCLC were evaluated in the global, randomized, 
double-blind, placebo -controlled, KEYNOTE -189 study ([STUDY_ID_REMOVED]), a Phase 3 study of  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 56 of 178 
Confidential and Proprietary   11 February 2020  pemetrexed and a platinum -based drug with or without pembrolizumab, followed by 
pembrolizumab or placebo plus p emetrexed maintenance therapy ( Gandhi, 2018).   
The most common adverse event observed for the chemotherapy drugs  alone (any severity 
regardless of causality at incidence at least 25%) included nausea, anemia, fatigue, consti pation, 
decreased appetite, cough, and dyspnea.  The most common adverse event observed for the 
chemotherapy drugs alone (of Grade 3 or higher s everity regardless of causality at incidence at 
least 5%) included anemia, neutropenia, thrombocytopenia, and dy spnea.  Additional details on 
the safety profiles of carboplatin , cisplatin, and pemetrexed are provided in the respective 
Package Insert or Sum mary of Product Characteristics.  
2.1.11  Safety Summary of Paclitaxel Formulations in Patients with 1L NSCLC  
A large, in ternational, randomized Phase  3 trial compared the efficacy and safety of 100  mg/m2 
of weekly nab -paclitaxel with 200  mg/m2 Cremophor -based pacl itaxel (both combined with 
carboplatin targeting an area under the curve [AUC] of 6 every 3  weeks [q3w]) in 1052  patients 
with advanced NSCLC ( Socinski, 2012).   
The most common nonhematologic Grade ≥ 3 treatment -related AE s with nab-paclitaxel  and 
Cremophor -based paclitaxel were fatigue .  The most common nonhematologic grade ≥3 TRAEs 
with nab-paclitaxel and Cremophor -based paclitaxel were fatigue (5% and 6%, respectively), 
sensory neuropathy (3% and 12%), anorexia (2% and <  1%), nausea (<  1% and <  1%), myalgia 
(< 1% and 2%), and arthralgia (0% and 2%) .  The most common hematologic Grade ≥ 3 
treatment -related AEs were neutropenia (47% and 58%), leukopenia (24% and 23%), 
thrombocytopenia (18% and 9%), and anemia (27%).   Additional details on the safety profiles of 
carboplatin, paclitaxel, and nab -paclitaxel are provided in the respective Package Insert or 
Summary of Product Characteristics.  
2.1.12  Safety Summary of Nab -Paclitaxel in Patients with TNBC  
Patients treated in the f irst or second line setting for metastatic TNBC will receive 
nab-paclitaxel.  Clinical data on nab -paclitaxel in combination with nivolumab are based on 
small numbers of patients ( Wainberg,  2017).  Data on single -agent nab -paclitaxel are therefore 
provided here.  
In the 229 patients with metastatic breast cancer treated with single -agent nab -paclitaxel in the 
randomized controlled trial in patients with metastatic breast cancer, common Grade  3 to 4 
hematological toxicities i ncluded neutropenia (Grade 4, 9%) with febrile neutropenia in 2%; 
severe anemia and thrombocytopenia were rare.  Common severe non -hematological toxicities 
included sensory neuropathy (10%), myalgias/arthralgias (8%) and asthenia (8%).  
Cardiovascular toxi cities included asymptomatic hypotension during the 30 -minute infusion, in 
5% of patients in the randomized metastatic breast cancer trial.  Severe cardiovascular events 
possibly related to single -agent nab -paclitaxel occurred in approximately 3% of patien ts in the 
randomized trial.  These events included chest pain, cardiac arrest, supraventricular tachycardia, 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 57 of 178 
Confidential and Proprietary   11 February 2020  edema, thrombosis, pulmonary thromboembolism, pulmonary emboli, and hypertension.  
Electrocardiogram (ECG) abnormalities were reported in 60% of pa tients, including non -specific 
repolarization abnormalities, sinus bradycardia, and sinus tachycardia.  Most required no 
intervention. Alopecia was nearly universal, occurring in 90% of patients (Summary basis of 
approval; Gradishar, 2005).  
Additional details on the safety profile of nab -paclitaxel are provided in the Package Insert or 
Summary of Product Characteristics.  
2.1.13  Safety Summary of Eribulin in Patients with TNBC  
Patients treated in the first or second line setting f or metastatic TNBC will receive eribulin.  
Clinical data on eribulin in combination with nivolumab are in progress.  Data on single -agent 
eribulin are therefore provided here.  
Based on a large international, randomized clinical trial comparing eribulin to treatment of 
physician’s choice conducted in 762  patients, t he most common nonhematologic Grade ≥ 3 AEs 
included fatigue (8%), peripheral neuropathy ( 8%), and dyspnea (4%).  The most common 
hematologic grade ≥ 3 AEs were neutropenia ( 21%) and anemia ( 2%).  Alopecia occurred in 
45% of patients ( Cortes, 2011).   
Additional details on the safety profile of eribulin are provided in the Package Insert or Summary 
of Product Characteristics.  
2.2 Overall Benefit/Risk  
NKTR-214 was designed  to mitigate the serious toxicities associated with rapid systemic 
immune activation seen w ith administration of aldesleukin.  The goal of engineering a 
PEGylated form of IL -2 that reduces the treatment -limiting toxicities of aldesleukin, i.e.,  those 
necessitating in -hospital administration, appears to have been realized with NKTR -214 at the 
doses tested.  The safety profiles of nivolumab and ipilimumab are well characterized and 
manageable when administered alone or in combination, including regimens where  they are 
administered in combination with additional immuno -oncology products.  Nonclinica l data as 
well as clinical experience with high -dose IL-2 and checkpoint inhibitor combinations indicate 
the potential for improvement in therapeutic response compar ed with either agent given alone.  
Thus, the potential benefit of combination therapy appea rs to outweigh the known risks of these 
agents and warrants clinical investigation.  
2.3 Data Monitoring Committee  
The detailed and frequent safety monitoring that will b e undertaken in this open -label study 
precludes the necessity for an independent Data Monit oring Committee .  A separate Safety 
Review Committee will meet to review safety data (see Section  9.3). 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 58 of 178 
Confidential and Proprietary   11 February 2020  3.0 STUDY OBJECTIVES  
3.1 Primary Objectives  
The primary objectives of this study are:  
• To evaluate the safety and tolerability, and de fine the MTD and/or RP2D of NKTR -214 in 
combination with nivolumab  or in combination with nivolumab and other anti -cancer 
therapies 
• To evaluate the efficacy of NKTR -214 in combination with nivolumab or in combination 
with nivolumab and other anti -cancer therapies by assessing the objective response rate 
(ORR) by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST  1.1) at the 
RP2D 
3.2 Secondary Objectives  
The secondary objective of this study is:  
• To evaluate the efficacy of NKTR -214 in combination w ith nivolumab or  in combination 
with nivolumab and other anti-cancer therapies by assessing OS, progression -free survival 
(PFS), clinical benefit rate (CBR), and duration of response (DOR)  
  
 
  
 
  
  
 
 
 
  
 
 
  
  
 
 

Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 59 of 178 
Confidential and Proprietary   11 February 2020  4.0 SELECTION OF STUDY P OPULATION  
Under Amendment 7, the  study is closed to patient screening and enrollment.  
For the purposes of patient eligibility determination, note the following definitions:  
• For the purposes of eligibility, “neoadjuvant therapy” is defined as systemic chemotherapy 
administered prior to de finitive local surgery in a patient without distant me tastases; 
“adjuvant therapy” is defined as systemic therapy administered following definitive local 
therapy (surgery or radiation) in a patient without distant metastases (with no evidence of 
disease). 
• A “line of therapy” is defined as any regimen – single-agent or combination therapy, 
cytotoxic therapy, immuno -oncology therapy separately or in combination – that is given for 
patients with advanced disease, and that is stopped for any reason, including p rogression of 
disease, toxicity, physician decision, o r patient withdrawal of consent.  
4.1 Inclusion Criteria  
Under Amendment 7, the study is closed to patient screening and enrollment.  
Each patient will be entered into this study only if he/she meets all of t he following criteria:  
For Dose Escalation (Part 1), D ose Expansion (Part 2), and Parts 3 and 4 (For Triplet 
Combination):   
 Provide written, informed consent to participate in the study and follow the study procedures  
 Male or female patients, age 18  years or older at the time of signing the informed consent 
form (ICF) 
 Life expectancy >12  weeks 
 Patients must not have received prior interleukin -2 (IL-2) therapy.  
 Eastern Cooperative Oncology Group (ECOG) performance status of  0 or 1 
 Measurable disease per RECI ST 1.1 
 Demonstrated  adequate organ function, as  defined below, within 28  days of treatment 
initiation 
a. White blood cell (WBC) count ≥  2000/μL (after at least 7  days without growth factor 
support) 
b. Absolute neutrophil count (ANC) ≥  1500/μL (after at least 7  days without growth 
factor support)  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 60 of 178 
Confidential and Proprietary   11 February 2020  c. Platelet coun t ≥ 100 × 103/μL (no transfusions allowed within 7 days of Cycle 1 Day 1 
to meet entry criteria)  
d. Hemoglobin ≥  9.0 g/dL (no transfusions allowed within 7 days of Cycle 1 Day 1 to 
meet entry criteria)  
e. Serum cre atinine ≤ 2 mg/dL (or glomerular filtration rate  ≥ 40 mL/min); patients with 
urothelial carcinoma who are cisplatin ineligible (creatinine clearance <  60 mL/min) 
may be enrolled if the glomerular filtration rate is ≥  30 mL/min. 
f. Aspartate aminotransferase ( AST) and alanine transaminase (ALT) ≤  3× upper l imit of 
normal (ULN)  
g. Total bilirubin within normal limits (total bilirubin ≤  2× ULN if associated with 
hepatobiliary metastases or Gilbert’s syndrome)  
h. Lipase and amylase ≤ 1.5 × ULN.  Patients with pancreatic metastases and lipase 
and/or amylase <  3× ULN may enroll.  Patients may not enroll if there are clinical or 
radiographic signs of pancreatitis.  
 A documented left ventricular ejection fraction (LVEF) >  45% using standard 
echocardiogram or multigated  acquisition (MUGA) scan test within 60  days prior to Cycle  1 
Day 1. 
 Oxygen saturation ≥  92% on room air  
 Clinically significant toxic effect(s) of the most recent prior anti -cancer therapy must be 
Grade 1 or resolved (except alopecia and sensory neuropathy ); patients with Grade 2 adrenal 
insufficiency related to prior anti -cancer therapy (defined as requiring medical intervention, 
such as concomitant steroids) or Grade 2 hypothyroidism (defined as requiring hormone 
replacement therapy ) may be enrolled provi ded that clinical symptoms are adequately 
controlled and the daily do se is 10 mg or less of prednisone or equivalent.  If the patient 
received major surgery or radiation therapy of >  30 Gy, they must have recovered from the 
toxicity and/or complications fr om the intervention.  
 Women of childbearing potential (WCBP) must agre e and commit to the use of highly 
effective methods of birth control throughout the duration of the study until 6 months 
following the last dose of study drug.  Acceptable methods are def ined as those that result, 
alone or in combination, in a low failure rate (i.e., less than 1% per year) when used 
consistently and correctly, such as surgical sterilization, an intrauterine device, or hormonal 
contraception in combination with a barrier me thod.  It is currently unknown whether 
NKTR-214 may reduce the effect iveness of systemically acting hormonal contraceptives, and 
therefore women using systemically acting hormonal contraceptives should add a barrier 
method.  In certain countries (if permit ted by law), WCBP may agree to abide by 
heterosexual sexual abstinenc e during the time of participation in this study.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 61 of 178 
Confidential and Proprietary   11 February 2020  
 Male patients and their female partners of childbearing potential must agree and commit to 
use a double -barrier contraception (e.g., cond om with spermicidal 
foam/gel/film/cream/suppository) throughout the d uration of the study until 6 months 
following the last dose of study drug; in addition to their female partner using either an 
intrauterine device or hormonal contraception and continuing  until 6 months following the 
last dose of study drug.  This criterio n is not applicable for male patients who have had a 
vasectomy > 6 months before signing the informed consent form (ICF).  
 Patients must not have active brain metastases:    
a. Participants with brain metastases  are eligible if these have been treated and there is no 
MRI evidence of progression for at least 8 weeks after treatment is complete and 
within 28 days prior to first dose of study treatment administration.   There must also 
be no requirement for immunosuppressive doses of systemic corticosteroids  
(>10 mg/day prednisone equivalents) for at least 2 weeks prior to study treatment 
administration.  Stable dose of anticonvulsants is allowed.  Treatment for CNS 
metastases may include stereotact ic radiosurgery (e.g. GammaKnife, CyberKnife, or 
equivalent) or neuro surgical resection.  Patient who received whole brain radiation 
therapy are not eligible.  
b. No new or progressing brain metastasis of any size  
c. No stereotactic radiation or craniotomy within  4 weeks of Cycle  1 Day 1 
d. No new central nervous system lesions on re peat radiographic imaging 4  weeks or more 
from last treatment  
e. No clinically significant symptoms secondary to brain metastases  
f. Head imaging must occur on study in accordance with Section 5.7. 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 62 of 178 
Confidential and Proprietary   11 February 2020  
 Sample of fresh bas eline tumor biopsies (fresh baseline biopsy is defined as a biopsy 
specimen taken during screening) is required, except if inaccessible and with Medical 
Monitor approval (e.g., a biopsy specimen from a sample taken since completion of the most 
recent prior  systemic treatment and no longer than 6  months prior to study start may be 
acceptable in lieu of a fresh biopsy with Medical Monitor approval ).  Patients must a lso 
consent to allow acquisition  of existing formalin -fixed paraffin -embedded (FFPE) material 
(archival tumor tissue), either a block or unstained slides for performance of correlative 
studies. 
For Parts 1 and 2   
Under Amendment 7, the study is closed to patient screening and enrollment.  
For Disease -Specific Tumor Types  
 Melanoma  
a. Histologically conf irmed stage  III (unresectable) or stage  IV melanoma, as per 
American Joint Committee on Cancer (AJCC) staging system.  
b. Patients must consent to BRAF testing or ha ve documented BRAF status as per 
regionally acceptable V600 mutational status testing.  
c. Uveal me lanoma will be excluded.  
d. “Isolated limb perfusion” is not considered systemic chemotherapy.  
Cohort 1a − Melanoma (1L)  
a. Have not received prior anti-cancer therapy for advanced or metastatic melanoma  
For Part 2:   
b. Prior to disease  metastasis , patients must n ot have received neoadjuvant or adjuvant 
therapy with any immuno -oncology regimens, including, but not limited to, checkpoint 
inhibitors such as anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti -cytotoxic 
T-lymphocyte antigen  4 (anti-CTLA-4) antibody,  or any other antibody or drug 
specifically targeting T  cell co-stimulation or checkpoint pathways, indoleamine 
2,3-dioxygenase pathway inhibi tors, cancer vaccines, adoptive cell therapies, or other 
cytokine therapies.  
c. Patients must not have received any p rior therapy for melanoma (including therapy for 
neoadjuvant, adjuvant, locally advanced or metastatic disease, including all systemic 
therapy including tyrosine kinase inhibitors [BRAF, MEK, mTOR], bevacizumab, I -O 
therapy, cytotoxic chemotherapy, and/or isolated limb perfusion).  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 63 of 178 
Confidential and Proprietary   11 February 2020  Cohort 1b − Melanoma (2 -3L, anti -PD-1 or anti -PD-L1 relapse/refractory)  
a. Patients must have received only 1 prior lin e of therapy with an anti -PD-1 or anti-PD-L1 
containing regimen (doublet -based therapy), which must be their most recent anti -cancer 
treatment.  Patients must not have received neoadjuvant or adjuvant therapy with any 
immuno-oncology regimens.   
b. Patients m ust have confirmed radiographic or biopsy -proven disease progression at least 
4 weeks after initial disease progression, or unequivocal radi ographic progression as per 
the Investigator based on a single imaging assessment; this assessment must be within 
90 days from last dose of anti -PD-1 or anti-PD-L1 containing regimen.  Patients must 
consent to providing pre -study scans (if available) to co nfirm radiographic progression.  
c. Patients may have received only 1 prior line of therapy with molecular -targeted ther apy. 
d. Patients who have received only 1  prior regimen of cytotoxic chemotherapy but have not 
received prior molecular targeted therapy, are  eligible. 
e. Patients may not have primary refractory disease  to prior anti-PD-1 therapy 
(radiographic or clinical progr ession within 120 days of initiation of immun o-oncology 
therapy).  
Cohort 1c − Melanoma BRAF wild type  (2L, anti-PD-1 or anti -PD-L1 
relapse/refractory ) 
a. Patients must be BRAF wild type.  
b. Patients must have received only 1 prior line of therapy with single-agent anti -PD-1 or 
anti-PD-L1 therapy, which must be their most recen t anti-cancer treatment.  Patients 
must not have received anti -CTLA-4 alone or in combination with anti -PD-1 or 
anti-PD-L1.  Patients must not have received neoadjuvant or adjuvant  therapy with any 
immuno-oncology regimens.  
c. Patients are not eligible who re ceived adjuvant or first -line therapy for 
advanced/metastatic disease consisting of molecular target therapies including, but not 
limited, to BRAF, MEK, or C -KIT targeted therapies  (single agent or in any 
combination), or intralesional therapy.  
d. Patients ar e not eligible who received doublet immuno -oncology therapy, including 
checkpoint inhibitors combined with either systemic or intralesional therapy.  Patients 
are not eligible who received cytotoxic chemotherapy such as dacarbazine, paclitaxel 
or others.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 64 of 178 
Confidential and Proprietary   11 February 2020  e. Patients must have confirmed radiographic or biopsy -proven disease progression at 
least 4 weeks after initial disease progression, or unequivocal radiographic progression 
as per the  Investigator based on a single imaging assessment; this assessment must be 
within 90 days from last dose of anti -PD-1 or anti-PD-L1 therapy.   
f. Patients must consent to providing pre -study scans (if available) to confirm 
radiographic progression.  
Cohort 1d  – Melanoma ( 1L, following  prior adjuvant therapy ) 
a. Have not received prior a nti-cancer therapy for advanced or metastatic melanoma  
b. Patient must have received prior adjuvant therapy for melanoma; adjuvant therapy 
may consist of any immuno -oncology regimens (single -agent or combination therapy) 
or molecularly targeted therapy (such as tyrosine kinase inhibitors).  The disease -free 
interval from last dose of adjuvant therapy to a diagnosis of advanced or metastatic 
melanoma must be less than 180  days.  
Cohort 1e − Melanoma  
a. Patients who were enrolled under an earlier version of the pro tocol who are no longer 
eligible for Cohorts 1a through  1d. 
 Renal Cell Carcinoma (RCC)  
a. Advanced (not amenable to curative surgery or radiation therapy) or metastatic (AJCC 
stage IV) RCC 
b. Histologically confirmed RCC with a clear -cell component  
Cohort 2a − R CC (1L)  
a. Have not received prior anti -cancer therapy for  advanced or metastatic RCC . 
b. Prior to disease metastasis, patients must not have received neoadjuvant or adjuvant 
therapy with any immuno -oncology regimens, including, but not limited to, checkpoint 
inhibitors such as anti -PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti -cytotoxic 
T-lymphocyte antigen  4 (anti-CTLA-4) antibody, or any other antibody or drug 
specifically targeting T  cell co-stimulation or checkpoint pathways, indoleamine 
2,3-dioxygenase pathway inhibitors, cancer vaccines, adoptive cell ther apies, or other 
cytokine therapies.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 65 of 178 
Confidential and Proprietary   11 February 2020  Cohort 2b − RCC (2 -3L, anti -PD-1 or anti -PD-L1 relapse/refractory)  
a. Patients must have received only 1 prior line of therapy with an anti -PD-1 or 
anti-PD-L1 containing regimen, which must be their most recent anti -cancer treatment.  
Patients must not have r eceived neoadjuvant or adjuvant therapy with any 
immuno-oncology regimens . 
b. Patients must have confirmed radiographic disease progression at least 4 weeks after 
initial disease progression, or unequivocal radiographic progression as per the 
Investigator bas ed on a single imaging assessment; this assessment must be within 
90 days from last dose of anti -PD-1 or anti-PD-L1 containing regimen. Patients must 
consent to providing pre -study scans (if available) to  confirm radiographic 
progression.  
Cohort 2c – Renal  Cell Carcinoma  
a. Patients who were enrolled under an earlier version of the protocol who are no longer 
eligible for Cohorts 2a or 2b.  
 Non-Small Cell Lung Cancer (NSCLC)  
a. Histologically confirmed or cytologi cally confirmed diagnosis of stage IV NSCLC  
(unless otherwise noted)  
b. Patients with nonsquamous NSCLC must lack both epidermal growth factor receptor 
(EGFR)-sensitizing mutation/deletion and anaplastic lymphoma kinase (ALK) 
translocation by local testing ( assessment of ROS1 mutation status is not required, 
unless otherwise noted).  For ALK or EGFR testing, an FDA -approved test or 
validated assay should be used as applicable for selection of patients.  For patients 
with squamous NSCLC, testing for EGFR, ALK,  or ROS1 is not required.  
Cohorts 3a.1, 3a.2, 3a.3 , and 3a.4  − NSCLC (1L)  
a. Patients must have known PD -L1 status as per validated immunohistochemistry 
testing.  Up to 20 efficacy-evaluable patients will be enrolled in each subgroup of PD -
L1 negative (PD -L1 < 1%; Cohort  3a.1), PD-L1 highly positive (PD-L1 ≥ 50%; 
Cohort 3a.3), or PD-L1 low/intermediate (PD -L1 ≥ 1% - < 50%; Cohort  3a.2).  For 
patients who do not have known PD -L1 status, testing must be done  using an 
FDA-approved PD -L1 test.  An abbreviated c onsent may be presented to the patient 
prior to the Screening p eriod to permit early assessment of the PD -L1 status of the 
tissue sample.  Patients enrolled in Cohort 3a who do not have a PD -L1 status assessed 
by central testing will be assigned to Cohort 3a.4. 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 66 of 178 
Confidential and Proprietary   11 February 2020  b. Patients must not have received prior anti -cancer therapy  for advanced or metastatic 
NSCLC; patients must not have received prior immuno -oncology in any setting 
(including neoadjuvant, adjuvant, locally advanced or metastatic disease).  
Cohort 3b − NS CLC (2L, I -O therapy naive) following  platinum -based t herapy  
a. Patients must have experienced disease recurrence or progression during or after one 
prior platinum doublet -based chemotherapy regimen for advanced or metastatic 
disease.  Patients are not eligib le who refused prior platinum -based therapy.  
b. Patients who received platinum -containing adjuvant, neoadjuvant, or definitive 
chemoradiation therapy given for locally advanced disease and developed recurrent 
(local or metastatic) disease withi n 6 months of completing therapy are eligible.  
c. Patients must not have received any prior immuno -oncology in any setting  regimens, 
including, but not limited to, checkpoint inhibitors such as anti -PD-1, anti-PD-L1, 
anti-PD-L2, anti-CD137, or anti -cytotoxic T-lymphocyte a ntigen 4 (anti -CTLA-4)  
antibody, or any other antibody or drug specifically targeting T  cell co-stimulation or 
checkpoint pathways, indoleamine 2,3 -dioxygenase pathway inhibitors, cancer 
vaccines, adoptive cell therapies, or other cytokine therapies. 
Coho rt 3c − NSCLC (2 -3L, anti -PD-1 or anti -PD-L1 relapse/refractory)  
a. Patients must have received only 1 prior line of therapy with anti -PD-1 or anti-PD-L1 
therapy.  Patients are eligible if they received sequential therapy (e.g., cytotoxic 
chemotherapy followe d by anti PD -1 or anti PD -L1 therapy, or vice versa). Patients 
must not have received neoadjuvant or adjuvant therapy with any immuno -oncology 
regimens.  
b. Patients must not have received anti -CTLA-4 alone or in combination with anti -PD-1 
or anti-PD-L1, unless the anti-CTLA-4 therapy stopped >  1 year prior to Cycle  1 
Day 1. 
c. Prior to the anti -PD-1 or anti-PD-L1 therapy regimen, patients must have received 
zero or 1 prior line of cytotoxic chemotherapy for metastatic disease.  
d. Patients must have confirmed ra diographic disease progression at least 4 weeks after 
initial disease progression, or unequivocal radiographic progression as per the 
Investigator based on a single imaging assessment; this assessment must be within 
90 days from last dose of anti -PD-1 or anti-PD-L1 containing regimen.  Patients must 
consent to providing pre -study scans (if available) to confirm radiographic 
progression.  
e. Patients may not have primary immuno -oncology refractory disease (radiographic or 
clinical progression within 120 days of initiation of immuno -oncology therapy).  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 67 of 178 
Confidential and Proprietary   11 February 2020  Cohorts 3d.1 and 3d.2 − NSCLC (1L nonsquamous) (in combination with 
platinum/pemetrexed and maintenance pemetrexed [Cohort  3d.1] or without 
maintenance pemetrexed [Cohort  3d.2])  
a. Patients must have nonsquamous NSCLC.  The patient will be excluded if the 
histology is considered predominantly squamous cell NSCLC.  Mixed tumors will be 
categorized by the predominant cell type; if small cell elements are present, the patient 
is ineligible.  
b. Patients must not have received p rior anti-cancer therapy for advanced or metastatic 
NSCLC; patients who received adjuvant or neoadjuvant therapy are eligible if the 
adjuvant/neoadjuvant therapy was completed at least 12 months prior to the 
development of metastatic disease.  Patients mus t not have received prior 
immuno-oncology therapy in any setting (including neoadjuvant, adjuvant, locally 
advanced or metastatic disease).  
c. Patients must be candidates for platinum/pemetrexed chemotherapy and willing to take 
folic acid and vitamin B 12 supplemen tation. 
d. Patients must not have received radiation therapy to the lung that is >  30 Gy within 
6 months of the first dose of study medication.  
Cohort 3e − NSCLC (1L squamous) (in combination with platinum/taxane)  
a. Patients must have squamous NSCLC.  
b. Patients must not have received prior anti -cancer therapy for advanced or metastatic 
NSCLC; patients who received adjuvant or neoadjuvant chemotherapy (after surgery 
and/or radiation therapy) and developed recurrent or metastatic disease within 
6 months of  completing therapy are eligible.  Patients must not have received prior 
immuno-oncology therapy in any setting (including neoadjuvant, adjuvant, local ly 
advanced or metastatic disease).  
c. Patients must be candidates for platinum/taxane chemotherapy.  
d. Patients must not have received radiation therapy to the lung that is >  30 Gy within 
6 months of the first dose of study medication.  
e. Known hypersensitivity to  the selected cytotoxic chemotherapy study drugs.  
Cohort 3f  − NSCLC (3L+, ALK -translocation/ROS1 rearran gement positive ) 
a. Patients must have ALK -translocation positive or ROS1 rearrangement NSCLC by 
local pathology report (assessment of ROS1 mutation statu s is not required) .  For ALK 
testing, an FDA -approved test or validated assay must be used.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 68 of 178 
Confidential and Proprietary   11 February 2020  b. Patients must  have received at least two prior anti -cancer therapies for advanced or 
metastatic NSCLC (these may have included chemotherapy and must have included a t 
least one ALK -directed and/or ROS -1-directed therapy), be ineligible to receive these 
therapies due to toxicity, or no longer be considered a candidate for additional tyrosine 
kinase inhibitor therapy; patients must not have received prior immuno -oncology 
therapy in any setting (including neoadjuvant, adjuvant, locally advanced or metastatic 
disease). 
c. Patients may not have received more than one prior cytotoxic -based regimen (e.g., 
carboplatin with paclitaxel).  
Cohort 3g − NSCLC (3L+, EGFR mutation/deleti on) 
a. Patients must have EGFR mutation or relevant deletion NSCLC by local pathology 
report.  For EGFR test ing, an FDA -approved test or validated assay should be used.  
b. Patients must have received at least two prior anti -cancer therapies for advanced or 
metastatic NSCLC (these may have included chemotherapy and must have included at 
least one EGFR -directed small  molecule therapy), be ineligible to receive these 
therapies due to toxicity, or no longer be considered a candidate for additional tyrosine 
kinase inh ibitor therapy; patients must not have received prior I -O therapy in any 
setting (including neoadjuvant, adjuvant, locally advanced or metastatic disease).  
c. Patients may not have received more than one prior cytotoxic -based regimen (e.g., 
carboplatin with p aclitaxel).  
Cohort 3h − NSCLC (2L, anti PD 1 or anti PD L1 relapse/refractory)  
a. Patients must have receive d only 1 prior line of therapy with anti -PD-1 or anti-PD-L1 
therapy in combination with doublet platinum-containing cytotoxic chemotherapy , 
which must be their most recent anti -cancer treatment .  Patients are not eligible if they 
received sequential therapy (e.g., cytotoxic chemotherapy doublet therapy followed by 
anti PD-1 or anti PD -L1 therapy or vice versa).  Patients must not have received 
neoadjuvan t or adjuvant therapy with any immuno -oncology regimens.  
b. Patients must not have received  more than 1 prior line of cytotoxic chemotherapy for 
metastatic disease.  
c. Patients must have confirmed radiographic disease progression at least 4 weeks after 
initial disease progression, or unequivocal radiographic progression as per the 
Investigator base d on a single imaging assessment; this assessment must be within 90 
days from last dose of anti -PD-1 or anti-PD-L1 containing regimen.  Patients must 
consent to providi ng pre study scans (if available) to confirm radiographic 
progression.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 69 of 178 
Confidential and Proprietary   11 February 2020  d. Patients may not have primary immuno -oncology refractory disease (radiographic or 
clinical progression within 120 days of initiation of immuno -oncology therapy). 
Cohort 3i – NSCLC  
a. Patients who were enrolled under an earlier version of the protocol who are no longer 
eligible for Cohorts 3a.1 to 3h.  
 Urothelial Carcinoma  
a. Histologically or cytologically documented locally advanced or transitional cell 
carcinoma of the urothelium including re nal pelvis, ureters, urinary bladder, or urethra.  
Patients with mixed histologie s are required to have a dominant transitional cell 
pattern. 
Cohort 4a − Urothelial Carcinoma (1L)  
a. Enrollment of urothelial carcinoma 1L patients will target accrual of up to 20 patients 
who are cisplatin -ineligible and up to 20 patients, who, after consul tation with the 
Investigator, choose to forego front -line chemotherapy.  
b. Treatment naive patients who refuse chemotherapy standard of care or treatment naive, 
cisplatin-ineligible patients who meet at least one of the following criteria:  
• Creatinine clearanc e (calculated or measured) < 60 mL/min. Cisplatin -ineligible 
patients must have a creatinine clearance < 60 mL/min and GFR ≥ 30  mL/min. 
• Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade ≥  2 
audiometric hearing loss  
• CTCAE v4.03 Grade ≥  2 peripheral neuropathy  
c. No prior chemotherapy for inoperable loca lly advanced or metastatic urothelial 
carcinoma.  Prior local intravesical chemotherapy is allowed if completed at least 
4 weeks prior to the initiation of study treatment.  
d. For patients who recei ved prior adjuvant/neoadjuvant chemotherapy or chemo -
radiation for urothelial carcinoma, a treatment -free interval of more than 12  months 
between the last treatment administration and the date of recurrence is required to be 
considered treatment naive in t he metastatic setting.  Patients must not have received 
neoadjuvant or adjuvant therapy with any immuno -oncology regimens.  
Cohort 4b – Urothelial Carcinoma (2 -3L, anti -PD-1 or anti -PD-L1 relapse/refractory)  
a. Patients must have progressed on only one prior l ine of therapy that contains 
platinum-based chemotherapy in t he metastatic setting or post platinum -based 
chemotherapy in an adjuvant setting with progression <  6 months.   
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 70 of 178 
Confidential and Proprietary   11 February 2020  b. Patients must have received only one prior line of therapy with single -agent anti -PD-1 
or anti-PD-L1 therapy, which must be their most recent an ti-cancer treatment.  Patients 
must not have received anti -CTLA-4 alone or in combination with anti -PD-1 or 
anti-PD-L1.  Patients must not have received neoadjuvant or adjuvant therapy with any 
immuno-oncology regimens.  
c. Patients must have confirmed radiogr aphic disease progression at least 4 weeks after 
initial disease progression, or unequivocal radiographic progression as per the 
Investigator based on a single imaging assessment; this assessment  must be within 90 
days from last dose of anti -PD-1 or anti-PD-L1 therapy.  Patients must consent to 
providing pre -study scans (if available) to confirm radiographic progression.  
d. Patients may not have primary immuno -oncology refractory disease (radiographi c or 
clinical progression within 120 days of initiation of im muno-oncology therapy).  
Cohort 4c − Urothelial  
a. Patients who were enrolled under an earlier version of the protocol who are no longer 
eligible for Cohorts 4a or 4b.  
 Cohort 5 − Triple -Negative Brea st Cancer  (1-2L, I -O therapy naive)  
a. Patients must have diagnosis of advanced triple -negative breast cancer (TNBC) 
(“advanced” is defined either locally advanced breast cancer not amenable to curative 
surgery or radiotherapy or distant metastases).  
• Less than 1% of tumor cell nuclei test positive for estrogen and progesterone 
receptors dete rmined by using standard IHC  
• Human epidermal growth factor receptor 2 (HER2) negative as determined by local 
pathologist, using IHC or in situ hybridization  
• Patients must have had triple negative phenotype of breast cancer in all available 
biopsies that ha ve been examined during the course of the disease.  
b. Patients must have received 0 or 1  prior line of therapy with systemic cytotoxic 
chemotherapy for advanced  TNBC or patient refuses standard of care.  Substitution 
within a class of anti -cancer therapy (e.g ., nab-paclitaxel for paclitaxel; carboplatin for 
cisplatin) is permitted; otherwise patients who discontinued therapy for reasons other 
than progressive dis ease are still considered to have received 1  prior line of therapy.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 71 of 178 
Confidential and Proprietary   11 February 2020  c. Patients are excluded whose dis ease-free interval (for patients with prior neoadjuvant 
or adjuvant chemotherapy: the interval between the last dose of neoadjuvant or 
adjuvant chemotherapy to the diagnosis of advanced breast cancer; for patients 
originally diagnosed with Stage I/II/III b reast cancer who did not receive prior 
neoadjuvant or adjuvant chemotherapy: the interval between date of original diagnosis 
of breast cancer and date of dia gnosis of advanced breast cancer) is less than 6 months 
and no clinically significant tumor -related symptoms in the judgment of the 
investigator.  Patients with a diagnosis of de novo Stage IV breast are eligible.  
d. Patients are excluded if the screening LDH  > 2 × ULN (based on the central 
laboratory).  
e. Must not have received any prior immuno -oncology regi mens, including, but not 
limited to, checkpoint inhibitors such as anti -PD-1, anti-PD-L1, anti-PD-L2, 
anti-CD137, or anti -CTLA-4 antibody, or any other antib ody or drug specifically 
targeting T  cell co-stimulation or checkpoint pathways, indoleamine 2,3 -dioxygenase 
pathway inhibitors, cancer vaccines, adoptive cell therapies, or other cytokine 
therapies.  
Cohort 5a − Triple -Negative Breast Cancer  (1-2L, I -O the rapy naive)  
a. Patients must be candidates for NKTR -214 in combination with nivolumab.  
Cohort 5b − Tri ple-Negative Br east Cancer  (1-2L, I -O therapy naive) in combination 
with nab -paclitaxel  
a. Patients must be candidates for single -agent nab -paclitaxel; patient s may not have 
received paclitaxel or docetaxel for metastatic carcinoma and may not have relapsed 
with metastatic disease within 1 year of adjuvant paclitaxel or docetaxel treatment.  
b. Patients may not have received prior nab -paclitaxel in any setting.  
Coho rt 5c − Triple -Negative Breast Cancer (1 -2L, I -O therapy naive) in combination 
with eribulin  
a. Patients must be a candidate for single -agent eribulin; patients may not have relapsed 
with metastatic disease within 1 year of adjuvant taxane -based treatment.  
b. Patients may not have received prior eribulin in any setting.  
Cohort 5d – TNBC  
a. Patients who were enr olled under an earlier version of the protocol who are no longer 
eligible for Cohorts 5a to 5c.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 72 of 178 
Confidential and Proprietary   11 February 2020  
 Cohort 6 − Hormone -Receptor Positive, HER2 Negative Breast Ca ncer  
a. Patients must have diagnosis of advanced hormone -receptor positive breast carcinoma 
(“advanced” is defined either locally advanced breast cancer not amenable to curative 
surgery or radiothe rapy or metastatic disease).  
• ≥ 1% of tumor cell nuclei test p ositive for estrogen or progesterone receptors 
determined by using standard IHC  
• HER2 negative as determined by local pathologist, using IHC or in situ hybridization  
• For patients whose primary tu mor was HER2 -positive or hormone -receptor positive, 
eligibility will be based on the first biopsy for advanced disease.   
b. Patients must have either archival or fresh tumor biopsy that demonstrates 
≥ 1% positive PD -L1 staining by the central pathology labora tory.  An abbreviated 
consent may be presented to th e patient prior to the Screening period to permit early 
assessment of the PD -L1 status of the tissue sample.  
c. Patients must have received prior aromatase inhibitor and fulvestrant therapy for 
advanced brea st cancer.  (Progression after prior adjuvant therap y with an aromatase 
inhibitor within 12  months will count as a line of therapy).  Hormonal therapy may 
have been administered as single -agent or in combination with CDK4 -6 inhibitors 
(such as palbociclib and others), mTOR inhibitors (everolimus and others) , PI3K 
inhibitors (buparlisib and others), or other agents used in combination with hormonal 
agents (AKT inhibitors, WNT inhibitors, or others).  
d. Must not have received any prior immuno -oncology regimens, including, but not 
limited to, checkpoint inhibitors  such as anti -PD-1, anti-PD-L1, anti-PD-L2, 
anti-CD137, or anti -CTLA-4 antibody, or any other antibody or drug specifically 
targeting T  cell co-stimulation or checkpoint pathways, indoleamine 2,3 -dioxygenase 
pathway inhibitors, cancer vaccines, adoptive ce ll therapies, or other cytokine 
therapies.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 73 of 178 
Confidential and Proprietary   11 February 2020  Cohort 6a − Hormone -Receptor Positive, HER2 -Negative Breast Cancer (I -O therapy 
naive following hormonal therapy)  
a. Patients must not have received prior cytotoxic chemotherapy (such as tubulin -
targeting agents (pac litaxel, docetaxel, nab -paclitaxel, eribuli n, vinca alkaloids, 
epothilones, and others), anti -metabolites (5 -fluorouracil, capecitabine, gemcitabine, 
and others), platinum agents (carboplatin, cisplatin, and others), alkylating agents 
(cyclophosphamide and  others), topoisomerase 1 or 2 inhibitors ( irinotecan, 
doxorubicin, epirubicin, etoposide, and others) or VEGF -targeted monoclonal 
antibodies (bevacizumab and others).  Prior systemic therapy must be reviewed by the 
Medical Monitor prior to registration fo r the trial.  
Cohort 6b − Hormone -Receptor P ositive, HER2 -Negative Breast Cancer (I -O therapy 
naive following hormonal and cytotoxic therapy)  
a. Patients must have received at least one and up to 2  prior lines of cytotoxic 
chemotherapy (such as tubulin -targeting agents (pa clitaxel, docetaxel, nab -paclitaxel, 
eribulin, vinca alkaloids, epothilones, and others), anti -metabolites (5 -fluorouracil, 
capecitabine, gemcitabine, and others), platinum agents (carboplatin, cisplatin, and 
others), alkylating agents (cyclop hosphamide an d others), topoisomerase 1 or 2 
inhibitors (irinotecan, doxorubicin, epirubicin, etoposide, and others).  Substitution 
within a class of anti -cancer therapy (e.g., carboplatin for cisplatin) is permitted; 
otherwise patients who discontinued th erapy for rea sons other than progressive disease 
are still considered to have received a prior line of therapy.  Prior systemic therapy 
must be reviewed by the Medical Monitor prior to registration for the trial.  
 Cohort 7 − Gastric Carcinoma (2 -3L, I -O the rapy naive)  
a. Patients must have diagnosis of advanced gastric adenocarcinoma or gastroesophageal 
carcinoma (GC) (“advanced” is defined either locally recurrent surgically unresectable 
advanced cancer or metastatic disease).  
b. Patients must have either archiva l or fresh tu mor biopsy that demonstrates PD -L1 
staining (Combined Positive Sc ore ≥ 1 as determined by an FDA -approved test or 
validated assay).  An abbreviated consent may be presented to the patient prior to the 
Screening period to permit early assessmen t of the PD -L1 status of the tissue sample.  
c. Patients must have received no more than two prior lines of therapy including 
fluoropyrimidine - and platinum -containing chemotherapy, and (if appropriate) 
HER2-targeted systemic therapy for gastric cancer.  These drugs may have been 
administered in the neoadjuvant, adjuvant, locally advanc ed or metastatic setting.  
Patients may have progressed or been intolerant to these therapies. (“Systemic 
therapy” includes all  agents, including cytotoxic, molecularly targeted or other).  
Substitution within a class of anti -cancer therapy (e.g., capecitab ine for fluorouracil 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 74 of 178 
Confidential and Proprietary   11 February 2020  [5-FU]; carboplatin for cisplatin) is permitted; otherwise patients who discontinued 
therapy for reasons other than progressive disease are still considered to have received 
a prior line of therapy.  
d. Must not have received any prior imm uno-oncology regimens, including, but not limited 
to, checkpoint inhibitors such as anti -PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or 
anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T  cell 
co-stimulation or checkpoint pathways, i ndoleamine 2,3 -dioxygenase pathway 
inhibitors, cancer vaccines, adoptive cell therapies, or other cytokine therapies.  
 Cohort 8 a – Colorectal Carcinoma (2 -3L, I-O therapy naive); microsatellite  instability  
(MSI) -high  
a. Patients must have diagnosis of advanced  colorectal carcinoma (CRC) (“advanced” is 
defined either locally advanced unresectable cancer or metastatic disease).    
b. Patients must have either archival or fresh tumor biopsy that demonstrates 
microsatellite instability (MSI) high or mismatch repair def icient (dMMR) disease .  
An abbreviated consent may be presented to the patient prior to the Screening period 
to permit early a ssessment of the CD8+ TIL status of the tissue sample.  
c. Patients who had disease progression during, after, or were intolerant to, prior 
treatment with fluoropyrimidine -, oxaliplatin -, or irinotecan -based chemotherapy 
(patients must have received either flu oropyrimidine and oxaliplatin -containing 
chemotherapy OR fluoropyrimidine and irinotecan -containing chemotherapy for 
colorectal ca rcinoma cancer (“FOLFOX” [fluorouracil, leucovorin, and oxaliplatin] or 
“FOLFIRI” [5 -fluorouracil, leucovorin, and irinotecan] ); and (if appropriate) EGFR -
targeted and/or VEGF -targeted systemic therapy.  These drugs may have been 
administered in the neoadj uvant, adjuvant, locally advanced or metastatic setting.  
(“Systemic therapy” includes all agents, including cytotoxic, m olecularly targeted or 
other).  Substitution within a class of anti -cancer therapy (e.g., capecitabine for 5 -FU) 
is permitted; otherwis e patients who discontinued therapy for reasons other than 
progressive disease are still considered to have received a  prior line of therapy.  
d. Must not have received any prior immuno -oncology regimens, including, but not 
limited to, checkpoint inhibitors su ch as anti -PD-1, anti-PD-L1, anti-PD-L2, 
anti-CD137, or anti -CTLA-4 antibody, or any other antibody or drug specifically 
targeting T cell co-stimulation or checkpoint pathways, indoleamine 2,3 -dioxygenase 
pathway inhibitors, cancer vaccines, adoptive cell therapies, or other cytokine 
therapies.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 75 of 178 
Confidential and Proprietary   11 February 2020  Cohort 8b – Colorectal Carcinoma ( 3-4L, I-O therapy naive); MS I-non-high  
a. Patients must have diagnosis of advanced colorectal carcinoma (CRC) (“advanced” is 
defined either locally advanced unresectable cancer or metas tatic disease).    
b. Patients must have either archival or fresh tumor biopsy that demonstrates MSI not 
high (MSI -stable or MSI -low) or mismatch repair proficient (pMMR) disease.  In 
addition, tumor tissue must demonstrate CD8+ tumor infiltrating lymphocytes (≥ 10% 
by IHC) by central laboratory.  An abbreviated consent may be presented to the patient 
prior to the Screen ing period to permit early assessment of the CD8+ TIL status of the 
tissue sample.  
c. Patients must have received at least two but no more than 3 prior lines of therapy 
including fluoropyrimidine -, oxaliplatin and irinotecan -containing chemotherapy 
colorectal  cancer; and (if appropriate) EGFR -targeted and/or VEGF -targeted systemic 
therapy.  These drugs may have been administered in the neoadjuvant, adjuvant, 
locally advanced or metastatic setting.   (“Systemic therapy” includes all agents, 
including cytotoxic, molecularly targeted or other).  Substitution within a class of 
anti-cancer therapy (e.g., capecitabine for 5 -FU) is permitted; otherwise patie nts who 
discontinued therapy for reasons other than progressive disease are still considered to 
have received a  prior line of therapy.  
d. Must not have received any prior immuno -oncology regimens, including, but not 
limited to, checkpoint inhibitors such as a nti-PD-1, anti-PD-L1, anti-PD-L2, 
anti-CD137, or anti -CTLA-4 antibody, or any other antibody or drug specifically  
targeting T  cell co-stimulation or checkpoint pathways, indoleamine 2,3 -dioxygenase 
pathway inhibitors, cancer vaccines, adoptive cell therapi es, or other cytokine 
therapies.  
 Cohort 9 –Small Cell Lung Cancer ( 2L, I-O therapy naive)  
a. Patients must have diagnosis of limited-stage or extensive -stage SCLC.   
b. Patients must have received no more than 1 prior line of platinum -based therapy.  
Substitutio n within a class of anti -cancer therapy (e.g., carboplatin for cisplatin) is 
permitted; ot herwise patients who discontinued therapy for reasons other than 
progressive disease are still considered to have received a  prior line of therapy.    
c. Must not have re ceived any prior immun o-oncology regimens, including , but not limited 
to, checkpoint inhib itors such as anti -PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or 
anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T  cell 
co-stimulation or ch eckpoint pathways, indoleamine 2,3 -dioxygenase pathway 
inhibitors, cancer vaccines, adopti ve cell therapies, or other cytokine therapies.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 76 of 178 
Confidential and Proprietary   11 February 2020  For Parts 3 and 4 (NKTR -214/nivolumab/ipilimumab)  
Under Amendment 7, the study is closed to patient screening and enro llment. 
For Disease -Specific Tumor Types  
 Cohorts 10a.1 and 10a.3 − Renal Cell Carcinoma (1 L), as follows:  
• Cohort 10a.1: concurrent dosing schedule 1 (this cohort was closed to enrollment  
under Amendment 6.0 ) 
• Cohort 10a.3: concurrent dosing schedule 3  
a. Advanced (not amenable to curative surgery or radiation therapy) or metastatic (AJCC 
stage IV) RCC.  
b. Histologically confirmed RCC with a clear -cell component.  
c. Patients must not have received prior anti -cancer therapy for advanced or metastatic 
RCC. 
d. Prior to dise ase metastasis, patients must not have received neoadjuvant or adjuvant 
therapy with any immuno -oncology regimens, including, but not limited to, checkpoint 
inhibitors such as anti -PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti -cytotoxic 
T-lymphocyte an tigen 4 (anti-CTLA-4) antibody, or any other antibody or drug 
specifically targe ting T cell co-stimulation or checkpoint pathways, indoleamine 
2,3-dioxygenase pathway inhibitors, cancer vaccines, adoptive cell therapies, or other 
cytokine therapies.  
 Cohort  11a.1 − Non -Small Cell Lung Cancer (1L)  
a. Histologically confirmed or cytologically confirmed diagnosis of stage IV NSCLC  
b. Patients with nonsquamous NSCLC must lack both epidermal growth factor receptor 
(EGFR)-sensitizing mutation /deletion and anaplastic ly mphoma kinase (ALK) 
translocation by loca l testing (assessment of ROS1 mutation status is not required) .  
For ALK or EGFR testing, an FDA -approved test or validated assay should be used as 
applicable for selection of patients.  For patients with squamous N SCLC, testing for 
EGFR and ALK is not req uired. 
c. Patients must not have received prior anti -cancer therapy for advanced or metastatic 
NSCLC.   
d. Patients must not have received neoadjuvant or adjuvant therapy with any immuno-
oncology regimens.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 77 of 178 
Confidential and Proprietary   11 February 2020  
 Cohorts 12a.2 a nd 12a.3 − Melanoma (1L), as follows:  
• Cohort 12a.2:  concurrent dosing schedule 2  
• Cohort 12a.3:  concurrent dosing schedule 3  
a. Histologically confirmed stage  III (unresectable) or stage  IV melanoma , as per 
American Joint Committee on Cancer (AJCC) staging s ystem. 
b. Patients must consent to BRAF test ing or have documented BRAF status as per 
regionally acceptable V600 mutational status testing.  
c. Uveal melanoma will be excluded.  
d. Have not received prior anti -cancer therapy for advanced or metastatic melanoma.  
e. Prior to disease metastasis, patients must not  have received neoadjuvant or adjuvant 
therapy with any immuno -oncology regimens, including, but not limited to, checkpoint 
inhibitors such as anti -PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti -cytotoxic 
T-lymphocyte antigen  4 (anti-CTLA-4) antibody, o r any other antibody or drug 
specifically targeting T  cell co-stimulation or checkpoint pathways, indoleamine 
2,3-dioxygenase pathway inhibitors, cancer vaccines, adoptive cell therapies, or other 
cytokine therapies . 
f. Prior to disease metastasis, patients m ust not have  received neoadjuvant or adjuvant 
tyrosine kinase (BRAF, MEK, mTOR), bevacizumab or intralesional therapy .   
 Cohort 13a.2 – Urothelial Carcinoma (1L)  
a. Histologically or cytologically documented locally ad vanced or transitional cell 
carcinoma of the urothelium including renal pelvis, ureters, urinary bladder, or urethra.  
Patients with mixed histologies are required to have a dominant transitional cell 
pattern. 
b. Treatment naive patients who refuse chemothera py standard of care or treatment naive, 
cisplatin-ineligible patients who meet at least one of the following criteria:  
• Creatinine clearance (calculated or measured) < 60 mL/min.  Cisplatin-ineligible 
patients must have a creatinine clearance <  60 mL/min and  GFR ≥ 30 mL/min.  
• Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade ≥  2 
audiometric hearing loss  
• CTCAE v4.03 Grade ≥  2 peripheral neuropathy  
c. No prior chemotherapy for inoperable locally advanced or metastatic urothelial 
carcinoma.  Prior local intravesical chemoth erapy is allowed if completed at least 
4 weeks prior to the initiation of study treatment.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 78 of 178 
Confidential and Proprietary   11 February 2020  d. For patients who received prior adjuvant/neoadjuvant chemotherapy or 
chemo-radiation for urothelial carcinoma, a treatment -free interval of  more than 
12 months betwe en the last treatment administration and the date of recurrence is 
required to be considered treatment naive in the metastatic setting.  Patients must not 
have received neoadjuvant or adjuvant therapy with any immuno -oncology regi mens.   
4.2 Exclusion Criteria  
Under Amendment 7, the study is closed to patient screening and enrollment.  
A patient will be excluded from this study if he/she meets any of the following criteria:  
 Use of an investigational agent or an investigational device wi thin 28 days before 
administration of first dose of study drug  
 Females who are pregnant or breastfeeding  
 Patients who have  an active, known or suspected autoimmune disease .  Patients  requiring 
systemic treatment within the past 3  months or a documented his tory of clinically s evere 
autoimmune disease that  requires systemic steroids or immunosuppressive  agents.  
(Exceptions include any patient on 10 mg or less of prednisone or equivalent, patients with 
vitiligo, hypothyroidism stable on hormone replacement, T ype I diabetes, Grav es’ disease, 
Hashimoto's disease, alopecia areata, eczema, or with Medical Monitor approval.)  
 History of allergy or hypersensitivity to study drug components  
 Has a known additional malignancy that is progressing or requires active treat ment. 
Exceptions inc lude basal cell carcinoma of the skin , squamous cell carcinoma of the skin that 
has undergone potentially  curative therapy, or in situ cervical cancer.  An incidental finding 
of prostate cancer (identified upon resection of the prostate ) is acceptable, provided that the 
following criteria are met: Stage T2N0M0 or lower; Gleason score ≤  6, and prostate -specific 
antigen (PSA) below lower limit of normal by local laboratory.  
 History of organ or tissue transplant that requires systemic use of imm une suppressive agents  
 Evidence of clinically significant interstitial lung disease or active, noninfectious 
pneumonitis  
 Prior surgery or radiotherapy within 14  days of therapy.  Patients must have recovered from 
all radiation -related toxicities, and not r equire corticosteroids.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 79 of 178 
Confidential and Proprietary   11 February 2020  
 Patients who have had <  28 days since the last chemotherapy, biological therapy, or 
< 14 days from approved tyrosine kinase inhibitor (TKI) therapy (sunitinib, sorafenib, 
vemurafenib, dabrafenib, cobimetinib, erlotinib, gefitinib, afatinib, osimertinib), <  14 days 
from last dose of hormonal therapy (for patients with breast cancer) or systemic or inhaled 
steroid therapy at doses greater than 10  mg of prednisone or equivalent before administration 
of the first dose of study drug.  
 Parts 1 and 2: Patients in whom prior anti PD -1 / anti-PD-L1 therapy was intolerable and 
required discontinuation of treatment; Parts 3 and 4: Patients in whom prior anti PD -1 / 
anti-PD-L1 therapy and/or prior CTLA -4 therapy was intolerable and required 
discontinuation of treatment; patients who have discontinued prior checkpoint inhibitor 
therapy due to adrenal insufficiency that is now managed by replacement steroid therapy may 
be eligible for the trial upon Medical Monitor approval.  
 NSCLC patients who requi re supplemental oxygen  
 Uveal melanoma is excluded.  
 Active infection requiring systemic therapy  
 Has known hepatitis  B virus (HBV) infection (e.g., hepatitis B surface antigen [HBsAg] 
reactive) or hepatitis  C virus (HCV) infection (e.g., HCV ribonucleic acid  [RNA] qualitative 
is detected)  
 Has known immunodeficiency or active human immunodeficiency virus (HIV -1/2 
antibodies)  
 Prolonged Fridericia’s corrected QT interval  (QTcF) >  450 ms for men and >  470 ms for 
women at Screening  
 History of  unstable or deteriora ting cardiac disease  or cerebrovascular disease  within the 
previous 2 years prior to screening  including, but not limited to, the following:  
a. Unstable angina or myocardial infarction  
b. Congestive heart failure (New York Heart Association [NYHA] Class  III or IV) 
c. Uncontrolled clinically significant arrhythmias  
d. Prior cerebrovascular  accident or transient ischemic attack . 
 Need for >  2 antihypertensive medications for management of hypertension (including 
diuretics) 
 Known current drug or alcohol abuse  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 80 of 178 
Confidential and Proprietary   11 February 2020  
 Any condition  including medical, emotional, psychiatric, or logistical that, in the opinion of 
the Investigator, would preclude the patient from adhering to the protocol or would increase 
the risk associated with study participation or study drug adm inistration or interfere with the 
interpretation of safety results (e.g.,  a condition associated with diarrhea or acute 
diverticulitis).  
For sites located in France only  
 Vulnerable populations described in Article L. 1121 -6 of the French Public Health Code  
 Legally p rotected majors or majors who are unable to express their consent as described in 
Article L. 1121 -8 of the French Public Health Code  
For sites located in Italy only  
 Patients may not be enrolled if they have first -line urothelial cancer with cisplatin -eligible 
disease (Cohort  4a and Cohort  13a.2). 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 81 of 178 
Confidential and Proprietary   11 February 2020  5.0 TREATMENT PLAN  
5.1 Overview  
This is a Phase 1/2, open-label, multicenter study of NKTR -214 in combination with nivolumab 
or in combination with nivolumab and other anti -cancer therapies in patients with locally 
advanced or meta static melanoma, RCC, NSCLC, urothelial carcinoma, triple -negative breast 
cancer (TNBC), hormone -receptor-positive breast cancer, gastric, colorectal , or SCLC.  The 
study is divided into a Screening period, Treatment period, End of Treatment perio d, and 
Long-Term Follow -up period.  
The NKTR -214 treatment period of the study is divided into a 21 -day (q3w) cycle with 
associated evaluations and procedures.  Treatment cycle is defined by the frequency of 
NKTR-214 administration (see Table 7). 
Results of the assessments must be reviewed and documented before administering the first dose 
of the next cycle.  Every effort should be made to schedule visits within the protocol -specified 
windows.  NKTR -214 treatment period may b e evaluated at different frequencies based on safety 
and biomarker data collected in an ongoing NKTR -214 monotherapy clinical trial 
([STUDY_ID_REMOVED]).  
The study will be cond ucted in 4  parts:  Part  1, Dose Escalation, Part  2, Dose Expansion  
(Figure 1), Part 3 (Schedule Finding for Triplet), and Part 4 (Dose Expansion of Tr iplet)  
(Figure 2).  The sponsor will notify sites when individual cohorts are open for screening and 
when screening is closed.  Certain cohorts may on ly open at select participating sites.  
If multiple cohorts in the same tumor type are open for enrollment, the sponsor will assign the 
appropriate cohort (whether this is a Part  2 NKTR-214/nivolumab doublet cohort  [with or 
without other anti -cancer therapi es] or one of the dosing schedules investigating the 
NKTR-214/nivolumab/ipilimumab triplet in Parts  3 and 4). 
All procedures are outlined in the Schedule of Events (Section  1.2). 
5.2 Screening Period  
Patients will provide written informed consent to participate in the study before completing any 
protocol-specified procedures or evaluations not considered to be part of the patient’s standard 
care.  For those cohorts that requ ire assessment of PD -L1 or tumor in filtrating lymphocytes 
(TILs) by immunohistochemistry as part of screening procedures, an abbreviated  informed 
consent that only permits assessment of PD -L1 status by the central laboratory may be used.  If 
eligible, a pa tient must sign the full study info rmed consent before any other screening 
procedures may proceed.  After signing the ICF, patients will be evaluated for entry criteria 
during the Screening period within 28  days before administration of study drug(s).  Rescreening 
after screen failure will be allowed.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 82 of 178 
Confidential and Proprietary   11 February 2020  For melanoma patients whose BRAF mutation status is unknown, the patient must have 
submitted sample(s) for BRAF status testing prior to the first administration of study drugs.  
5.3 Treatment Period  
Patients will b e treated until disease progression , death, unacceptable toxicity, symptomatic 
deterioration, achievement of maximal response, the Investigator’s decision to discontinue 
treatment, the patient decides to discontinue treatment or withdraw consent, lost to f ollow up, or 
Nektar Therapeutics de cides to terminate the trial.  
Patients with progressive disease (PD) per RECIST  1.1 but with otherwise stable or improved 
performance and clinical status may continue to be treated in the event of a perceived benefit per 
Investigator; see Section  5.3.9 for treatment beyond progression.  Patients with a PR or stable 
disease (SD) will continue to receive NKTR -214 combination until achievement of a confi rmed 
CR, disease progression , or intolerability to therapy.  It is at the discretion of the Investigator to 
continue treating patients with a confirmed CR, for a maximum treatment of 2 years.  
5.3.1 Administration of Study Drug  
Each patient’s NKTR-214 dose will b e determined by the NKTR -214 dose escalation scheme 
and the patient’s weight in kilograms.  The patient’s weight in kilograms will be determined 
before the start of each 3 -week cycle.  If the patient’s weight is within 10% of the Cycle  1 Day 1 
weight, the study drug doses do not need  to be recalculated depending on institutional 
guidelines/preference.  If the patient’s weight has changed more than 10% from the Cycle 1 
Day 1 weight, the dose of NKTR -214 must be recalculated and subsequent weight measurements  
should be compared with thi s new baseline weight to determine if further NKTR -214 dose 
recalculations are necessary.    
When administered on the same day, NKTR -214 will be administered first before nivolumab, 
ipilimumab, or other anti -cancer therapy . NKTR-214 will be administered IV over 
30 (± 5) minutes at a starting dose of 0.006  mg/kg every 3 weeks (±  3 days).  Patients should be 
carefully monitored for infusion reactions during NKTR -214 administration.  If an acute infusion 
reaction is noted, patients should be managed according t o Section  5.15.  
Nivolumab administration should start at least 30 minutes from the end of NKTR -214 
administrat ion.  It is highly recommended that ipilimumab  administration should start within 
30 minutes after co mpletion of nivolumab administration.    
The ipilimumab  infusion is set at 30 minutes for both the 1  mg/kg and 3  mg/kg doses.  The safety 
of this shortened infusion time was investigated and demonstrated to show an acceptable 
tolerability profile  (Momtaz, 2015 and Gassenmaier,  2018; also see Section  2.1.8).   
Institutional guidelines for administration of other anti -cancer therapies should be follo wed in 
Part 2. 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 83 of 178 
Confidential and Proprietary   11 February 2020  • NKTR-214 administered IV over 30  (± 5) minutes at a starting dose of  0.006 mg/kg q3w  
• Nivolumab (anti -PD-1) administered IV over 30  (± 5) minutes at either a 360  mg flat dose 
q3w (Parts  2, 3, and 4); 1  mg/kg q3w ×  4 doses or 3  mg/kg q3w ×  4 doses (Parts  3 and 4) 
• Parts 3 and 4:  Ipilimumab (anti -CTLA-4) administered IV over 30 (±  5) minutes at 1  mg/kg 
q6w, 1 mg/kg q3w × 4 doses or 3 mg/kg q3w  × 4 doses (Parts  3 and 4) 
• Part 2: Cohort 3d.1 (NSCLC): NKTR -214 followed by nivolumab (q3w) followed by  
investigator’s choi ce of cisplatin 75  mg/m2 administered IV or carboplatin AUC  5 with 
pemetrexed 500  mg/m2 q3w by IV administration for 4  cycles followed by maintenance 
NKTR-214, nivolumab, and pemetrexed  
• Part 2: Cohort 3d.2 (NSCLC): NKTR -214 followed by nivolumab (q3w) followed by 
investigator’s choice of cisplatin 75  mg/m2 administered IV or carboplatin AUC  5 with 
pemetrexed 500  mg/m2 q3w by IV administration for 4  cycles followed by maintenance 
NKTR-214 and nivolumab (see Section  5.13.12 for treatment discontinuation criteria of 
maintenance NKTR -214 and nivolumab).  
• Part 2: Cohort 3e (NSCLC):  NKTR -214 followed by nivolumab (q3w) followed by either 
Cremophor -based paclitaxel 200 mg/m2 on Day 1 of each 21 -day cycle or nab -paclitaxel 
100 mg/m2 by IV infusion on Days  1, 8, and 15 of each 21 -day cycle for 4  cycles with either 
carboplatin AUC  6 administered IV on cycle Day  1 q3w for 4  cycles or cisplatin 75  mg/m2 
q3w for 4 cycles followed by maintenance NKTR -214 and nivolumab (see Section 5.13.12 
for treatment discontinuati on criteria of maintenance NKTR -214 and ni volumab).  
• Part 2: Cohort 5b (TNBC): NKTR -214 followed by nivolumab (q3w) followed by 
nab-paclitaxel 260  mg/m2 q3w by IV administration  
• Part 2: Cohort 5c (TNBC): NKTR -214 followed by nivolumab (q3w) followed by eribulin 
mesylate 1.4  mg/m2 (equivalent to eri bulin 1.23  mg/m2) by IV administration on Days  1 
and 8 q3w; dose modification based on liver function tests sho uld be made as outlined in the 
Package Insert or Summary of Product Characteristics.  
5.3.2 Part 1:  Dose Escalation  
Dose escalation is described in Table 5 and will be carried out as listed in Table 6. 
The first NKTR-214 dose to be studied wa s determined based on a monotherapy trial with 
NKTR-214 (i.e., 0.006 mg/kg q3w).  Once a dose escalation cohort has been evaluated for safety 
by a Safety Review Committee, which includes the Sponsor Medical Monitor and 1  site 
Investigator, the Sponsor may choose to concurrently enroll patients and dose NKTR -214 at 
lower dose levels and different dose schedules to assess the benefit/risk profile within the 
anticipated 50  patients.  The sponsor may also evaluate other doses and dose schedules based on 
the safety findings from ongoing clinical trials.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 84 of 178 
Confidential and Proprietary   11 February 2020  For dose escalation cohorts, the Sponsor and at least one Investigator will jointly decide the 
following:  
• Dose escalation to the next cohort and/or dose schedule  
• RP2D 
• Dose levels of NKTR -214 for a given cohort may  be reduced depending on the severity, 
duration, and frequency of toxicities observed at the previous dose level tested  
• Decision to evaluate NKTR -214 in combination with nivolumab in addition al patients at 
lower doses and different dose schedules to assess  the benefit/risk profile within the 
anticipated total number of 50  patients 
Table  5: Part 1:  Dose Escalation Scheme  
Cohort  NKTR -214 Nivolumab q2w  Nivolumab q3w  
1 0.006 mg/kg q3w  240 mg  
2 0.006 mg/kg q3w   360 mg 
3 0.006 mg/kg q2w  240 mg  
4 0.009 mg/kg q3w   360 mg 
 
Table  6: Part 1:  Dose Escalation Guide  
Number of Patient s with DLT at a 
Given Dose Level  Dose Escalation Decision Guide  
0 out of 3 Enter 3 patients at the next higher dose level. 
1 out of 3  Enter at least 3 more patients at this dose level.  If 0 of these additional 
3 patients experience a DLT, will proceed to the next dose level.  If 1 or 
more of this group suffers a DLT, the n the dose escalation is stopped, and 
this dose is declared the maximally administered dose (MAD).  Three 
additional patients will be entered at a lower dose level if only 3 patients 
were treated previously at that dose.  
≥ 2 Dose escalation will be stopped.  This dose level will be declared the MAD 
(highest dose administered).  Three additional patients will be entered at a 
lower dose level if only 3 patients were treated previously at that dose.  
≤ 1 out of 6 at highest d ose level 
below the MAD  This is the MTD.  Depending on toxicity, PK and/or phar macodynamic 
markers, this may also be the RP2D.  At least 6 patients must be entered at 
the recommended dose for Phase 2.  
Abbreviations:  DLT = dose -limiting toxicity; MAD  = maximally administered dose; MTD = maximum tolerated 
dose; PK = pharmacokinetics;  RP2D = recommended Phase 2 dose  
 
The dose-limiting toxicity (DLT) evaluation period for the combinations will be a minimum of 
3 weeks (21  days).  For example, for q2w dosing th e DLT window is 2  cycles (28  days), for q3w 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 85 of 178 
Confidential and Proprietary   11 February 2020  dosing the DLT window is 1  cycle (21 days), and for q4w dosing the DLT window is 1  cycle 
(28 days) (Table 7).  Any DLT past the DLT window is a delayed DLT.  
Table  7: Part  1:  Treatment Cycle Duration and DLT Window  
Dosing Schedule  
of NKTR -214 Cycle Definition  DLT Window  
q2w 14 days 28 days 
q3w 21 days 21 days 
q4w 28 days 28 days 
Abbreviations:  DLT = dose -limiting toxicity; q2w = every 2 weeks; q3w = every 3 weeks; q4w  = every 4 weeks  
 
Patients will be enrolled in groups of at least 3  patients in each cohort for the dose escalation 
cohorts unless unacceptable toxicity is observed.  The first patient of each escalating dose cohort 
will be monitored for safety and tolerability on Cycle  1, Days 1 through  5 before additional 
patients are dosed within the same cohort .  Enrollment into a new cohort with an escalating dose 
of NKTR -214 cannot begin until the DLT window has elapsed since the last patient’s first dose 
in the previous cohort.  
The definition of a DLT is provided in Section  5.11.  If no DLTs occur in a cohort of at least 
3 patients, a new coho rt of 3 patients may be treated at the next higher dose le vel (Table 6).  If 
only 1 of 3 patients in a cohort experiences a DLT, that cohort will be expanded to 6  patients.  If 
3 patients have already been enrolled into a cohort and additional patients have signed the ICF  
and are undergoing the screening process, they may be enrolled to the cohort with Sponsor 
approval; however, these patients are not required to be included in the dose escalation decision 
for that cohort.  If only 1  of the 6 patients experiences a DLT, th en the next cohort of 3  patients 
may be treated at the next higher dose level.  If 2  or more patients within a cohort experience 
DLTs, then that dose level will be above the MTD (the highest dose tested where no more than 
1 of 6 patients has experienced a DLT), and new patients will be enrolled at the previous lower 
(tolerated) dose level until that cohort has 6  patients.  Moreover, the  cohort Safety Review 
Committee or Sponsor may determine that inadequate information has been obtained in a cohort 
of 3 patients and to further understand the benefit/risk profile at a given dose level, additional 
patients may be enrolled.  
All drug-related AEs after the DLT window will continue to be collected and evaluated by the 
Investigators and the Sponsor on an ongoing ba sis and may be taken into consideration in 
determining the MTD and/or RP2D.  During dose escalation, patients who are withdrawn from 
the study during the DLT window for reasons other than occurrence of a DLT will be replaced.  
Additional cohorts of up to 12  patients may be enrolled at doses deemed to be safe to more fully 
explore the safety, tolerability, pharmacokinetics, biomarker asse ssments, and preliminary 
efficacy of the NKTR -214 dose in combination with nivolumab.  It is estimated that 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 86 of 178 
Confidential and Proprietary   11 February 2020  approximately 5 0 patients will be enrolled into the dose escalation phase of the study.  If 
additional cohorts are enrolled, the sample size will in crease accordingly.  
At least 1  study Investigator and the Sponsor Medical Monitor will meet and decide the RP2D 
regimen to be studied in Part  2 before the initiation of Part  2.  The RP2D may be determined 
based on the MTD dose or a dose lower than MTD.  Th e RP2D may also be determined based on 
a biological effect of the study drugs as determined by anti -tumor activity and immu ne 
activation.  The Sponsor will amend the protocol to include the RP2D and will also communicate 
the RP2D via an administrative dosi ng letter to allow enrollment to begin, where permitted, 
before the protocol amendment is finalized . 
5.3.3 Rationale for Recommen ded Phase 2 Dose for Part 2  
Two data analyses of patients receiving NKTR -214 and nivolumab in Study 16 -214-02 are 
provided in this section; the rationale for the recommended Phase  2 dose for Part  2 based on a 
data cut of October  05, 2017 is provided below and Section 5.3.3.1 provides u pdated safety and 
efficacy data as of February 8, 2018.  
The safety of NKTR -214 as a single agent has been assessed in 5 monotherapy  cohorts 
administered NKTR -214 q3w (22  patients) a t doses ranging from 0.003 mg/kg to 0.012 mg/kg; a 
dosing frequency of q2w (6 patients) was further explored at 0.006  mg/kg (Table 8 and see 
Clinical Experience with NKTR -214 in Section  2.1.4).  The safety of NKTR -214 in combination 
with nivolumab at doses shown in Table 8 has been assessed in 38  patients. 
Table  8: Patient Exposure Supporting the RP2D  
 NKTR -214 
Dosing 
Frequency  Nivolumab  
(Flat Dosea) 
Dosing 
Frequency  NKTR -214 
Dose (mg/kg)  No. Patients 
Examined for 
Safety  Positive Biomarker Data 
and/or Evidence of 
Clinical Activity?  
NKTR-214 
Monotherapy  q3w n/a 0.003, 0.006, 
0.009, 0.012  22 Yes 
q2w n/a 0.006 6 Yes 
NKTR-214+ 
Nivolumab  q3w q2w 0.006 4 Yes 
q2w 0.006 3 Yes 
q3w 0.006 25 Yes 
q2w 0.003 3 Yes 
q3w 0.009 3 Yes 
Abbreviations:  q2w = every 2 weeks; q3w = every 3 weeks; n/a = not applicable.  
a. Nivolumab q2w = 240 mg, q3w = 360 mg.  
 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 87 of 178 
Confidential and Proprietary   11 February 2020  The Safety R eview Committee reviewed the totality of data and concluded the following for all 
5 combination dose cohorts with a data cut of October 05, 2017:  
• Two patients at the NKTR -214 0.009 mg/kg q3w + nivolumab 360 mg q3w dose level 
experienced dose limiting toxic ities: Grade 3 hypotension and Grade 4 metabolic acidosis, 
each of which resolved within 5 days and the patients continued on treatment at a lower dose 
of NKTR -214. 
• There were no Grade ≥  3 treatment -related adverse events (TRAEs) at NKTR -214 
0.006 mg/kg q3w + nivolumab 360 mg q3w: the recommended Phase 2 dose.  
• TRAEs that occurred in ≥  50% of the patients included fatigue, flu -like symptoms (combined 
MedDRA preferred t erms of influenza -like illness, pyrexia, and chills), rash (combined 
MedDRA p referred terms of rash, rash erythematous, rash macular, rash maculopapular, and 
rash pruritic), and pruritus.  
• TRAEs were consistent across all five dose cohorts.  
• Management guide lines implemented in the combination program for hypotension were 
effective t o mitigate the risk for Grade ≥  3 hypotension.  
• No Grade ≥  3 immune -mediated AEs were observed.  
• Cytokine-related AEs such as fever, chills, pruritus, fatigue, and rash are predicta ble based 
on the mechanism of action and were generally of mild severity and short duration.  
• The addition of NKTR -214 did not exacerbate nivolumab -related AEs that are commonly 
classified as immune -mediated AEs.  
• NKTR-214 alone or in combination with nivolu mab did not produce capillary leak 
syndrome, which is commonly observed in pa tients treated with high -dose IL-2. 
Tumor response data were available as of October 05, 2017 for 34 patients, including 10 with 
metastatic melanoma, 19 with renal cell carcinoma (RCC), and 5  with non-small cell lung cancer 
(NSCLC).  Of these 34 response -evaluable patients, 21 were treated at 0.006  mg/kg NKTR -214 
with nivolumab 360  mg flat dose q3w; 17 patients had partial or complete responses and 13 had 
stable disease.  Given the  totality of data, including safety/tolerability, reproducible PK, dose -
independent PD profile, immune cell activation, and promising efficacy data (see Clinical 
Experience with NKTR -214 in Section  2.1.4), the Safety Review C ommittee approved 
NKTR-214 0.006  mg/kg q3w plus nivolumab 360  mg q3w as the recommended dose to be 
administered in the expansion cohorts included in Part  2 of the study.  
Additional dosing schedules may be explored during the expansion phase.  Any change to  the 
recommended dose or frequency (either of NKTR -214 or nivolumab) will require endorsement 
by the Safety Review Committee, prior written approval by ethics committees, and notification 
to/approval by regulatory authorities in accordance wi th regulatory requirements.  Where 
permitted this notification may be in the form of an administrative letter followed by a formal 
protocol amendment (see Section  11.1 on Changes to the Protocol).  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 88 of 178 
Confidential and Proprietary   11 February 2020  5.3.3.1  Update of Safe ty and Efficacy Data  for Protocol Amendment 6 (dated 
18 June  2018)  
As of February 8, 2018, a total of 130 patients have received NKTR -214 in combination with 
nivolumab for various tumor types in this study.   Of the 130  patients, 38  were in the dose 
escalation part of the study and 92  in the dose expansion part.  A total of 117  patients have 
received the RP2D (NKTR -214 0.006 mg/kg q3w with nivolumab 360  mg q3w) in the dose 
escalation phase (25  patients) and t he dose expansion phase (92  patients). 
The majorit y of treatment -emergent AEs (TEAEs) were mild in severity, and the most common 
treatment -related AEs were Grade 1 or 2 flu -like symptoms (in 70.8% of patients), Grade  1 
or 2 fatigue (47.7%), and Grade 1 or 2 rash (42.3%).  Overall, 14 patients (10.8%) expe rienced 
treatment -related AEs of Grade 3 or 4 severity, the most common being syncope in 3  patients 
(2.5%).  No patient discontinued study treatment due to treatment -related AEs and there were no 
treatment -related deaths.  
Two patients at the NKTR -214 0.009  mg/kg q3w + nivolumab 360 mg q3w dose level 
experienced dose limiting toxicities: Grade 3 hypotension and Grade 4 metabolic acidosis, each 
of which resolved within 5 days and the patients continued on trea tment at a lower dose of 
NKTR-214. 
Five patients i n the dose escalation phase had a total of 7 SAEs that were considered possibly 
related or related to NKTR -214 or nivolumab, or both, and 9 patients in the dose expansion 
phase had a total of 12 SAEs that w ere considered possibly related or related to NKTR -214 or 
nivolumab, or both.  The individual SAEs were as follows:  
• related to NKTR -214 only:  Grade 1 face edema, Grade 2 headache, Grade 2 and Grade  3 
pyrexia (2 patients), Grade 3 lung infection (empyema),  and Grade 3 rash erythematous  
• related to nivoluma b only:  Grade 1 autoimmune hepatitis, Grade  2 hypophysitis, and 
Grade 2 hypothyroidism  
• related to NKTR -214 and nivolumab:  Grade 1 pyrexia, Grade 2 autoimmune 
hypothyroidism, Grade 3 hypotension, Grade 3 h yperthyroidism, Grade 3 syncope, Grade  3 
rash, Grade 3 dehydration, Grade 3 pain, Grade 3 hyponatremia, and Grade  4 acidosis.  
Tumor response data were available for the 24 patients who received the RP2D in the dose 
escalation phase, including 7 with metastatic melanoma, 14 with renal cell carcinoma (RCC),  
and 3 with NSCLC ( Table 9).  Of these 24 response -evaluable patients, 15  patients (62.5 %) had 
partial or complete responses and 5 (20.8%) had stable disease.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 89 of 178 
Confidential and Proprietary   11 February 2020  Table 9: 16-214-02: Overall Inv estigator -Assessed Tumor Response for 
Patients Treated at the NKTR -214 Recommended Phase  2 Dose and 
Nivolumab 360 mg q3w in the Do se Escalation Study Phase  
 1L RCC - Esc 
(N=11)  2L RCC - Esc 
(N=4)  Melanoma - Esc 
(N=7)  NSCLC - Esc 
(N=3)  All 
(N=25)  
Efficacy Evaluable 
Populationa - RECIST 
1.1, n (%)  11 3 7 3 24 
  ORR (CR+PR)  7 (63.6%)  0 6 (85.7%)  2 (66.7%)  15 (62.5%)  
    95% CI of ORR 30.8%, 89.1%  0%, 60.2%  42.1%, 99.6%  9.4%, 99.2%  40.6%, 81.2%  
    CR 0 0 1 (14.3%)  1 (33.3%)  2 (8.3%) 
  PR 7 (63.6%)  0 5 (71.4%) 1 (33.3%)  13 (54.2%)  
  SD 1 (9.1%) 3 (100.0%)  1 (14.3%)  0 5 (20.8%)  
  DCR (CR+PR+SD)  8 (72.7%)  3 (100.0%)  7 (100.0%) 2 (66.7%)  20 (83.3%)  
  PD 3 (27.3%)  0 0 1 (33.3%)  4 (16.7%)  
CR = complete response; DCR  = disease control rate; Esc  =patient as pa rt of dose escalation study phase; ND  = not 
done. PD = progressive disease; PR  = partial response; SD = stable disease; RCC  = renal cell carcinoma; 
RECIST = Response Evaluation Criteria in Solid Tumors  
a. Number of patients with baseline and at least one post -baseline tumor assessment.  
Source: Tables 14.2.1.2 and 14.2.2.2; Database: 07Feb2018; Created: 12Mar2018  
 
5.3.4 Part 2:  Dose Expansion  
All procedures are outlined in the Schedule of Events (Section  1.2).  Enrollment  into a dose 
expansion cohort will commence once the RP2D is established and communicated to sites. 
Approximately 936 patients will be enrolled ( Table 10).  During dose expansion, patients who 
drop out prior to com pletion of Cycle  1 will not be replaced.  Sponsor may choose not to open or 
complete all expansion cohorts.  
Part 2 is closed to patient screening and enrollment under Amendment 7.0.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 90 of 178 
Confidential and Proprietary   11 February 2020  Table  10: Part 2 Treatment Cohorts ( All Patients Receive NKTR -214 plus 
Nivolumaba) 
Part 2 Cohorts:  All Patients Receive NKTR -214 plus Nivolumaba 
Indication  Cohort Description  
Melanoma  1ab 1L 
1bb 2-3L, anti-PD-1 or anti-PD-L1 relapse/refractory  
1cc 2L, BRAF wild type anti -PD-1 or anti-PD-L1 relapse /refractory  
1dc 1L, following prior adjuvant therapy  
1e Patients enrolled under an earlier protocol version who are no longer eligible for Cohorts 1a 
to 1d 
RCC   2ab 1L 
2bc 2-3L, anti-PD-1 or anti-PD-L1 relapse/refractory  
2c Patients enrolled unde r an earlier protocol version who are no longer eligible for Cohorts 2a 
or 2b 
NSCLC 3a.1f 1L, PD-L1< 1%  
3a.2f 1L, PD-L1 ≥ 1% - < 50%  
3a.3f 1L, PD-L1 ≥ 50% 
3a.4f 1L, PD-L1 status unknown  
3bd 2L, I-O therapy naïve following platinum -based therapy  
3cc 2L-3L, anti-PD-1 or anti-PD-L1 relapse/refractory  
3d.1f 1L, nonsquamous  in combination with platinum/pemetrexed (+  maintenance pemetrexed)  
3d.2f 1L, nonsquamous in combination with platinum/pemetrexed (no  maintenance pemetrexed)  
3ef 1L squamous  in combination with platinum/taxane  
3fe 3L+, ALK-translocation/ROS1 rearrangement positive  
3ge 3L+, EGFR mutation/deletion  
3hf 2L, following platinum -based doublet cytotoxic chemotherapy combined with anti -PD-1 
3i Patients enrolled under an earlie r protocol version who are no longer eligible fo r Cohorts 
3a.1 to 3h  
Urothelial  4ad 1L, cisplatin ineligible  
4ad,g 1L, refused standard of care  
4bc 2-3L, anti-PD-1 or anti-PD-L1 relapse/refractory  
4c Patients enrolled under an earlier protocol versi on who are no longer eligible for Cohorts 4a 
and 4b 
TNBC 5ab 1-2L, I-O therapy na ive 
5bc 1-2L, I-O therapy naive in combination with nab -paclitaxel  
5cc 1-2L, I-O therapy naive in combination with eribulin  
5d Patients enrolled under an earlier protoc ol version who are no longer eligible for Cohorts 5a 
to 5c 
 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 91 of 178 
Confidential and Proprietary   11 February 2020  Table  10: Part 2 Treatment Cohorts ( All Patients Receive NKTR -214 plus 
Nivolumaba) (Cont’d)  
Part 2 Cohorts:  All Patients Receive NKTR -214 plus Nivolumaba 
Indication  Cohort Description  
HR+ HER2 - 
BC 6ac I-O therapy naive following hormonal therapy  
6bc I-O therapy naive following hormonal and cytotoxic therapy  
Gastric 7d 2-3L, I-O therapy na ive 
CRC 8ac 2-3L, I-O therapy naive; MSI -high 
8bc 3-4L, I-O therapy naive; MSI -non-high 
SCLC 9e  2L, I-O therapy na ive 
Abbreviations: CRC  = colorectal carcinoma; HR+  HER2- BC = hormone-receptor positive, HER2 -negative breast 
cancer; I-O = immuno-oncology; MSI  = microsatellite  instability; NSCLC  = non-small cell lung cancer; 
RCC = renal cell carcinoma; RP 2D = recommended Ph ase 2 dose; SCLC = small cell lung cancer; 
TNBC = triple-negative breast cancer  
a. All patients receive the RP2D:  NKTR -214 0.006 mg/kg q3w with nivolumab 360  mg q3w 
b. Cohorts closed under Amendment 5.1.  
c. Cohorts closed with an administrative letter da ted 29 March 201 9. 
d. Cohorts closed under Amendment 6.  
e. Cohorts never opened for screening.  
f. Cohorts closed with an administrative letter dated 22 January 2020 . 
g. For sites located in Italy only:  patients may not be enrolled if th ey have 1L urothelial cancer with 
cisplatin-eligible disease.  
 
5.3.4.1  Other Anti -Cancer Study Drugs Administered in Part 2  
In Part 2, patients in the 4 cohorts described below have additional anti -cancer study drugs 
administered with the RP2D (NKTR -214 0.006 mg/k g q3w with nivolumab 360  mg q3w).  The 
details of the dosing regimens for these cohorts are described below.  For each of these 4  cohorts, 
an initial group of 6  patients should be enrolled and observed for at least 1  cycle before 
additional patients are en rolled into  the cohort.  The Safety Review Committee will review these 
patients before full enrollment will occur (see Section 9.3).  Institutional guidelines for 
administration of other anti -cancer therapies should be followed.  
5.3.4.1.1  Cohorts 3d.1 and 3d.2:  NSCLC (1L nonsquamous)  
Patients receive NKTR -214 followed by nivolumab (q3w) followed by investigator’s choice of 
cisplatin 75  mg/m2 administered IV or carboplatin AUC  5 with pemetr exed 500 mg/m2 q3w by 
IV administration for 4  cycles.  Following the fourth cycle, Cohort  3d.1 will continue to receive 
NKTR-214, nivolumab, and pemetrexed at a dose of 500  mg/m2 q3w as maintenance therapy and 
Cohort 3d.2 will receive NKTR -214 and nivoluma b maintenance, but not pemetrexed.  Patients 
receive premedication with folic acid, vitamin  B12, and glucocorticoids administered according 
to local guidelines for pemetrexed use.  Unless otherwise stipulated at the medical center, the 
following supportive  care should be used:  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 92 of 178 
Confidential and Proprietary   11 February 2020  • Dexamethasone should be admin istered at a dose of 4 mg by mouth twice daily the day 
before, the day of, and the day after pemetrexed administration.   
• At least 5 daily doses of folic acid must be taken during the 7 -day period precedin g the first 
dose of pemetrexed; and dosing should c ontinue during the full course of therapy and for 
21 days after the last dose of pemetrexed.   
• Patients must receive one intramuscular injection of vitamin B 12 (1000 μg) during the week 
preceding the first  dose of pemetrexed and every 3  cycles thereafter.  Subsequent vitamin B 12 
injections may be given the same day as pemetrexed.  
5.3.4.1.2  Cohort 3e:  NSCLC (1L squamous)  
Patients in this cohort will  be treated for a total of  4 cycles of NKTR-214 followed by nivolumab 
(q3w) followed by either Cremophor -based paclitax el 200 mg/m2 on Day 1 of each 21 -day cycle 
or nab-paclitaxel 100  mg/m2 IV on Days  1, 8, and 15 of each 21 -day cycle with investigator’s 
choice of either carboplatin AUC  6 IV on cycle Day 1 q3w for 4 cycles or cisplatin 75  mg/m2 
q3w for 4  cycles.  Following  the fourth cycle, Cohort  3e will continue to receive NKTR -214 and 
nivolumab maintenance. Standard supportive care for infusion -related reactions may be 
administered.  
5.3.4.1.3  Cohort 5 b:  TNBC in Combination with Nab -Paclitaxel  
Patients receive NKTR -214 followed b y nivolumab (q3w) followed by nab -paclitaxel 260  mg/m2 
by IV administration q3w.  Standard supportive care for infusion -related reactions may be 
administered.    
5.3.4.1.4  Cohort 5c:  TNB C in Combination with Eribulin  
Patients receive NKTR -214 followed by nivolumab ( q3w) followed by eribulin mesylate 
1.4 mg/m2 (equivalent to eribulin 1.23  mg/m2) by IV administration on Days  1 and 8 q3w.  Dose 
modification for patients with baseline liver f unction test abnormalities should follow the 
Package Insert or Summary of Produc t Characteristics.  Standa rd supportive care for 
infusion-related reactions may be administered.    
5.3.5 Part 3: Schedule Finding for Triplet (NKTR -214, Nivolumab, and Ipilimumab)  
The safety and tolerability of NKTR -214 in combination with nivolumab and ipilimum ab will be 
evaluated in approximately 36 1L patients with metastatic or advanced RCC, NSCLC, 
melanoma, or urothelial carcinoma.  
Dose schedules and scenarios for triplet therapy  are summarized in Table 11.  The dose-limiting 
toxicity (DLT) evaluation period for the triplet therapy (NKTR -214/nivolumab/ipilimumab) will 
begin with the first dose of ipilimumab and the evaluation period will be a minimum of 3  weeks 
(21 days). 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 94 of 178 
Confidential and Proprietary   11 February 2020  Table  12: Part 3, Cohort A:  Concurrent Dosing Schedules  
Dosing 
Schedules  Indication  Na NKTR -214 q3w  Nivolumab  
q3w Ipilimumab  
q3w or q6w  Maintenance 
Doseb 
q3w 
1 RCCc  
12 0.006 mg/kg 360 mg flat dose  1 mg/kg q6w  n/a 
NSCLCd 
2 Urotheliald  
12 0.006 mg/kg 1 mg/kg × 4 doses 3 mg/kg q3w  × 4 doses NKTR-214 
0.006 mg/kg + 
nivolumab  
360 mg  Melanomad 
3 RCCd 
12 0.006 mg/kg 3 mg/kg × 4 doses 1 mg/kg q3w  × 4 doses 
Melanomad 
a. Enrollment will be up to 12 patients.  
b. NKTR-214 at 0.006 mg/kg and nivolumab at 360  mg will be dosed continuously q3w after the last dose of 
ipilimumab for dosing schedules 2 and 3 following the 4 doses of nivolumab and ipilimumab.  
c. This cohort is a historical cohort for both concurrent and staggered dosing  and was closed to patient enrollment 
under Amendment 6 . 
d. Cohorts closed with an administrative letter dated 22 January 2020 . 
 
The Safety Review Committee will jointly decide the following:  
• Dose and schedule for the next cohort  
• RP2D 
• Dose levels of NKTR -214, for a given dosing schedule, may be reduced depending on the 
severity, duration, and frequency of toxicities observed at the previous dose level tested.  
• Decision for a recommended phase 2 dose schedule will be determined by both safety and 
pharmacolog ical parameters.  
• Decision to evaluate the triplet in additional  patients at lower doses and/or different dose 
schedules within the anticipated 36 patients to better assess the benefit/risk profile  
The Sponsor may choose to concurrently enroll patients at l ower dose levels and/or different 
dose schedules to assess the benefit/risk profile within the anticipated 36 patients.  In Part  3, the 
RP2Ds will be established for each of the 3  dosing schedules (it may be necessary for a separate 
RP2D be established for  patients with me lanoma and urothelial cancers, if the tolerability is 
different between these 2  groups).  When an RP2D is established in Part  3, enrollment for that 
dosing schedule will begin in Part  4.  The sponsor will decide which dosing schedules will  be 
opened in Par t 4. 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 95 of 178 
Confidential and Proprietary   11 February 2020  5.3.6 Part 4:  Dose Expansion of Triplet (NKTR -214 plus Nivolumab plus 
Ipilimumab)  
Enrollment into the dose expansion cohorts will commence once the RP2D for the triplet has 
been established in Part 3 for each respective tumor type.  The ma ximum of patients  in each 
cohort is listed in Table 25 (based on a Historical and Target ORR); the total will include any 
patients from each of the 6  cohorts in Part 3 , thus approximately 106 additional patients may  be 
enrolled into Part 4 (Table 13).  Patients will be enrolled simultaneously to each indication; for 
patients with melanoma, enrollment will occur simultaneously with dose schedule assigned 
alternately based on date of screen ing until one of the respective dosing schedule’s enrollment is 
fulfilled.   
Part 4 is closed to patient screening and enrollment under Amendment 7.0.  
Table 13: Part 4 Indications and Dosing Schedules  
Indication  Cohort  Concurrent Do sing Schedulea 
RCC  10a.1b 1 
10a.3d 3 
NSCLC 11a.1d 1 
Melanoma  12a.2d 2 
12a.3c 3 
Urothelial  13a.2d 2 
a. If staggered dosing is to be tested, matching cohorts will be named as follows:  the letter ‘a’ will be substituted 
with ‘b’ (e.g., for the urothelial indication, concurrent dosing Cohort 13a.2 will be named staggered dosing 
Cohort 13b.2). 
b. This cohort is a historical cohort for both concurrent and staggered dosing and was closed to patient enrollment 
under Amendment 6 . 
c. This cohort was closed with an admi nistrative letter on 29 March 2019.  
d. Cohorts closed  with an administrative letter dated 22 January 2020 . 
 
If multiple cohorts in the same tumor type are open for enrollment, the sponsor will assign the 
appropriate cohort (whether this is a Part  2 NKTR-214/nivolumab doublet cohort [with or 
without other anti -cancer therapies] or one of the dosing schedules investigating the 
NKTR-214/nivolumab/ipilimumab triplet in Parts  3 and 4). 
5.3.7 Monitoring, Vital Signs, and Hydration Guidelines  
The study site must  be equippe d for medical emergencies.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 96 of 178 
Confidential and Proprietary   11 February 2020  5.3.7.1  Frequent Vital Signs  
Refer to Section  7.16 for vital sign measurements.  
For Part 1 Cycle 1 only, monitoring windows will be as follows:  
• Cycle 1 Day 1 (dosing day) monitor predose, and every hour for 3 hours (q1h × 3) 
• Cycle 1 Day 2 monitor every hour for 4 hours (q1h × 4) 
• Cycle 1 Day 3 monitor every hour for 2 hours (q1h × 2) 
For Parts 2, 3, and 4, vital signs should be monitored according to the Appendix  2 Schedule of 
Assessments.   
If the patient experienced a Grade ≥ 2 infusi on-related reaction or hypotension on the dosing day, 
the patient may be monitored overnight at the discretion of the Investigator.  Longer periods of 
monitoring may be implemented at the discretion of the Inves tigator. 
5.3.7.2  Hydration  Guidelines  
Important safet y information and hydration instructions are to be provided to patients.  
Adequate hydration mitigates the development of hypotension  associated with NKTR -214 
administration.  Hydration and renal function must be  assessed within 24 hours, or as soon as 
locally feasible, prior to each study drug administration (see Appendix 1B for the list of analytes 
that require collection and evaluation prior to study drug administration) .  For patients who must 
delay study treatment due to creatinine increase , see additional information regarding criteria to 
delay (Sections 5.13.1 to 5.13.3), resume (Section 5.13.11), or permanently discontinue study 
treatment  (Section 5.13.12).  Underlying reasons for decreased oral intake (e.g., nausea) should 
be addressed and treatment (e.g., IV hydration) should be provided.  The Investigator may 
modify these recommendations based on the needs of the individual patient.  Patients will also be 
provided a handout with hydration guidance.  
Patients should be administered  1 liter of IV fluids on the day of  each dosing of NKTR -214.  For 
the next 3 days (Days 2–4) after NKTR -214 administration, instruct patients to drink at least 
2 liters per day of self -administered oral hydration.   Advise patients to restrain from activity  that 
may contribute to dehydration (including, but not limite d to, strenuous activity, long hot 
showers, and saunas ) for Days 1 to 4 of every cycle of NKTR -214 treatment .  Per clinical 
judgment, IV fluids may be administered in any cycle.  The Investigator may decide to forego 
administering IV fluids to a patient or adjust the recommendation  for self-administered oral 
hydration to a particular patient if this is deeme d in the best interest of the patient (e.g., evidence 
of fluid overload).  Advise participants with orthostatic symptoms to call their treating oncologi st 
and consider increasing  oral hydration.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 97 of 178 
Confidential and Proprietary   11 February 2020  Patients with pre -existing adrenal impairment requiring corticost eroid supplementation may be at 
increased risk for hypotensive episodes during treatment with NKTR -214 (Section 5.13.4). 
Between Days 3 and 5, inc lusive, following administration of the first two doses of NKTR -214 
in Cycles 1 and 2, site personnel must contact the patient (by telephone or clinic visit) to remi nd 
the patient of the oral hydration guidelines, to assess for any symptomatology and compl iance 
with the guidelines, and document the results of the discussion (Section 1.2).  In subsequent 
NKTR-214 administrations in Cycle  3 and beyond, the oral hydration follow -up should be 
conducted as clinically indicated for patients receiving the NKTR -214/nivolumab doublet (with 
or without other anti -cancer therapies) in Part  2; the oral hydration follow -up is mandatory  for 
patients receiving the NKTR -214/nivolumab/ipilimumab triplet in Parts  3 or 4 following st udy 
drug administration in any cycle . 
5.3.7.3  Optional Home Health Visits  
In addition to planned study site visits, vital signs (temperature, pulse, respiration, systolic and 
diastolic blood pressure, and oxygen saturation), concomitant medications, and potential AEs 
may be assessed at a Home Health visit as needed.  The results  of these measurements will be 
provided to the Investigator or designee.  The Investigator will be responsible for assessing any 
AEs and for following up with the patient. 
5.3.8 Duration of Treatm ent 
Patients will be treated until:  
• Disease progression  
• Death 
• Unacceptable toxicity  
• Symptomatic deterioration  
• Achievement of maximal response or up to 2 years of therapy  
• Investigator’s decision to discontinue treatment  
• Patient decision to discontinue treat ment  
• Patient withdraws consent  
• Lost to follow up  
• Nektar Therapeut ics decides to terminate the study  
5.3.9 Treatment Beyond Progression  
Accumulating evidence indicates that a minority of patients with solid tumors treated with 
immunotherapy may derive clinical b enefit despite initial evidence of PD. Patients will be 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 98 of 178 
Confidential and Proprietary   11 February 2020  permitted to continue on treatment beyond initial RECIST 1.1 -defined PD, i ncluding following 
radiotherapy or surgery on a target lesion, as long as they meet the following criteria:  
• Investigator -assessed clinical benefit and without rapid disease progression.  
• Continue to meet all other study protocol eligibility criteria.  
• Patient tolerates study drug(s).  
• Patient has stable ECOG performance status of 0 or 1.  
• Treatment beyond progression will not delay a n imminent intervention to prevent serious 
complications of disease progression (e.g., central nervous system metastases).  
The assessment of clinical benefit should take into account whether the patient is clinically 
deteriorating and unlikely to receive f urther benefit from continued treatment.  All decisions to 
continue treatment beyond initial progression or radiotherapy/surgery o n a target lesion must be 
discussed with the Medical Monitor, and an assessment of the risk/benefit of continuing with 
study drug(s) must be documented in the study records.  The ICF contains language explaining 
treatment beyond progression; should the Inv estigator recommend continuing treatment 
following disease progression, the patient must be re -consented prior to continuing s tudy 
treatment.  
For patients who stay on treatment beyond RECIST 1.1 -defined PD, all study procedures 
(Section 1.2) should be performed continuously, including radiographic assessment by computed 
tomography (CT)  (preferred) or magnetic resonance imaging (MRI) every 8  weeks as described 
in Section 8.2.  Patients will be discontinued from the treatment upon further evidence of disease 
progression, defined as an additiona l 20% or greater increase in the total tumor burden from the 
time of initial disease progressio n, unless otherwise approved by the Medical Monitor.  The total 
tumor burden is calculated as the sum of the longest diameter (SLD) of all target tumors and 
SLD of all new measurable lesions.  A new lesion is measurable if the longest diameter is at least 
10 mm except for pathological lymph nodes, which must have a short axis of at least 15  mm.  
Any new lesions that are non -measurable at the time of initial appear ance and become 
measurable later will be included in the calculation of total tumor burden. 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 99 of 178 
Confidential and Proprietary   11 February 2020  5.4 End of Treatment (EOT)  
Patients may choose to discontinue the trial at any time, for any reason, and without prejudice to 
further treatment.  Patients may discontin ue treatment of all or one of the study drugs based on 
AEs (see Section  5.13 pertaining to Study Drug Discontinuation).  The EOT visit should occur 
30 (+10) days after the last study therapy used in the study is permanently discontinued or be fore 
a new antineoplastic regimen starts , whichever occurs earlier . 
Reasons for EOT are listed below:  
• Disease progression in the absence of clinical benefit as determined by the Investigator.  
• Occurrence of a clinically signif icant AE found to be unacceptab le or non-resolution of a 
clinically significant AE for >  6 weeks. 
• Symptomatic deterioration in the absence of tumor progression per RECIST 1.1.  
• Achievement of maximal response after at least 6  months of dosing with study dru g(s); 
patients may receive a maximum of 2  years therapy under this protocol.  
• Noncompliance of the patient with protocol -mandated procedures based on the judgment and 
agreement of both the Investigator and Sponsor.  
• At the discretion of the Investigator ( continued partici pation is no longer in the patient’s best 
interest in the opinion of the Investigator).  
• If a female patient becomes pregnant, administration of the study drugs must be discontinued 
immediately.  
• Patient’s decision to discontinue treatment.  
• Patient withdraws  consent for the study.  
• Lost to follow -up (defined as after three attempts at contact by phone followed by one 
attempt by sending a certified letter).  
• The study is terminated by the Sponsor.  
In the event of a patient’s withdrawal, the Investi gator will pro mptly notify the Sponsor and 
make every effort to complete the End of Treatment procedures specified in the Schedule of 
Events (Section  1.2). 
A patient may also be withdrawn from investigational pr oduct/study by the Sponsor, Regulatory 
Authorities, or Institutional Review Boards  (IRBs)/ Independent Ethics Committees  (IECs). 
5.4.1 Patients in Cohort 3 d or Cohort 3 e 
Patients enrolled in Cohorts 3 d or 3e who discontinue NKTR -214 and/or nivolumab may remain 
on study and continue to receive the other protocol -defined anticancer therapies.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 100 of 178 
Confidential and Proprietary   11 February 2020  5.5 Long -Term Follow -up 
Long-term follow -up should continue until  withdrawal of consent, death, los t to follow-up, or 
study termination by the Sponsor.  At the long -term follow -up visits, data will be collected 
regarding toxicity, as well as information related to start of new anticancer  therapy and survival .  
See also Section  7.5 and Section 7.8.  Timing for long-term follow -up will be as follows:  
• Long-term follow -up visits should occur every 30  (+ 10) days for 3 visits after the last dose 
of any of the study treatment medication s (whichever is the last to be administered), then 
every 90 ( ± 10) days, or as need ed for data deliverables for survival status, which may be 
captured by telephone contact.   However, if the date of decision to discontinue all study 
drugs is greater than 40 days from the last dose of any study treatment medication , long-term 
follow-up visits should begin from the date of EOT decision .  In addition, a safety follow -up 
visit should take place 100  days after the last administration of nivolumab/ipilimumab; this 
visit may be combined with the 90 -day visit with the window of ± 10 days.  Per clinical 
judgment, the patient may come in earlier.   The long-term follow -up visit and EOT visit may 
occur on the same date. When these two visits occur on the same date, all the requirements of 
the EOT visit and the long -term follow -up visits should be fulfi lled. 
• All patients will be c ontacted for survival and information about initiation of  new anticancer  
therapy every 3 months. Survival follow up should continue until patien t withdrawal of 
consent for survival follow up, death, loss to follow -up, or study t ermination by the Sponsor . 
• For patients who do not discontinue study drug treatment for progression of disease by 
RECIST v 1.1 or withdrawal of consent, radiographic tumor assessments will  occur every 
90 (± 10) days and continue to be collected until disea se progression, patient withdraws 
consent, death, initiation of a new systemic antineoplastic regimen, or study termination by 
the Sponsor.  
• A sample for immunogenicity test ing for NKTR -214 will be collected at the first 30 -day 
follow up visit.  
For AE and SAE reporting periods, please refer to Sections  7.5 and 7.7. 
5.6 End of Study  
End of study is defined as no more than 3  years after the last patient received their first dose of 
NKTR-214, or Sponsor decision  to terminate the study, whichever comes first.  .  
5.7 Tumor and Radiographic Assessments  
Tumor assessments for all patients will be performed at Screening and every 8  weeks (± 7 days).  
If a patient has an unconfirmed PR o r CR, a scan is recommended no sooner  than 4 weeks later 
(e.g., if the initial observation of PR was seen at Week 8, a Week 12 scan should occur); 
subsequent tumor assessments must remain on the original 8 -week assessment schedule (i.e., at 
Week 16, Week  24, then at Week  32, Week  40, etc.)  For patients with unconfirmed progressive 
disease, subsequent tumor assessments must remain on the original 8 -week assessment schedule 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 101 of 178 
Confidential and Proprietary   11 February 2020  (i.e., at Week  16, Week  24, then at Week  32, etc.), unless an early scan is clinicall y indicated.  
 
Radiographic assessments (chest/abdomen/pelvis) are  required for all patients for tumor 
measurements.  Imaging of the brain on -study at 8 -week intervals must occur for patients with 
known brain metastases at baseline.   
Documented tumor measurements are required using CT scans, MRI, physical examination, 
and/or digital photography, as appropriate.  Any imaging used to assess disease at any time point 
will be submitted for an independent radiology review.  
The same method of assessment (CT or MRI and/or digital photography) and the same techniqu e 
for acquisition of images must be used for all study assessments (contrast must be used unless 
medically contraindicated).  Baseline imaging should be done at the same institution/facility that 
will be used to measure response during the patient’s participation in the study.  Radiographic 
assessments and efficacy analyses will be conducted by the Investigator site as well as the 
independent radiology review.  
5.8 Pharmacokinetic Measurements  
Blood samples for pharmacokinetic (PK) analyses of NKTR -214 and its m etabolites will be 
collected in all cycle s. 
Part 1:  For Cycle  1 only, blood samples will be collected on Days  1 to 5, 8, and 11.  PK 
sample times are predose and at the following times after initiation of NKTR -214 dosing:  
30 min ± 2 min (end of NKTR -214 infusion), 1.5  hr ± 10 min, 3 hr ± 10 min, and 6 hr 
+ 2 hrs.  PK assessments for Cycles  ≥ 2 will be on Day  1 (predose and 30  min ± 2 min 
[end of NKTR -214 infusion]) and Day  8. 
For all other Parts of the study except Part  1, blood samples will be collected according to 
the Appendix  2 Schedule of Assessments.    
Blood samples for PK analyses of nivolumab and ipilimumab will be collected as follows:  
Part 1 (nivolumab only): predose Cycle  1 Day 1, end of infusion Cyc le 1 Day 1, and 
predose Cycle  3 Day 1, Cycle 8 Day 1, Cycle 16 Day 1, Cycle 24 Day 1, Cycle 36 Day 1 
or a maximum of 2 years  
For all other Parts of the study except Part  1, blood samples will be collected according to 
the Appendix  2 Schedule of Assess ments. 
In the event of a possible study drug(s) -related serious adverse event (SAE) throughout the 
study, it is advised that additional PK blood samples are drawn as close to the event as possible 
to help characteri ze any possible relationships between dru g exposure and the clinical event.  

Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 102 of 178 
Confidential and Proprietary   11 February 2020  Blood samples for PK analysis will be collected and processed as outlined in a Laboratory 
Manual that will be provided to the site.  All on -treatment time points are intended to al ign with 
days on which study drug is admi nistered; if dosing occurs on a different day, the PK sampling 
should be adjusted accordingly.  If it is known that a dose is going to be delayed, then the 
predose sample should be collected just prior to the delaye d dose.  However, if a predose sample 
is collected but the dose is subsequently delayed, an additional predose sample should not be 
collected.  
For all PK blood samples, the date and actual time collected must be recorded.  
5.9 Immunogenicity Measurements  
Immunogenicity samples for NKTR -214 will be dra wn as follows:  
Part 1: predose Cycle  1 Day 1, predose on Cycle  2 Day 1 and predose on Day  1 of all 
odd-numbered cycles thereafter (Cycles  3, 5, 7, etc .), EOT, and the first 30 -day follow -up 
visit. 
For all other Parts of the study except Part  1, immunogenic ity sample s will be collected 
according to the Appendix  2 Schedule of Assessments.   
Immunogenicity samples for nivolumab/ipilimumab will be drawn as follows:  
Immunogenicity samples for nivolumab in Part 1 will be collected as follows:  predose Cycle  1 
Day 1, and predose Cycle  3 Day 1, Cycle 8 Day 1, Cycle 16 Day 1, Cycle 24 Day 1, Cycle 36 
Day 1, or a maximum of 2 years.  If dosing occurs on a different day, the immunogenicity 
sampling should be a djusted accordingly.  
Immunogenicity samples for nivolumab in  Part 2 and immunogenicity samples for  nivolumab 
and ipilimumab in Parts  3 and 4 will be collected according to the Appendix  2 Schedule of 
Assessments.  If dosing occurs on a different day, the immunogenicity s ampling should be 
adjusted accordingly.  
If it is known that a dose is going to be delayed, then the predose sample sho uld be collected just 
prior to the delayed dose.   
However, if a predose sample is collected but the dose is subsequently delayed, an addit ional 
predose sample should not be collected.  
Serum samples for immunogenicity assessments  will be collected and proce ssed as outlined in 
the Laboratory Manual that will be provided to the site.   
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 103 of 178 
Confidential and Proprietary   11 February 2020  5.10 Biomarker Measurements (Blood and Tumor Collection)  
Refer to the Laboratory Manual for specific instructions  on sample processing, storage, and 
shipping. 
  
 
 
 
   
 
 
  
 
  
  
  
 
 
  
  
  
   
 
 
 
 
 
  
 
 
 
   

Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 104 of 178 
Confidential and Proprietary   11 February 2020   
 
 
5.10.2  Tumor T issue Biopsy Collection Times and Analysis  
A fresh tumor biopsy obtained from core biopsy, punch biopsy, excisional biopsy, or surgical 
specimen (fine -needle aspiration, cytology specimens, and bone lesions are not accep table) will 
be required during Screening.  Sufficient, recent tumor tissue obtained within 6  months prior to 
enrollment from a metastatic tumor lesion or from an unresectable primary tumor lesion which 
has not been previously irradiated (formalin -fixed paraffin-embedded block or minimum  of 
20 slides, obtained from core biopsy, punch biopsy, excisional biopsy, or surgical specimen) may 
be submitted in lieu of a fresh tumor biopsy during the Screening period. Exceptions may be 
made with the Sponsor’s Medical Monitor approval in cases where  fresh tumor tissue and/or 
archival t umor samples are inaccessible.  
Target lesions should not be biopsied unless there are no other lesions suitable for biopsy.  If a 
target lesion is used for biopsy, the lesion must be ≥  2 cm in the longest diameter.  
One optional tumor biopsy may be collected during Days  15-21 (Week 3) in Cycle 1; 1  optional 
on-treatment tumor tissue biopsy may be collected at least 30  days after Cycle  1 Day 1 but prior 
to the Week  8 scan. An additional tumor  tissue biopsy may be collected  at the time of suspected 
or known disease progression.   
Pretreatment and on -treatment biopsies should be taken from the same lesion, if feasible.  
Biopsies should only be performed on lesions that have not been exposed to p rior radiation.  
Tumor tissue bi opsies will be used for characterization of infiltrating immune cell populations 
using a panel of markers, using IHC, flow cytometry, mass spectroscopy, or other similar 
techniques.  Biopsy samples may also be used to investi gate molecular signatures.  DNA  and/or 
RNA may be extracted from these samples for somatic mutation analysis and gene expression 
analysis.  Genes to be assayed may include, but not be limited to, those with known driver 
mutations in solid tumors.  These sa mples will be analyzed by the S ponsor or designee.  
5.10.3  Stool Sample Analysis  
A stool sample from a single bowel movement will be collected by patients participating in 
Parts 2-4 of the study prior to administration of the first dose and at Cycle  3 Day 1 ± 10 days.  
Patients will be provided  with a materials kit and instructions for collecting the stool sample.  
Stool samples will be processed to extract and sequence microbial DNA and RNA as outlined in 
a Laboratory Manual.  

Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 105 of 178 
Confidential and Proprietary   11 February 2020  5.11 Determination of Dose -Limiting Toxicit ies (DLTs)  
Based on the nonclin ical toxicology, safety data from the dose escalation study (Study 
15-214-01; [STUDY_ID_REMOVED] ) and the half -lives of NKTR -214 and metabolites (approximately 
20 hours), drug -related toxicity is most likely to occur 1  to 5 days following treatment.  In Part  1 
of the study, DLTs will be assessed during the DLT window shown in Table 7.  If DLTs are not 
observed, dose escalation will be permitted and enrollment of the next dosing cohort may beg in.  
Intra-patient dose escalation is not permitted.  In Part 3, t he DLT evaluation p eriod will begin 
with the first dose of ipilimumab and the evaluation period will be a minimum of 3  weeks 
(21 days).  If DLTs are not observed, patients will continue to e nroll until 12  patients have been 
evaluable for safety.   Grading of AEs is described in Section  7.3. 
5.11.1  DLTs Related to Study Drug(s)  
Examples of AEs related to study drug(s) that will be defined as a DLT include t he following:  
• Any Grad e ≥ 3 drug -related non -hematological AE that does not resolve to Grade 1 or 
baseline within 7  days except those listed in Section  5.11.2. 
• Any drug-related Grade  ≥ 2 myocarditis, Grade  ≥ 2 uveitis, Grade  ≥ 3 pneumonitis, or 
Grade ≥ 3 neurotoxicity  
• Any Grade 4 drug -related hematological AE that is clinically significant.  
• Any Grade 4 nausea or vomiting.  
• Any Grade ≥3 drug -related hypotension lasting  > 48 hours post -dose, cytokine -release 
syndrome, capillary leak synd rome, pulmonary edema, symptomatic hypereosinophilic 
syndrome, or qualifying drug -induced liver injury (DILI)  
All AEs that meet DLT criteria must be recorded in the electronic data captur e system within 
approximately 24  hours of awareness.  
5.11.2  Grade 3 or 4 AEs  that Should Not be Considered a DLT  
The following Grade  3 or 4 AEs should not be considered a DLT:  
• Endocrinopathy AEs, such as adrenal insufficiency, adrenocorticotropic hormone (ACTH) 
deficiency, hyper - or hypothyroidism, that resolve or are adequately c ontrolled with 
physiologic hormone replacement (corticosteroids, thyroid hormones) or glucose intolerance 
managed with glucose -controlling agents.  
• Asymptomatic amylase or lipase elevations.  
• Lymphopenia <  14 days in duration or not associated with clinical manifestations.  
• Electrolyte imbalances/abnormalities that are not associated with clinical sequelae and are 
corrected with supplementation/appropriate management within 72  hours of their onset.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 106 of 178 
Confidential and Proprietary   11 February 2020  • Tumor flare defined as local pain, irritation, or rash localiz ed at sites of known or suspected 
tumor. 
• Grade 3 nausea or vomiting that can be medically managed to ≤  Grade 2 within 72 hours.  
• Grade 3 hypotension dur ing Cycles  1 or 2 that lasts ≤  48 hours post -dose. 
• Fatigue that improves to ≤  Grade 2 within 7  days. 
5.12 Dela yed Dose -Limiting Toxicities (DLTs)  
Delayed DLTs are AEs as defined in Section 5.11.1 that occur after the DLT window listed in 
Table 7.  Delayed DLTs will not be used to determine the MTD for dose escalation.  Delayed 
DLTs will be collected and evaluated by the Investigators and the Medical Monitor on an 
ongoing basis.  
All AEs that meet DLT criteria must be recorded in the electronic  data capture (EDC) system 
within 24  hours of awareness.  
5.13 Dose Delay and Reduction Criteria  
Dose delays of more than 1 drug are allowed for management of treatment -related toxicities 
during a give treatment cycle.  For dose delay and reduction criteria, see  grading of AEs 
described in Section  7.3.  Tumor assessments for all patients should continue as per protocol 
even if dosing is delayed.  
5.13.1  Nivolumab Dose Delay Criteria  
Dose reductions for nivolumab are not permit ted in this study.  Nivolumab may be delayed based 
on observed drug -related toxicities.  If nivolumab is delayed, NKTR -214 administration can 
continue in the absence of NKTR -214-related toxicity that would warrant  a dose delay  and once 
the criteria to resu me are met ( Section 5.13.11).  If the Investigator cannot determine which 
study drug is causing the toxicity, then all study drugs should be delayed.  
Nivolumab administration should be delayed for the following:  
• Grade 2 non -skin, drug-related AE, except for fatigue  
• Grade 2 drug -related creatinine, AST, ALT and/or total bilirubin abnormalities  
• Grade 3 skin, drug-related AE  
• Grade 3 drug -related laboratory abnormality, with the following exceptions:  
o Grade 3 lymphopenia or asymptoma tic amylase or lipase does not require dose delay   
o Grade  3 AST, ALT, total bilirubin will require dose discontinuation .  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 107 of 178 
Confidential and Proprietary   11 February 2020  • Patient has acute infection (e.g., fever, upper or lower respiratory tract infection) requiring 
systemic antibiotic therapy. Patient may resume study treatment once free of signs or 
symptoms for 72 hours after completion of antibiotic therapy (See Section 5.13.11). 
• Any AE, laboratory abnormality, or inter -current illness that, in the judgment o f the 
Investigator, warrants delaying the dose of study medication.  
Patients who require delay of nivolumab should be re -evaluated weekly or more frequently if 
clinically indicated and resume nivolumab dosing when re -treatment criteria are met.   Dose 
delays of up to 6 weeks are permitted.  
5.13.2  Ipilimumab Dose Delay Criteria  
Dose reductions for ipilimumab are not permitted in this study.  Dose delays are permitted for 
ipilimumab. Per recommendation of the Investigator and approval of the Sponsor’s Medical 
Monitor, ipilimumab may be delayed based on observed drug -related toxicities.   If ipilimumab is 
delayed, NKTR -214 or nivolumab administration can continue in the absence of NKTR -214- or 
nivolumab -related toxicity that would warrant a dose delay  and once the crite ria to resume are 
met (Section 5.13.11).  If the Investigator cannot determine which study drug is causing the 
toxicity, then all study drugs should be delayed.  
Ipilimumab must be delayed for the fo llowing reasons.   
• Any Grade ≥  2 pneumonitis (in the case of Grade  1 pneumonitis, delay should be considered 
but is not required).  
• Any Grade ≥  2 non-skin, drug -related AE, except for fatigue and asymptomatic laboratory 
abnormalities that are corrected with  supplementation/appropriate ma nagement within 
72 hours of onset, or Grade  3/4 endocrinopathies that can be successfully treated with 
administration of replacement therapy.  
• Any Grade ≥  3 skin drug -related AE, except when occurring during the first 48  hours of 
NKTR-214 administration.  
• Any Grade 3 drug-related laboratory abnormality with the following exceptions for 
lymphopenia, creatinine, AST, ALT, or total bilirubin or asymptomatic amylase or lipase:  
– Grade 3 lymphopenia does not require a dose delay.  
– If a patient has a baseline AST, ALT , or total bilirubin that is within normal limits, delay 
dosing for drug -related Grade ≥  2 toxicity.  
– If a patient has baseline AST, ALT, or total bilirubin within the Grade  1 toxicity range, 
delay dosing for drug -related Grad e ≥ 3 toxicity.  
– Grade 2 serum c reatinine requires a dose delay, if not resolved to a Grade 1 or baseline 
prior to the next dose.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 108 of 178 
Confidential and Proprietary   11 February 2020  – Any Grade  3 or Grade 4 drug -related amylase and/or lipase abnormality that is not 
associated with symptoms or clinical manifest ations of pancreatitis does not  require dose 
delay.   
• Any AE, laboratory abnormality, or inter -current illness that, in the judgment of the 
Investigator, warrants delaying the dose of study medication.  
5.13.3  NKTR -214 Dose Delay and Reduction Criteria  
Dose delays  and reductions are permitted f or NKTR -214.  Per recommendation of the 
Investigator , NKTR-214 may be delayed or reduced (to 0.003 mg/kg) based on observed 
drug-related toxicities.  Medical Monitor consultation is required for dose reduction .  If the 
NKTR-214 dose is reduced to 0.003 mg/ kg, the dose should remain at this level throughout the 
remainder of the study .  If NKTR-214 is delayed, nivolumab or ipilimumab administration can 
continue in the absence of nivolumab - or ipilimumab -related toxicity that would warrant a dose 
delay and once the criteria to resume are met ( Section 5.13.11). 
NKTR-214 may be delayed or reduced for the following reasons:  
• For persistent Grade 2 drug-related toxicity, at the discretion of the Investigator , with the 
exception of: 
o Grade ≥ 2 creatinine increase:  
− For patients who must delay study treatment due to Grade ≥ 2 creatinine increase due 
to a non-inflammatory cause, delay retreatment with study drug for approximately 
3 to 5 days.  After the dosing delay, the pa tient may resume stud y drug when serum 
creatinine has returned to Grade ≤ 1, as assessed within 24 hours prior to redosing.  
For further  guidance, refer to the Renal AE Management Algorithm in current 
Nivolumab I nvestigator’s Brochure. 
• Patient has acute infection (e.g., fever,  upper or lower respiratory tract infection) requiring 
systemic antibiotic therapy. Patient may resume study treatment once free of signs or 
symptoms for 72 hours after completion of antibiotic therapy (See Section 5.13.11) 
• Grade ≥ 3 toxicity at least possibly related to NKTR -214: NKTR -214 dosing must be 
delayed until resolution to Grade 1 or baseline (unless otherwise requiring permanent 
discontinuation, per Section 5.13.12), with the following except ions: 
o Grade ≥ 3 lymphopenia  
o Grade ≥ 3 asymptomatic amylase or lipase elevation  
NKTR-214 dosing may resume at the same dose or at a lower dose when toxicity resolves  to 
Grade 1 or returns to baseline , except for instances where the potential recurrence of t he event 
poses an undue risk for the patient (see Section  5.13.12 for permanent d iscontinuation  criteria).  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 109 of 178 
Confidential and Proprietary   11 February 2020  5.13.4  Monitoring and Management of Adrenal Insufficiency and H ypophysitis  
Adrenal insufficiency and hypophysitis have been ob served in patients receiving nivolumab and 
ipilimumab.   Consider prompt evaluation when patients have signs or symptoms of hypophysitis 
or adrenal insufficiency  which includes levels of early -morning ACTH, cortisol, 
thyroid-stimulating hormone  (TSH), and free thyroxine ( T4).  Co-management with an 
endocrinolog ist is recommended  for patients with pre -existing adrenal insufficiency . 
5.13.5  Monitoring and Management of NKTR -214-induced Eosinophilia  
Frequent and significant eosinophilia has been observed in patients r eceiving NKTR -214, 
primarily starting at Cycle 2 or late r, consistent with the known effect of IL -2 therapy.  Clinical 
data analysis demonstrated that frequency of selected AEs (primarily Grade 1 or 2 in severity) 
such as rash, pruritus, edema, nausea, vom iting, diarrhea, and dizziness increased with level of 
eosinophilia.  Isolated cases of hypereosinophilic syndrome and other eosinophilic disorders 
have been reported.   
Absolute eosinophil count (AEC) should be closely monitored per protocol.  If a study patient is 
suspected to have eosinophilic disorder (symptoms may involve skin, lungs, digestive tract, 
heart, blood, and nervous systems) with AEC at or above 5000/µL (5 ×  109/L) level, NKTR -214 
treatment may need to be withheld, and the patient should be treated as clinically indicated.   
5.13.6  Monitoring and Management of Elevated Hepatic Transaminases  
Elevated hepatic transaminases are an overlapping toxicity that can occur for both NKTR -214 
and nivolumab.  The elevations in hepatic transaminases associated wit h NKTR-214 typically 
occur at the time of peak ac tive cytokine concentration in the blood (Days 2 -4), and are often 
accompanied by other cytokine -related toxicities such as flu -like symptoms, rash or pruritus.  
The transient elevations in hepatic transamin ases are usually mild or moderate in severity, no t 
associated with increased total bilirubin, resolve spontaneously without treatment, and 
predominantly occur in Cycle 1 and Cycle 2.  Grade 3 abnormalities with these characteristics 
have been observed in P IVOT-02 study during Cycle 1, and patients were a ble to continue study 
treatment uninterrupted with close laboratory monitoring.    
Hepatic events, including elevated liver function tests, have also been observed for nivolumab. 
Most cases were of low or mod erate severity.  Higher grade abnormalities are c oncerning for 
immune mediated hepatitis, and typically occur with a later onset (median time to onset of 
3.3 months) (nivolumab package insert) .  Immune-mediated hepatitis generally result s in a quick 
rise in liver function tests, and respond s to corticoste roids or immune -modulating agents.  For 
transa minase elevations occurring in C ycle 2 onwards potentially involving an immune -
mediated mechanism, follow the immune -mediated hepatic adverse event management 
guidelines in the current nivolumab Investigator’s B rochure or package insert  for 
appropriate management.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 110 of 178 
Confidential and Proprietary   11 February 2020  5.13.7  Cohorts 3d.1 and 3d.2 (NSCLC) Dose Delay and Reduction Criteria for 
Platinum and Pemetrexed  
Dose delays and reductions are required for hematological a nd non-hematological toxicity.  
Recommended dose m odifications for key chemotherapy toxicities are outlined in Table 14, 
Table 15, and Table 16.  These serve as a guide and do not replace investigator judgment and 
applicable local label recommendations.  
Table 14: Dose Levels for Platinum and Pemetrexed  
Drug  Dose Level 0  Dose Level -1 Dose Level -2 Dose Level -3 
Cisplatin 75 mg/m2 56 mg/m2 38 mg/m2 Discontinue  
Carboplatin  AUC 5, maximum dose 
750 mg AUC 3.75, maximum 
dose 562.5  mg AUC 2.5, maximum 
dose 375 mg Discontinue  
Pemetrexed  500 mg/m2 375 mg/m2 250 mg/m2 Discontinue  
 
Table 15: Recommended Dose Modifications for Hematologic Toxicity for 
Platinum and Pemetrexed  
  Pemetrexed  Platinum  
Platelets  ANC  DOSE LEVEL  
≥ 50 × 103/μL AND ≥ 0.5 × 103/μL Dose Level 0  Dose Level 0  
≥ 50 × 103/μL AND < 0.5 × 103/μL Dose Level -1 Dose Level -1 
< 50 × 103/μL without bleeding AND  ANY Dose Level -1 Dose Level -1 
< 50 × 103/μL with ≥ Grade 2 bleeding 
AND ANY Dose Level -2 Dose Level -2 
ANY AND  < 1.0 + fever ≥ 38.5°C  
(101°F) Dose Level -1 Dose Level -1 
 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 111 of 178 
Confidential and Proprietary   11 February 2020  Table 16: Recommended  Dose Modifications for Non -Hematologic Toxicity for 
Platinum and Pemetrexed  
Event  Pemetrexed  Cisplatin  Carboplatin  
CTC Grade  DOSE LEVEL   
Nausea or vomiting  3 or 4 Dose Level 0  Dose Level 0  Dose Level 0  
Diarrhea 3 or 4 Dose Level -1 Dose Level -1 Dose Level 0 
Mucositis  3 or 4 Dose Level -2 Dose Level 0 Dose Level 0  
Neurotoxicity  2 Dose Level 0  Dose Level -2 Dose Level 0  
Neurotoxicity  3 or 4 Discontinue  Discontinue  Dose Level -1 
Transaminase Elevation  3 Dose Level -1 Dose Level -1 Dose Level -1 
Transaminase Elevation  4 Discontinue  Discontinue  Discontinue  
Other non -hematological toxicity  3 or 4 Dose Level -1 Dose Level -1 Dose Level -1 
Abbreviations:  CTC = common terminology criteria  
 
Creatinine clearance (CrCl ) will be based on the original weigh t-based Cockcroft and Gault 
formula.  CrCl must be ≥ 45 mL/min prior to the administration of chemotherapy.  Pemetrexed 
and/or cisplatin may be delayed for up to 42  days to allow the patient time to recover from the 
toxicity.  If a  patient’s CrCl value has not returned to ≥ 45 mL/min within 4 2 days after the  
previous dose, cisplatin and/or pemetrexed must be discontinued.  
5.13.8  Cohort 3e (NSCLC) Dose Delay and Reduction Criteria for Platinum and 
Taxane  
Dose delays and reducti ons are required for hematological and non -hematological toxicity.  
Recomme nded dose modifications for key chemotherapy toxicities are outlined in Table 17, 
Table 18, and Table 19.  These serve as a guide and do not replace investigator judgment and 
applicable local label recommendations.  
Table 17: Dose Levels Platinum and Taxane  
Drug  Dose Level 0  Dose Level -1 Dose Level -2 Dose Level -3 
Cisplatin 75 mg/m2 56 mg/m2 38 mg/m2 Discontinue 
Carboplatin  AUC 6 AUC 4.5 or 5  AUC 3 or 4  Discontinue  
Nab-Paclitaxel  100 mg/m2 75 mg/m2 50 mg/m2 Discontinue  
Paclitaxel  200 mg/m2 175 mg/m2 150 mg/m2 Discontinue  
 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 112 of 178 
Confidential and Proprietary   11 February 2020  Table 18: Recommended Dose Modifications for Hematologic To xicity Platinum 
and Taxane  
Platelets  ANC  Nab-Paclitaxel  Platinum  
DOSE LEVEL  
≥ 50 × 103/μL AND ≥ 0.5 × 103/μL Dose Level 0  Dose Level 0  
≥ 50 × 103/μL AND < 0.5 × 103/μL Dose Level -1 Dose Level -1 
ANY AND  Delay of initiation of 
next cycle by > 7 days 
due to < 1.5  × 103/μL Dose Level -1 No change  
< 50 × 103/μL without bleeding AND  ANY Dose Level -1 Dose Level -1 
< 50 × 103/μL with ≥ Grade 2 
bleeding AND  ANY Dose Level -2 Dose Level -2 
ANY AND  < 1.0 + fever ≥ 38.5°C  
(101°F) Dose Level -1 
Dose Level -2  
(2nd episode) 
Discontinue  
(3rd episode) Dose Level -1 
 
Table 19: Recommended Dose Modifications for Non -Hematologic Toxicity 
Platinum and Taxane  
Event  CTC Grade  Nab-Paclitaxel or 
Paclitaxel  Cisplatin  Carboplatin  
DOSE LEVEL  
Nausea or vomiting  3 or 4 Dose Level 0  Dose Level 0  Dose Level 0  
Diarrhea 3 or 4 Dose Level -1 Dose Level -1 Dose Level 0  
Neurotoxicity  2 Dose Level -1 Dose Level -2 Dose Level 0  
Neurotoxicity  3 or 4 Dose Level -1 or -2 
Dose Level -2  
(2nd episode) Discontinue Dose Level -1 or -2 
Dose Level -2  
(2nd episode) 
Transaminase Elevation  3 Dose Level -1 Dose Level -1 Dose Level -1 
Transaminase Elevation  4 Discontinue  Discontinue  Discontinue  
Other non -hematological toxicity  3 or 4 Dose Level -1 Dose Level -1 Dose Level -1 
 
CrCl will be based on the original weight -based Cockcroft and Gault formula.  CrCl must be 
≥ 45 mL/min prior to the administration of cisplatin.  Nab-paclitaxel, paclitaxel,  and/or platinum 
may be delayed for up to 42  days to allow the patient time to recover from the toxicity.  If a 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 113 of 178 
Confidential and Proprietary   11 February 2020  patient’s CrCl value has not returned to ≥ 45 mL/min within 42  days after the  previous dose, 
cisplatin must be discontinued.  
5.13.9  Nab-Paclitaxel Dose Delay and Reduction Criteria  
Dose delays and reductions are for hematological and non -hematological toxicity.  For these, 
please refer to country specific appro ved product label for dose modifications ( Abraxane 
package insert ).  
5.13.10  Eribulin Dose Delay and Reduction Criteria  
Dose delays and reductions are required for hematological and non -hematological toxicity.   
The administration of eribulin should be delayed on Day 1 or Day 8 for any of the following:  
• Absolute neutrophil count (ANC) <  1 × 103/μL  
• Platelets < 75  × 103/μL  
• Grade 3 or 4 non -hematological toxicities  
These recommendations in Table 20 serve as a guide and do n ot replace investigator judgment 
and applicable local label recommendations.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 114 of 178 
Confidential and Proprietary   11 February 2020  Table 20: Dose Recommendations for Eribulin  
Adverse Reaction After Previous Administration  Recommended Dose  
Hematological:  
1.1 mg/m2 (eribulin mesylate)  
0.97 mg/m2 (eribulin)  ANC < 0.5  × 103/μL lasting more than 7 days  
ANC < 1 × 103/μL neutropenia complicated by fever or infection  
Platelets < 25  × 103/μL l thrombocytopenia  
Platelets < 50  × 103/μL thrombocytopenia complicated by hemorrhage or 
requiring blood or platelet transfusion  
Non-hematological:  
Any Grade 3 or 4 in the previous cycle OR omission or delay of Day  8 dose in 
previous cycle for toxicity  
Reoccurrence of any hematological or non -hematological adverse reactions as 
specified above:    
Despite reduction to 1.1 mg/m2 (eribulin mesylate); 0.97 mg/m2 (eribulin)  0.7 mg/m2 (eribulin mesylate)  
0.62 mg/m2 (eribulin)  
Despite reduction to 0.7 mg/m2 (eribulin mesylate); 0.62 mg/m2 (eribulin)  Consider discontinuation  
 
5.13.11  Criteria to Resume NKTR -214, Nivolumab, or Anti -Cancer Stu dy Drugs  
Patients will be permitted to resume study drug(s) at the same dose level(s) following resolution 
of an AE to Grade  ≤ 1 or to ba seline within 6  weeks after the last dose, with the exception of 
patients who meet criteria for permanent discontinuati on as specified in Section  5.13.12.  
Patients who meet criteria for permanent discontinuation must not receive further study therapy.  
If the decision is made to resume study drug(s) dosing, the patient should restart treatment on the 
next regularly scheduled study drug(s) dosing visi t.  Skipped doses are not to be replaced.  
Patients may resume treatment when the drug -related AE(s) resolve(s) to Grade   1 or baseline, 
with the following exceptions:  
• Patients who de layed dosing for acute infection requiring systemic antibiotic therapy mu st be 
free of signs or symptoms of infection for 72 hours after completion of antibiotic therapy 
prior to resuming study treatment . 
• Patients may resume treatment in the presence of Gr ade 2 fatigue.  
• Patients who have not experienced a Grade 3 drug -related skin AE may resume study 
treatment in the presence of Grade 2 skin toxicity . 
• Patients with baseline Grade  1 AST/ALT or total bilirubin who require dose delays for 
reasons other than a 2-grade shift in AST/ALT or total bilirubin may resume treatment in the 
presence of Grade  2 AST/ALT or total bilirubin.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 115 of 178 
Confidential and Proprietary   11 February 2020  • Patients with combined Grade  2 AST/ALT and total bilirubin values meeting discontinuation 
parameters (see Section  5.13.12) should have treatment permanently discontinued.  
• Drug-related pulmo nary toxicity, diarrhea, or colitis must have resolved to baseline before 
treatment is resumed.  Patients with persistent Grade  1 pneumonitis after completion  of a 
steroid taper over at least 1  month may be eligible to resume study drug(s) treatment if 
discussed with and approved by the Medical Monitor.  
• Drug-related endocrinopathies adequately controlled with only physiologic hormone 
replacement may resume trea tment after consultation with the Medical Monitor.   Grade ≥ 3 
adrenal insufficiency or Grade ≥ 4 hypophysitis require discontinuation regardless of control 
with hormone replacement  (see Section  5.13.12 for permanent treatment discontinuation 
criteria).  Hospitalization  for diagnostic workup of adrenal insufficiency without severe 
symptoms should not require discontinuation.  
• Patients who delay study treatment due to any Grade   3 amylase or lipase abnormality that 
is not associated with symptoms or clinical manifestation s of pancreatitis may resume 
nivolumab when the amyl ase or lipase abnormality has resolved to Grade  < 3. 
• For patients who must delay study treatment due to Grade ≥ 2 creatinine increase  due to a 
non-inflammatory cause (see Sections 5.13.1, 5.13.2, and 5.13.3), delay retreatment with 
study drug for approximately 3 to 5 days.  After the dosing delay, the pa tient may resume 
study drug when serum creatinine has returned to Grade ≤ 1, as assessed within 24 hours , or 
as soon as locally feasible , prior to redosing  with study drug , except where  permanent 
discontinuation of study drug is required (see Section  5.13.12). 
• Dose delay of NKTR -214 that results in treatment delay of >  6 weeks requires treatment 
discontinuation, with exceptions as noted in Sec tion 5.13.12.  However, if the toxicity 
resolves to ≤  Grade 1 or baseline >  6 weeks after the last dose, but the patient does not 
otherwise meet the criteria for permanent discontinuation (see Section  5.13.12), and the 
Investigator believes that the patient is deriving clinical benefit, then the patient may be 
eligible to resume the study drug(s) following the approval of the Medical Monitor.  
For patients in Parts  3 and 4 (NKTR -214 plus nivolumab plus ipilimumab), treatment with 
NKTR-214 plus nivolumab may continue if patients experience toxicities or are unable to 
tolerate ipilimumab.  
5.13.12  Permanent Treatment Discontinuation Criteria  
Patients meeting any of the following criteria will be required to permanently discontinue all 
assigned study drug(s).  However, per the inves tigator’s assessment , treatment with NKTR-214 
or with nivolumab alone may continue if the toxicities listed below are considered not related to 
the respective drug, or are considered related to  ipilimumab and/or  other anti -cancer study drugs 
only once the criteria to resume are met (Section  5.13.11).  For CVA events and suspected TIA 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 116 of 178 
Confidential and Proprietary   11 February 2020  events, follow the criteria described below (additional details are provided in the CVA 
management algorithm  in Appendix 3).  
• Disease progression in the absence of clinical benefit (see details regarding continuing 
treatment beyond initial assessment of progression per RECIST 1.1 in Section  5.3.9). 
• Clinical deterioration, as assessed by the Investigator.  
• Any Grade  2 drug-related uveitis, eye pain, or blurred vision that does not respond to topical 
therapy and does not improve to Grade  1 severity within 6  weeks or requires systemic 
treatment.  
• Any Grade   2 drug-related pneumonitis or interstitial lung disease that does not resolve 
following dose delay and systemic steroids (also see Pulmonary Adverse Event Management 
Algorithm in the ni volumab Investigator’s Br ochure). 
• Grade 3 or 4 infusion reaction of any duration that occurs during the:  
− NKTR-214 infusion or prior to the nivolumab infusion requires discontinuation of 
NKTR-214. 
− Nivolumab infusion or later requires discontinuation of both  NKTR-214 and nivolumab.  
• Any Grade  3 non-skin, drug -related AE lasting >  7 days, with the following exceptions for 
uveitis, pneumonitis, myocarditis, bronchospasm, diarrhea, colitis (ipilimumab and 
nivolumab must be discontinued for ≥  Grade 3 colitis relat ed to ipilimumab), neurol ogic 
toxicity, hypersensitivity reactions, endocrinopathies, and laboratory abnormalities:  
– Grade 3 drug-related uveitis, pneumonitis, myocarditis, bronchospasm, diarrhea, colitis, 
neurologic toxicity, or hypersensitivity reaction of any duration  requires 
discontinuation.  
– Grade 3 drug-related endocrinopathies (excluding adrenal insufficiency) adequately 
controlled with only physiologic hormone replacement do not require discontinuation.  
o Note:  For Grade ≥ 3 adrenal insufficiency, tre atment needs to be discontinued 
regardless of control with hormone replacement (hospitalization for diagnostic 
workup of adrenal insufficiency without severe symptoms should not require 
discontinuation).  
– Grade 3 drug-related laboratory abnormalities do not  require treatment discontinuation 
except: 
▪ Grade 3 drug-related thrombocytopenia >  7 days or associated with clinically 
significant bleeding requires discontinuation.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 117 of 178 
Confidential and Proprietary   11 February 2020  ▪ Any drug -related liver function test abnormality t hat meets the following criteria 
require discontinuation (also see Hepatic Adverse Event Management Algorithm in 
the nivolumab Investigator’s Brochure):  
o AST or ALT >  5 × to 10 × ULN for >  2 weeks 
o AST or ALT >  10 × ULN 
o Total bilirubin >  5 × ULN 
o Concurrent A ST or ALT >  3 × ULN and total bilirubin >  2 × ULN 
• Any Grade  4 drug-related AE or laboratory abnormality, except for the following events, 
which do not require discontinuation:  
– Grade 4 neutropenia  7 days 
– Grade 4 lymphopenia or leukopenia ≤ 14 days in dura tion 
– Isolated Grade  4 amylase or lipase abnormalities that are not associated with symptoms 
or clinical manifestations of pancreatitis.  
– Isolated Grade  4 electrolyte imbalances/abnormalities that are not associated with clinical 
sequelae and are corrected with supplementation/app ropriate management within 
72 hours of their onset  
– Grade 4 drug-related endocrinopathy AEs (except adrenal insufficiency or hypophysitis)  
such as, hyper - or hypothyroidism, or glucose intolerance, that resolve or are adequately 
controlled with physiologic hormone replacement (corticosteroids at ≤  10 mg of 
prednisone or equivalent per day, thyroid hormones) or glucose -controlling agents, 
respectively, may not require discontinuation  per investigator discretion .  
o Note:  For Grade ≥ 3 adrenal insuf ficiency or Grade ≥ 4 hypophysitis, treatment 
needs to be discontinued regardless of control with hormone replacement 
(hospitalization for diagnostic workup of adrenal insufficiency without severe 
symptoms should not require discontinuation).  
• Any AE, labor atory abnormality, or intercurrent illness that, in the judgment of the 
Investigator, presents a substantial clinical risk to the patient with continued treatment.  
• Any dosing delay lasting >  6 weeks after the last dose, with the following exceptions:  
– Dosing delays to allow for prolonged steroid tapers to manage drug -related AEs are 
allowed.  Prior to re -initiating treatment in a patient with a dosing delay lasting >  6 weeks 
after the last dose and with no more than 3  missed doses, the Medical Monitor must b e 
consulted.  Tumor assessments should continue as per protocol even if dosing is delayed.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 118 of 178 
Confidential and Proprietary   11 February 2020  – Dosing delays >  6 weeks after the last dose that occur for nondrug -related reasons, may 
be allowed if approved by the Medical Monitor.  Prior to re -initiating treatm ent in a 
patient with a dosing delay lasting >  6 weeks after the last dose and with no more than 
3 missed doses, the Medical Monitor must be consulted.  Tumor assessments should 
continue as per protocol even if dosing is delayed, and patients must otherwis e meet the 
criteria for continued treatment at the time re -initiation of study therapy is considered.  
• Any new CVA event confirmed by imaging ( diffusion-weighted imaging [ DWI] MRI is 
preferred, unless contraindicated) , regardless of neurological symptoms (s ee Appendix 3): 
o For patients in Parts 3 or 4 receiving triplet immunotherapy: d iscontinue study treatment .  
o For patients in Part 2 receiving doublet immunotherapy:  s tudy treatment may be 
continued only aft er careful risk-benefit assessment by the Investigator .  
5.14 Management Algorithms for Immune -mediated AEs Associated with 
Immuno -Oncology Agents   
Immuno-oncology agents are associated with AEs that can differ in severity and duration from 
AEs caused by other therapeutic classes.  Nivolumab and ipilimumab are considered 
immuno-oncology agents in this protocol.  Early recognition and management of AEs associated 
with immuno -oncology agents may mitigate severe toxicity.  Management Algorithms including 
the use of  systemic corticosteroids (see the nivolumab and ipilimumab Investigator’s Brochures) 
have been developed to assist Investigators in assessing and managing AEs related to the 
following organs/ systems (including, but may not be limited to) : 
• Gastrointestinal  
• Renal 
• Pulmonary 
• Hepatic 
• Endocrinopathy  
• Skin 
• Myocarditis  
and  
• Neurological  
5.15 Treatment of NKTR -214, Nivolumab, or Ipilimumab -Related Infusion Reactions  
Infusion reactions have been reported during infusions with NKTR -214, nivolumab, or 
ipilimumab.  If such a reaction  were to occur with either the NKTR -214, nivolumab, or 
ipilimumab infusion, it might manifest with fever, chills, rigors, headache, rash, pru ritus, 
arthralgias, hypotension, hypertension, bronchospasm, or other allergic -like reactions.  Infusion 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 119 of 178 
Confidential and Proprietary   11 February 2020  reactions should be graded as outlined below (consistent with CTCAE v4.03 grading of 
infusion-related reactions; please also refer to Section 7.3). 
Treatment recommendations are provided below and may be modified based on  local treatment 
standards and guidelines, as appropriate:  
For Grade 1 symptoms (mild reaction; infusion interruption not indicated; intervention not 
indicated):  
• Remain at the bedside and monitor the patient until recovery from symptoms.  The following 
prophylactic premedications are recommended for future infusions:  diphenhydramin e 50 mg 
(or equivalent) and/or acetaminophen/paracetamol 325 to 1000  mg at least 30  minutes before 
subsequent infusions.  
For Grade 2 symptoms (moderate reaction requires therapy or infusion interruption but responds 
promptly to symptomatic treatment [e.g.,  antihistamines, non -steroidal anti -inflammatory drugs, 
narcotics, corticosteroids, bronchodilators, IV fluids]; prophylactic medications indicated for 
 24 hours): 
• Stop the NKTR -214, nivolumab, or ipilimumab infusion, begin an IV infusion of normal 
saline, and treat the patient with diphenhydramine 50  mg IV (or equivalent) and/or 
acetaminophen/paracetamol 325  to 1000 mg; remain at the bedside and monitor the patient 
until resolut ion of symptoms.  Corticosteroid and/or bronchodilator therapy may also be 
administered as appropriate.  If the infusion is interrupted, then restart the infusion at 50% of 
the original infusion rate when symptoms resolve; if no further complications ensue  after 
30 minutes, the rate may be increased to 100% of the original infusion rate.  If symptoms 
recur after restarting the nivolumab or ipilimumab infusion, then no further nivolumab or 
ipilimumab will be administered at that visit.  Administer diphenhydr amine 50 mg IV, 
remain at the bedside, and monitor the patient until resolutio n of symptoms.  
• For future infusions, the following prophylactic premedications are recommended:  
diphenhydramine 50  mg (or equivalent) and/or acetaminophen/paracetamol 325  to 1000 mg 
should be administered at least 30  minutes before the infusion.  If neces sary, corticosteroids 
(up to 25 mg of Solu -Cortef or equivalent) may be used.  
For Grade 3 or Grade 4  symptoms (severe reaction, Grade 3:  prolonged [i.e., not rapidly 
responsive to symptomatic medication and/or brief interruption of infusion]; recurrence o f 
symptoms following initial improvement; hospitalization indicated for other clinical sequelae 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 120 of 178 
Confidential and Proprietary   11 February 2020  [e.g., renal impairment, pulmonary infiltrates].  Grade 4:  life -threatening; pres sor or ventilatory 
support indicated):  
• Immediately discontinue infusion of NKT R-214, nivolumab, or ipilimumab.  Begin an IV 
infusion of normal saline and treat the patient as follows:  recommend bronchodilators, 
epinephrine 0.2  to 1 mg of a 1:1000 solution  for subcutaneous administration or 0.1  to 
0.25 mg of a 1:10,000 solution inje cted slowly for IV administration, and/or 
diphenhydramine 50  mg IV with methylprednisolone 100  mg IV (or equivalent), as needed.  
Nivolumab , ipilimumab , or NKTR-214 will be perma nently discontinued  (see 
Section 5.13.12).  The patient should be monitored until the Investigator is comfortable that 
the symptoms will not recur.  Investigators should follow their institutional guidelines for  the 
treatment of anaphylaxis.  Remain at the bedside and monitor the patient until recovery of the 
symptoms.  
In case of late -occurring hypersensitivity symptoms (e.g., appearance of a localized or 
generalized pruritus within 1  week after treatment), sympt omatic trea tment may be given 
(e.g., oral antihistamine or corticosteroids).   
5.16 Prior and Concomitant Medications  
Complications, including fatal events, have occurred in patients who received allogeneic 
hematopoietic stem cell transplantation (HSCT) before o r after niv olumab. 
Premedications should not be administered prior to the initial administration of NKTR -214, 
nivolumab, or ipilimumab, but if a patient reports symptoms (such as nausea and/or vomiting), 
prophylactic use of anti -emetics may be used.  
Recording of prio r medications should include prior cancer treatments:  previous 
immunotherapy, chemotherapy, targeted therapy, radiation, over -the-counter (OTC) medications, 
herbs, and dietary supplements.  
All medications (prescription and OTC), vitamin and min eral supple ments, and/or herbs taken by 
the patient from Screening through the EOT visit will be documented and recorded, including 
start and stop date, dose and route of administration, frequency, and indication.  Medications 
taken for a procedure (e.g.,  biopsy) sho uld also be included.   Additionally, document 
medication s or other therapeutic measure s administered for SAEs occurring within 100  days of 
last dose of nivolumab or ipilimumab (see Section  7.7). 
5.17 Permi tted Concomitant Medications/Treatment  
Patients are permitted the use of topical, ocular, intra -articular, intranasal, and inhalational 
corticosteroids (with minimal systemic absorptio n).  Patients  with pre-existing adrenal 
impairment requiring corticoster oid supplementation may be at increased risk for hypotensive 
episodes during treatment with NKTR -214 and may require co -management with an 
endocrinologist  (see Section  5.13.4).  A brief course of corticosteroids for prophylaxis (e.g., 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 121 of 178 
Confidential and Proprietary   11 February 2020  contrast dye allergy) or for treatment of non -autoimmune conditions (e.g.,  delayed-type 
hypersensitivity reaction caused by a contac t allergen) is permitted.  Use of corticosteroids for 
the management of autoimmune conditions (as outlined in the Inv estigator’s Brochures for 
nivolumab and ipilimumab) is permitted.   Short-term use of systemic corticosteroids or 
immunosuppressive  medication is permitted if administered for AE treatment.  
Prophylaxis for flu -like symptoms with either acetaminophen or ibup rofen is permitted on study 
per the Investigator’s discretion  (as appropriate, additional treatment measures may be provided 
based on local treatment standards and guidelines,  see Section  5.15).  Prophylaxis for flu -like 
symptoms can be initiated on either Day  1 or Day 2 of the dosing cycle and may  continue 
through Day 5 or longer as needed.  
Prophylaxis for rash and/or pruritus with anti -histamines is permitted on study per the 
Investigator’s discretion  (as appropriate, additiona l treatment measures may be provided based 
on local treatment standards  and guidelines,  see Section  5.15).  Prophylaxis for rash and/or 
pruritus can be initiated on either Day 1 or Day 2 of the dosing cycle and may continue thro ugh 
Day 5 or longer as needed.  
Concomitant palliative and supportive care for disease related symptoms (including 
bisphosphonates and RANK-L inhibitors) is allowed.  Prior palliative radiotherapy must have 
been completed  > 14 days before administration of first dose of study drug.  On -study palliative 
radiotherapy may occur only on non -target lesions and only after discussion with the Medical 
Monitor. On -study radiotherapy to target lesions is not permitted.   
If a patient receives radiotherapy or surgery o n a target lesion, the patient may be allowed to 
continue in the study (if written request is received from the study investigator) and may remain 
on study treatment for as long as there is clinical benefit as assessed by the inves tigator and in 
consultati on with the medical monitor.  
5.18 Prohibited and/or Restricted Concomitant Medications   
5.18.1  Prohibited Medications  
• Immunosuppressive agents  
• Immunosuppressive doses of systemic corticosteroids (except as stated in Section  5.17), 
defined as a daily dose of greater than 10  mg prednisone or equivalent.  
• Any antineoplastic therapy (i.e.,  chemotherapy, hormonal therapy , immunotherapy, 
investigational agent, or radiation therapy [except as described in Section  5.17]) is prohibited 
during the study.   
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 122 of 178 
Confidential and Proprietary   11 February 2020  • Any live / attenuated vaccines (e.g., varicella zoster, yellow fever, rotavirus, oral polio, and 
measles, mumps, rubella [MMR] , or Flumist® Quadrivalent ) are not allowed during study  
treatment  and until 100 days after the last dose of study drug .  Vaccination with inactivated 
viruses is permitted consis tent with the institutional guideline s.  Allow appropriate time 
interval between the most recent study treatment administration and the next date of study 
treatment.  If the patient experiences side effects  post flu vaccine or other inactivated 
vaccine, please manage study treatment administration per protocol guideline.  
In addition, prohibited medications listed in the current nivolumab or ipilimumab prescribin g 
information are not allowed.  For cohorts that administer NKTR -214 and nivolumab in 
combination  with cytotoxic chemotherapy, sites should follow prescribing guidelines listed in the 
current Package Insert or Summary of Product Characteristics.   
5.18.2  Blood Pr essure Medications  
Consideration should be give n to withholding antihypertensive medications incl uding diuretics, 
as well as other drugs with hypotensive properties (e.g.,  alpha blockers for benign prostatic 
hypertrophy)  prior to each dose of NKTR -214, particularly when therapy involves multiple 
anti-hypertensive drugs and classes other than thiazide diuretics.  If withholding antihypertensive 
medications, withhold no less than 12  hours and no more than 48  hours prior to each dose of 
NKTR-214.   
Patients wh o are on medications with antihypertensive effects for the treatment of coronary 
artery disease (e.g., beta -blockers, calcium channel blockers, nitrates, etc.) should be able to 
withhold these drugs.   
Antihypertensive medications may be reinitia ted in between doses of NKTR -214 at any time as 
clinically indicated (i.e., based on blood pressure monitoring results).  
For patients receiving beta-blockers, consider a step -wise tapering of doses before initiation of 
NKTR-214 to avoid reflex tachycardia . If Grade  ≥ 2 hypertension is observed in any cycle, 
patients should be monitored more frequently (at least weekly) until a new stable 
antihypertensive regimen is identified.   Patients may be monitored more frequently at the 
discretion of the investigator as clinically warranted.  
5.18.3  Effect of NKTR -214 on the PK of Concomitant Medications  
NKTR-214 may have the potential to affect the PK of co -administered drugs based on its 
intended pharmacology as a modulator of immune function.  NKTR-214 causes increases in 
circulating cytokines typical of those associated with an acute inflammatory response to infection 
or tissue injury.  The increases in inflammatory cytokines induced by NKTR -214 are generally 
moderate, persist for about one week after NKTR -214 dosing, and r eturn to baseline levels prior 
to the next dose.   Several of these cytokines (IFN -γ, IL-6, IL-10, etc.) have the potential to 
decrease the activity of multiple enzymes and drug transporters, and the suppressive effects can 
be additive ( Haas, 2005 ; Zidek, 2009 ).  Similar to changes that occur during a typical 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 123 of 178 
Confidential and Proprietary   11 February 2020  inflammatory response, NKTR -214 may lead to down regulation of drug metabolizing enzymes, 
such as CYP enzymes, hepatic flavin monooxygenases, U DP-glucuronosyltransferases, 
sulfotransferases, and glutathione S -transferases.   Consequently, treatment with NKTR -214 may 
lead to temporary decrease in clearance of drugs that are substrates of these Phase I and Phase II 
drug metabolizing enzymes, or drug  transporters.  Clinicians should carefully monitor patients 
who receive drugs with narrow therapeutic indices or drug s that are sensitive substrates of drug 
metabolizing enzymes or drug transporters for occurrence of adverse effects, and adjust the dose 
if needed. 
5.19 Adverse Events  
All AEs, either reported by the patient or observed by study staff, will be reported from the time 
of first study drug(s) administration until 100  days after the last dose of all study drug (s).  This 
trial will use the Medical Dict ionary for Regulatory Activities (MedDRA) for coding all AEs.  
AEs will be summarized by preferred term, system organ class, grade of severity , and 
relationship to each study drug (NKTR -214 and/or nivolumab and/or ipilimumab). For SAEs, 
additional reportin g requirements also apply (see Section 7.7). 
5.20 Assigning Patient  Numbers  
Each patient will be assigned a unique patient number after signing the ICF.  Patient numbers 
will be used on all patients’ study information.  Patient numbers wil l not be reassigned.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 124 of 178 
Confidential and Proprietary   11 February 2020  6.0 INVESTIGATIONAL PROD UCT(S)/STUDY DRUGS  
6.1 NKTR -214 Drug Description and Formulation  
 
 
  
 
 
  
 
 
 
 
 
6.2 NKTR -214 Drug Packaging and Labelin g 
NKTR-214 will be packaged and labeled according to current good manufacturing practices.  
Each vial will be labeled with th e study drug number/name, strength, name of the Sponsor, 
storage condition, lot number, and the required cautionary statement.  
6.3 NKTR -214 Drug Reconstitution and Handling  
 
 
 
 
 
 
 

Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 126 of 178 
Confidential and Proprietary   11 February 2020  The Site Drug Accountability Log will be reviewed by the monitor d uring site visits and at the 
completion of the study.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 127 of 178 
Confidential and Proprietary   11 February 2020  7.0 ASSESSMEN T OF SAFETY OR AE s AND SERIOUS AE s 
7.1 AE Definition and Assessment  
An AE is defined as any untoward medical occurrence in a clinical investigation patient 
administered a pharmaceutical product, at  any dose, not necessarily related to the treatment.  
An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally 
associated with the use of a medicinal product, whether or not conside red related to the 
medicinal product.  An AE can also arise from any use of the drug and from any route of 
administration, formulation, dose, or overdose.  This definition includes intercurrent illnesses or 
injuries, and exacerbation of preexisting conditi ons.  Clinical laboratory, vital sign, or physical 
examination abnormalities will only be reported as AEs if they are deemed clinically significant 
by the Investigator (e.g.,  associated with signs and symptoms, require treatment, or require 
follow-up). 
An AE does not include:  
• A medical or surgical  procedure (e.g., surgery, endoscopy, tooth extraction, or transfusion); 
an AE is the underlying condition that leads to the procedure.  
• Pre-existing diseases or conditions present or detected before start of study drug(s) 
administration that do not worsen or increase in severity or frequency after the administration 
of study drug(s).  
• Situations where an untoward medical occurrence has not occurred (e.g.,  hospitalization for 
elective surgery for a condition that has not worsened on study, social and/or conve nience 
admissions to grant families a respite in caring for a patient). 
• Overdose of either study drug(s) or concomitant medication without any signs or symptoms.  
7.2 Monitoring AEs  
All AEs will be assessed by the Inves tigator and recorded, including, but not l imited to, the 
following:  the event term, the date of onset and resolution, seriousness, severity, relationship to 
study drug(s), outcome, treatment of the event, and action taken with the study drug(s).  AEs will  
be reported from the time of first study drug(s) administration until 100  days after the last dose 
of all study drug (s).  For SAEs, additional reporting requirements also apply (see Section 7.7). 
An event occurring after the patient has provided inform ed consent, but before the first dose of 
study treatment, will be collected as medical history unless the event is either new and att ributed 
to protocol -mandated procedures by the Investigator or there is a significant change in the rate of 
occurrence or a n increase in the severity of the pre -existing condition which is judged to be 
clinically important and attributed to the protocol -mandated procedures by the Investigator.  
Under the latter 2  circumstances, the event will be considered an AE and will be ca ptured as 
such. 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 128 of 178 
Confidential and Proprietary   11 February 2020  Example 1:  
Thrombophlebitis associated with a blood draw for assessments required prior to dosing per 
protocol is an event that is related to protocol -mandated procedures.  In this scenario, the 
event of “thrombophlebitis” will be captured as an AE, and it will be documented as being 
“unrelated” to study drug(s), as applicable.  
Example 2:  
An ankle sprain following an une xpected fall from a flight of stairs while at home, after the 
patient has provided informed consent, but before the first d ose of study drug(s), is clearly 
unrelated to any protocol -mandated procedures and would therefore be captured as medical 
history. 
7.3 Grading of AEs  
The severity of an event and the seriousness are not to be considered synonymous.  The severity 
is grading the  intensity of an event.  The seriousness of event is based on the patient/event 
outcome or action criteria.  All AEs will be assessed  for severity using the National Cancer 
Institute Common Terminology Criteria for Adverse Events (NCI -CTCAE) version  4.03 
guidelines.  If a particular AE is not listed in the NCI -CTCAE, the following criteria will be 
used: 
• Grade 1 = Mild (event results in mild or transient discomfort, not requiring or needing only 
minimal intervention or treatment; does not limit or interfere with daily activities 
[e.g., insomnia, mild headache]).  
• Grade 2 = Moderate (event is sufficiently discomforting so as to limit or int erfere with daily 
activities; may require interventional treatment [e.g.,  fever requiring antipyretic medication]).  
• Grade 3 = Severe (event results in significant symptoms that prevent normal daily activities; 
may require hospitalization or invasive interv ention). 
• Grade 4 = Life threatening or disabling.  
• Grade 5 = Death.  
AEs will be reported with an individual start and stop d ate for each level of severity.  
7.4 Causality Relationship of AEs  
The relationship of each AE to each study drug (NKTR -214 and/or nivolum ab and/or 
ipilimumab and/or other cytotoxic chemotherapy) as applicable will be evaluated by the 
Investigator using the fol lowing definitions:  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 129 of 178 
Confidential and Proprietary   11 February 2020  • Not related:  The AE is clearly not related to the study drug(s).  The AE can be explained to 
be likely related t o other factors such as concomitant medications or the patient’s clinical 
state. 
• Possibly related:  The AE may be related t o the investigational agent(s).  A plausible 
temporal sequence exists between the time of administration of the investigational produ ct 
and the development of the AE, and it follows a known response pattern to the 
investigational product.  The reaction may  have been produced by the patient’s clinical state 
or other concomitant therapies or interventions.  
• Related:  The AE is clearly related to the investigational agent(s).  A plausible temporal 
sequence exists between the time of administration of the invest igational product and the 
development of the AE, and it follows a known response pattern to the investigational 
product.  The occurrence of this AE can be confirmed with a positive re -challenge test or 
supporting laboratory data.  
The causality criteria of related and possibly related will be considered “related” to the study 
drug(s) for regulatory reporting requirements.  
7.5 AE Reporting and Follow -up 
After initiation of study d rug treatment, all AEs will be reported from the time of first study 
drug(s) adminis tration until 100  days after the last dose of all study drug (s).  For patients 
initiating a new antineoplastic regimen, the decision date of study drug discontinuation and the 
EOT visit date must be prior to the start date of the new antineoplastic regimen .  
All ongoing AEs will be followed until resolution, the patient is lost to follow -up, patient death, 
or until the EOT visit, whichever is earlier.  In case the AE has not completely resolved by the 
EOT visit, the final outcome of these ongoing AEs will b e captured as “Not Recovered/Not 
Resolved” or “Recovering/Resolvin g”, whichever is applicable.  Any new AEs occurring after 
the EOT visit will not  be captured unless related to a study drug.  
After informed consent has been obtained but prior to initiation  of study treatment, only SAEs 
caused by a protocol -mandated inter vention (e.g., invasive procedures such as biopsies, 
discontinuation of medications) should be reported.  After initiation of study treatment, all SAEs 
will be reported  as described above.  After the end of the reporting period for SAEs,  the 
investigator m ust report any SAE that is believed to be related to prior exposure to study 
treatment or protocol -specified procedure.   
For specific instructions on identifying and reporting SAEs, see Sec tions 7.6 and 7.7. 
7.6 Serious AE Definition  
An SAE is defined as any untoward medical occurrence that at any dose:  
• Results in death.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 130 of 178 
Confidential and Proprietary   11 February 2020  • Is life threatening, i.e.,  in the opinion of the Investigator, the AE places the patient at 
immediate risk of death from the event as it occurred; it does not include a reaction that, had 
it occurred in a more severe form, might  have caused death.  
• Requires inpatient hospitalization or prolon gation of an existing hospitalization that occurs 
during the course of a patient’s participation in a clinical study, except for those due to the 
following:  
– A surgery or procedure that was pla nned before the patient entered the study and which is 
part of the planned study procedure.  
– Nonmedical reasons, in the absence of an AE.  
• Results in persistent or significant disability or incapacity.  
• Is a congenital anomaly or birth defect.  
• Is an important  medical event that, based upon appropriate medical judgment, ma y 
jeopardize the patient and may require medical or surgical intervention to prevent one of the 
other outcomes listed above.  
Death is an outcome of an AE and not an AE in itself.  All events l eading to death, regardless of  
relationship to study drugs, that  occur during the protocol -specified reporting period , must be 
reported with the exception of deaths attributed to disease progression (refer to Section 7.9).  An 
efficacy failure is not considered an SAE.  “Life -threatening” means that the patient was at 
immediate risk of death from the event as it occurred.  This does not include an even t that might 
have led to death if it had occurred with greater severity.  “Inpatient hospitalization” means the  
patient has been admitted to a hospital for medical reasons for any length of time.  The 
Investigator should attempt to establish a diagnosis of  the event based on signs, symptoms, 
and/or other clinical information.  In such cases, the diagnosis will be documented as the  AE 
and/or SAE and not the individual signs/symptoms.  
7.7 Serious AE Reporting  
Serious AEs occurring after the patient has provided informed consent, but before the first dose 
of study treatment, will be collected as medical history unless the event is either new and 
attributed to protocol -mandated procedures by the Investigator or t here is a significant change in 
the rate of occurrence or an increase in the severity of the pre -existing condition which is judged 
to be clinically important and attributed to the protocol-mandated procedures by the Investigator.  
Any new or clinically si gnificant changes in the patient’s medical and/or cancer history that 
occur immediately after the first dose of drug will be recorded as SAEs.  All SAEs, regardless of 
causality att ribution, will be reported to Nektar Therapeutics Drug Safety within 24 hours of 
when the site becomes aware of the event.  The duration of the reporting period is described in 
Section 7.5, AE Reporting and Follow -up. 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 131 of 178 
Confidential and Proprietary   11 February 2020  For SAEs that occur within 100 days of last dose of nivolumab or ipilimumab, medications and 
other therapeutic measures used to treat the SAE will be recorded on the eCRF.  
In addition, all SAEs that occur beyond 100 days after the last dose of all study drug(s) that are 
assessed by the Investigator as related  to study drug(s) will also be reported to Nektar 
Therapeutics Drug Safety within 24 hours of when the site becomes aware of the event.  
SAEs must be reported to Nektar Therapeutics Drug Safety via email or Fa x as listed at the 
beginning of this protocol.  
The Investigator must complete the SAE Report Form, assess the causality relationship to the 
study treatment as applicable, and send the completed SAE form via email or fax to Nektar 
Therapeutics Dr ug Safety.  A follow-up report and any additional records (such as hospital 
records, consultant reports, and autopsy findings) will be emailed or faxed to Nektar 
Therapeutics Drug Safety within 24 hours of receipt.  Any medication or other therapeutic 
measures used t o treat the event will be recorded  on the SAE Report Form . 
All SAEs will be followed as described in Section  7.8. 
Reporting of SAEs to the Instituti onal Review Board (IRB)/Independent Ethics Committee  (IEC) 
will be done in accordance with the standard operating procedures (SOPs) and policies of the 
IRB/IEC.  Adequate documentation must be provided to Nektar Therapeutics, showing that the 
IRB/IEC was p roperly notified.  Serious AEs will be reported by N ektar Therapeutics or 
designee to the Regulatory Authorities, per local regulations.  
7.8 Serious AE Follow -up 
All study treatment -related SAEs that have not resolved by the EOT visit (Section  5.4) will be 
followed u ntil any of the following occur (whichever comes first):  
• The event resolves.  
• The event has stabilized.  
• The event returns to baseline, if a baseline value is available.  
• It is unlikely that any additional information can be obtained (e.g.,  patient or health care 
practitioner refuses to provide additional information; lost to follow -up after demonstration 
of due diligen ce with follow -up efforts).  
• The patient dies or is lost to follow -up. 
All ongoing SAEs assessed as “unrelated” to study drug(s) will be followe d until resolution or 
until the EOT visit (Section  5.4), whichever is earlier.  In the case where an unrelated SAE has 
not completely resolved by the EOT visit, the final outcome of these ongoing SAEs will be 
captured as “Not Recovered/Not Resolved” or “Recove ring/Resolving”, whichever is applicable.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 132 of 178 
Confidential and Proprietary   11 February 2020  7.9 Disease Progression  and Death due to Disease Progression  – Not Reportable as an 
AE/SAE  
It is anticipated that during this study a proportion of patients will experie nce disease progression 
prior to study discontinu ation.  Progressive disease  (PD) in some patients may result in 
hospitalization or death.  Such events leading to hospitalization  or death of a study patient are 
typically considered “serious,” requiring sub mission of an SAE report.  However, because PD is 
an endpoint for this study, reporting the term “disease progression” as either an AE or SAE is not 
necessary.  
However, i f there are separate identifiable clinical manifestations of the PD, (e.g., pleural 
effusion or weight loss ), the primary manifestations may be reported as non-fatal AEs or SAEs.  
For all SAEs associated with fatal PD, the following criteria will apply:  
• Seriousness Criteria = Cannot equal Death  
• Severity = Cannot equal Grade 5  
• Outcome = Ongo ing at time of Death  
7.10 Immune -mediate d Adverse Event s  
Nektar will evaluate imAEs associated with either NKTR -214, nivolumab, and/or ipilimumab.  
Investigators should use clinical judgment when characterizing an AE as immune mediated, 
including the requireme nt for steroid treatment, and are encouraged to rule out neoplastic, 
infectious, metabolic, toxic, or other etiologies to the extent possible, before characterizing an 
event as immune mediated .   
See Section 5.14 for additional information on management algorithms  for immune mediated 
AEs. 
7.11 Adverse Events of Special Interest  
Cerebrovascular accident (CVA, any grade) is considered an “adverse event of special interest” 
(AESI) and should be assessed f or seriousness using the standard  seriousness definition .  
However, all CVAs are required to follow the timeline for SAE reporting ( within 24  hours as 
described in Section 7.7) from the sites to Nektar Drug Safety: pharmacovigilance@nektar.com .  
CVA Management Guidelines  are provided in Appendix 3. 
7.12 Potential Drug -Induced Liver Injury  
Wherever possible, timely confirmation of initial liver -related laborat ory abnormalities should 
occur prior to the reporting of a potential DILI event.  All occurrences of potential DILIs, 
meeting the defined criteria, must be reported as SAEs (see Section  7.7 for reporting details).  
A potential D ILI is defined as : 
• Treatment -emergent ALT or AST > 3 times ULN,  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 133 of 178 
Confidential and Proprietary   11 February 2020  AND 
• Total bilirubin > 2 times ULN or clinical jaundice, without initial findings of cholestasis 
(elevated serum alkaline phosphatase),  
AND 
• No other immediately apparent possible causes of ele vated liver enzymes and 
hyperbilirubinemia, including, but not limited to, viral hepatitis, pre -existing chronic or acute 
liver disease, or the administration of other drug(s) known to be hepatotoxic.  
7.13 Pregnancy  
The Sponsor must be notified within 24  hours of the initial report and any follow -up reports of a 
male patient’s female partner or a female patient becoming pregnant during the course of the 
study and for up to 5  months for female patients or 7 months for female partners of male patients 
after the la st dose of the study drug(s) via the Pregnancy Form.  Pregnancy , although reportable, 
is not considered an AE/SAE unless a female patient or male patient’s female partner 
experiences signs or symptoms of pregnancy complications; however, the contact inform ation 
for pregnancy reporting is the same as for SAE reporting and listed in Section  7.7.  In order for 
the Sponsor or designee to collect any pregnancy surveillance information, the pregnant patient 
or partner  must sign an informed consent form for disclosure information.   Information on this 
pregnancy will be collected on the Pregnancy Form.   Female patient(s) or female partner(s) of 
male patient(s) who become pregnant will be followed until the outcome of the  pregnancy is 
known.  Pregnancy follow -up should describe the outcome of the pregnancy, including any 
voluntary or spontaneous termination, details of the birth, and the presence or absence of any 
congenital abnormalities or birth defects in the offspring.  
If a female patient becomes pregnant, administration of the study drug(s) must be discontinued 
immediately.  
If, for whatever reason, the pregnancy has ended, confirmed by negative serum pregnancy test, 
treatment may be resumed at the discretion of the inv estigator (at least 3 weeks and not greater 
than 6 weeks after the pregnancy has ended) following approvals of the patient/IRB/IEC, as 
applicable.  
7.14 Clinical Laboratory Tests  
Clinical laboratory tests will be conducted according to the Schedule of Events (Se ction 1.2).  
Clinical laboratory tests will be performed by the local laboratory for Part  1 and Part 3 and 
central laboratory for Parts  2 and 4 (ex cept as designated in Appendix  1).  (For Parts  2 and 4, if 
the central laboratory tests are cancelled, lo st, or considered inadequate for analysis, the site may 
forward an identical set of local laboratory s amples for eligibility review.  Central laborator y 
testing must be repeated prior t o the first dose of study drug.  If local laboratory results are 
determined to be acceptable by the Medical Monitor [or designee] during eligibility review, 
enrollment may proceed.)  Clinical laboratory test data will be r eviewed by the Investigator or 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 134 of 178 
Confidential and Proprietary   11 February 2020  qualified Sub -Investigator.  Additi onal clinical laboratory tests may be ordered at the 
Investigator’s or qualified Sub -Investigator’s discretion.  Additional testing for PK and 
biomarkers will be performed by the designated central laboratory.  
The Investigator or qualified Sub -Investigator  will review all laboratory results for clinical 
significance.  Any laboratory result deemed clinically significant (i.e.,  is associated with signs 
and symptoms, requires treatment, or requi res follow up) will be recorded as an AE as described 
in Section  7.1. 
7.15 Physical Examinations  
Physical examinations should be conducted according to the Schedule of Events (Section  1.2).  
Full physical examinations should be conducted at screening, Day 1 of each cycle, Cycle 1 Day 2 
(C1D2), C1D3, C1D8, and EOT (evaluate all major organ systems, including the fol lowing 
categories:  general, head, eyes, ears, mouth/throat,  neck, heart, lungs, abdomen, lymph nodes, 
joints, extremities, integumentary, neurologic, and psychiatric).  Other examinations may be 
focused, at the discretion of the Investigator, to identify changes from baseline or evaluate 
changes based on the patie nt’s clinical symptoms.   
7.16 Vital Signs  
Vital sign measurements will be recorded according to the Schedule of Assessments  
 (Appendix 2).  Vital signs include pulse rate, respiratory rate, systolic and diastolic blood 
pressure, oxygen saturation (oxygen saturation on dosing days only ), and temperature.  It is 
preferred that the same arm be used for all blood pressure readings, if possible.  Instructions for 
more frequent vital sign monitoring after completion of study dr ug administration are provided 
in Section  5.3.7.1.  Weight is to be reported at each vital sign visit, height at screening visit only.  
7.17 Electrocardiograms  
Prior to each NKTR -214 PK sampling time in Cycle 1 of tre atment, 5 minutes of ECG data will 
be recorded ( for details see Appendix  2 Schedule of Assessments).   
Patients must be resting quietly in the supine position for at least 5  minutes before the ECG 
collection.  Five-minute ECG will be performed on a calibrated 12 -lead machine an d the 
5-minute recording will be converted into a summary ECG (simulated 10 -second ECG).  The 
summary ECG will be submitted to a designated ECG laboratory for interpretation of ECG and 
interval duration measurements.  Interpretation of ECGs and interval du ration measurements will 
be provided to the site.  
The Investigator or qualified Sub -Investigator will review all ECG interpretations and interval 
duration measurements for clinical signifi cance.  Any ECG interpretation deemed to be clinically 
significant w ill be reported as an AE as described in Section  7.1.   
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 135 of 178 
Confidential and Proprietary   11 February 2020  7.18 Echocardiograms  
Standard echocardiogram will be performed to assess cardiac function an d LVEF according to 
the Schedule of Events (Section  1.2).  In the event of an abnormal ECHO, the Investigator may 
perform a stress ECHO (either exercise or nuclear).   A MUGA scan can be performed to assess 
cardiac function and LVEF if a standard echocardiogram cannot be performed.  The same 
assessment method should be used for the same patient throughout the study. After a number of 
patients have been enrolled in the dose escalation, the Safety Review Committee m ay determine 
that an ECHO is not needed, in this case the ECHO assessment may be removed from study.  
7.19 Pregnancy Tests  
Serum or urine pregnancy tests will be performed on women of childbearing potential during 
screening.  Urine or serum pregnancy tests will be performed on women on Day  1 of each cycle 
prior to dosing and at EOT.  A negative pregnancy test result must be obtained before the 
administration of the study drug(s).  
A pregnancy test does not need to be performed on women who are postmenopausal for a t least 
1 year or surgically sterile for at least 5  months before signing the ICF , or for female pat ients 
who reach 1 year of postmenopausal status after study entry (or reach 5 month post -surgical 
sterilization after entering the study) . 
If a female patient becomes pregnant, administration of the study drug(s) must be discontinued 
immediately.  Requirements for reporting a pregnancy are provided in Section  7.13. 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 136 of 178 
Confidential and Proprietary   11 February 2020  8.0 ASSESSMENT OF EFFICA CY EVALUATIONS  
Response and pr ogression will be determined using RECIST  1.1 (Eisenhauer,  2009).   
8.1 Definitions  
At baseline, tumor lesions/lymph nodes will be categorized as measurable or non -measurable as 
described below.  
8.1.1 Measurable Disease  
Target tumor  lesions:  Must be accurately measured in at least one dimension (longest diameter 
in the plane of measurement is to be recorded) with a minimum size of:  
• 10 mm by CT scan (CT scan slice thickness no greater than 5  mm); when CT scans have 
slice thickness gr eater than 5  mm, the minimum size for a measurable lesion should be twice 
the slice thickness.  
Malignant lymph nodes :  To be considered pathologically enlarged and measurable, a lymph 
node must be ≥ 15 mm in short axis when assessed by CT scan (CT scan sli ce thickness 
recommended to be no greater than 5  mm).  At baseline and in follow -up, only the short  axis will 
be measured and followed.  
8.1.2 Non-measurable Disease  
All other lesions, including small lesions (longest diameter <  10 mm or pathological lymph 
nodes ≥ 10 to < 15 mm in short axis) as well as truly non -measurable lesions, are considered 
non-measurab le disease.  Lesions considered truly non -measurable include:  leptomeningeal 
disease, ascites, pleural or pericardial effusion, lymphangitic involvement of skin or lung, or 
abdominal masses/abdominal organomegaly identified by physical examination that ar e not 
measurable by reproducible imaging techniques.  
8.2 Specifications by Methods of Measurements  
The same method of assessment and the same technique should  be used to characterize each 
lesion at baseline and during follow -up.  Imaging -based evaluation shoul d always be done rather 
than clinical examination unless the lesion(s) being followed cannot be imaged but are assessable 
by clinical examination.  
Clinical lesions:  Clinical lesions will only be considered measurable when they are superficial 
and ≥ 10 mm diameter as assessed using calipers (e.g.,  skin nodules).  When lesions can be 
evaluated by both clinical examination and imaging, imaging evaluation should be undertaken 
since it is more objective and may also be reviewed at the end of the study.  For cut aneous 
lesions that are included in target lesions, digital photographs should be obtained and utilized for 
measurement.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 137 of 178 
Confidential and Proprietary   11 February 2020  CT, MRI:  CT is the best currently a vailable and reproducible method to measure lesions 
selected for response assessment.  If a slice t hickness >  5 mm is used for CT scanning, then the 
minimum longest diameter for a target lesion should be twice the slice thickness.  CT/PET is 
acceptable pro viding the CT component is of diagnostic quality (with slice thickness ≤ 10 mm). 
MRI is also accept able in certain situations (e.g.,  for body scans). 
Tumor markers :  Tumor markers alone cannot be used to assess objective tumor response.  If 
markers are ini tially above the ULN, however, they must normalize for a patient to be considered 
in complete respo nse. 
Cytology, histology :  These techniques can be used to differentiate between PR and CR in rare 
cases when the nature of a residual lesion is in question.   The cytological confirmation of the 
neoplastic origin of any effusion that appears or worsens dur ing treatment can be considered if 
the measurable tumor has met criteria for response or SD in order to differentiate between 
response (or SD) and PD.  
8.2.1 Tumor Response Evaluation  
8.2.1.1  Assessment of Overall Tumor Burden at Baseline and Measurable Disease  
To assess  objective response or future progression, it is necessary to estimate the overall tumor 
burden at baseline and use this as a comparator for subsequent measu rements.  Measurable 
disease is defined by the presence of at least one measurable lesion.  
8.2.1.2  Baseline  Documentation of ‘Target’ and ‘Non -target’ Lesions  
When more than one measurable lesion is present at baseline, all lesions up to a maximum of 
5 lesions tot al (and a maximum of 2  lesions per organ) representative of all involved organs 
should be identifie d as target lesions and will be recorded and measured at baseline (this means 
that in instances where patients have only 1  or 2 organ sites involved a maximu m of 2 and 
4 lesions, respectively, will be recorded).  Target lesions should be selected on the ba sis of their 
size (lesions with the longest diameter), be representative of all involved organs, but in addition 
should be those that lend themselves to repr oducible repeated measurements.  It may be the case 
that, on occasion, the largest lesion does not lend itself to reproducible measurement, in which 
circumstance the next largest lesion which can be measured reproducibly should be selected.  
Pathological no des which are defined as measurable and may be identified as target lesions must 
meet the criterion  of a short axis of ≥  15 mm by CT scan.  Only the short axis of these nodes will 
contribute to the baseline sum.  All other pathological nodes (those with sh ort axis ≥  10 mm but 
< 15 mm) should be considered non -target lesions.  Nodes that have a short axi s < 10 mm are 
considered non -pathological and should not be recorded or followed.  
A sum of the diameters (longest for non -nodal lesions, short axis for nodal lesions) for all target 
lesions will be calculated and reported as the baseline sum diameters.  If  lymph nodes are to be 
included in the sum, then as noted above, only the short axis is added into the sum.  The baseline 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 138 of 178 
Confidential and Proprietary   11 February 2020  sum diameters will be used as reference to further characterize any objective tumor regression in 
the measurable dimension of the dise ase. 
All other lesions (or sites of disease) including pathological lymph nodes should be identified as 
non-target lesions and should also be recorded at baseline.  Measurements are not required and 
these lesions should be followed as ‘present’, ‘absent’, or in rare cases ‘unequivocal 
progression’.  
8.2.1.3  Special Notes on the Assessment of Target Lesions  
Lymph nodes :  Lymph nodes identified as target lesions should always have the actual short axis 
measurement recorded (measured in the same anatomical plane as the baseline examination), 
even if the nodes regress to below 10  mm on study.  For PR, SD, and PD, the actual short axis 
measurement of the nodes is to be included in the sum of target lesions.  
Target lesions that become ‘too small to measure’ :  While on study, all lesions (nodal and 
non-nodal) recorded at baseline should have their actual measurements recorded at each 
subsequent evaluation, even when very small (e.g.,  2 mm).  However, if the lesion is believed to 
be present and is faintly seen but is too small to measure with any accuracy, a default value of 
5 mm should be assigned.  
8.2.2 Response Criteria using RECIST 1.1  
8.2.2.1  Evaluation of Target Lesions  
Table 21 provides the definitions of the criteria used to determine object ive tumor response for 
target lesions.  
Table  21: Criteria to Determine Objective Tumor Response for Target Lesions 
per RECIST 1.1  
Complete Response (CR)  Disappearan ce of all target lesions.  Any pathological lymph nodes (whether tar get or 
non-target) must have reduction in short axis to <  10 mm. 
Partial Response (PR)  At least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, 
taking as refer ence the baseline SLD  
Progressive Disease (PD)  At least a 20% incre ase in the SLD of target lesions, taking as reference the smallest 
SLD on study (this includes the baseline sum if that is the smallest on study).  In 
addition to the relative increase of 20%, the sum must also demonstrate an absolute 
increase of at least 5 mm relative to nadir.  (Note:  the appearance of one or more new 
lesions is considered progression.)  
Stable Disease (SD)  Neither sufficient shrinkage to qualify for PR nor s ufficient increase to qualify for PD, 
taking as reference the smallest sum diame ters while on study  
 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 139 of 178 
Confidential and Proprietary   11 February 2020  8.2.2.2  Evaluation of Non -Target Lesions  
Table 22 provides the definitions of the criteria used to determine the tumor response for the 
group of non -target lesions.  Although some non -target lesions m ay actually be measurable, they 
need not be measured and instead should be assessed only qualitatively at the tim e points of 
radiographic assessments.  
Table  22: Criteria to Determine Tumor Response for Non -Target Lesions per 
RECIST 1.1 
Complete Response (CR)  Disappearance of all non -target lesions and normalization of tumor marker level.  
All lymph nodes must be non -pathological in size (<  10 mm short axis).  
Non-CR/Non-PD Persistence of one or more non -target lesion(s) and/or mainte nance of tumor marker 
level above the normal limits  
Progressive Disease (PD)  Unequivocal progression of existing non -target lesions.  (Note:  the appearance of 
one or more new lesions is also considered progression).a 
NOTE:  If tumor markers are assessed  for a given patient and are initially above the ULN, they must normalize for 
a patient to be considered in complete CR.  
a. In this setting, when a patient has measurable disease, to achieve “unequivocal progression” on the basis of the 
non-target disease,  there must be an ov erall level of substantial worsening in the non -target disease such that, 
even in the presence of SD or PR in the target disease, the overall tumor burden has increased sufficiently to 
merit discontinuation of therapy.  A modest increas e in size of one or more non -target lesions is usually not 
sufficient to qualify for unequivocal progression status.  The designation of overall progression solely on the 
basis of change in non -target disease in the face of SD or PR of target disease will therefore be extreme ly rare 
(from Section  4.3.4 of RECIST  1.1). 
 
8.2.2.3  Confirmatory Measurement/Duration of Response  
8.2.2.3.1  Confirmation  
Confirmation of response (either PR or CR) is required.  Changes in tumor measurements must 
be confirmed by repeat assessments that should be performed ≥ 4 weeks after the criteria for 
response are first met.  
8.2.2.4  Evaluation of Overall Response Using RECIST 1.1  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 140 of 178 
Confidential and Proprietary   11 February 2020  Table  23: Best Overall Response When Confirmation of CR and PR Required  
Overall Response  
First Time Point  Overall Response  
Subs equent Time Point  BEST Overall Response  
CR CR CR 
CR PR SD, PD, or PRa 
CR SD SD provided minimum criteria for SD 
duration met, otherwise.  PD  
CR PD SD provided minimum criteria for SD 
duration met, otherwise.  PD  
CR NE SD provided minimum criteria for SD 
duration met, otherwise.  NE  
PR CR PR 
PR PR PR 
PR SD SD 
PR PD SD provided minimum criteria for SD 
duration met, otherwise.  PD  
PR NE SD provided minimum criteria for SD 
duration met, otherwise.  NE  
NE NE NE 
Abbreviations:  CR = complete response;  NE = inevaluable; PD = progressive disease; PR = partial response; 
SD = stable disease  
a. If a CR is truly met at the first time point, then any disease seen at a subsequent time point, even disease 
meeting PR criteria relative to baseline, makes the disease  PD at that point (since disease must have reappeared 
after CR).  Best response would depend on whether minimum duration (7  weeks) for SD was met.  However, 
sometimes ‘CR’ may be claimed when subsequent scans suggest small lesions were likely still present  and in 
fact the patient had PR, not CR at the first time point.  Under these circumstances, the original CR should be 
changed to PR and the best response is PR.  
Source:  Eisenhauer, 2009 
 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 141 of 178 
Confidential and Proprietary   11 February 2020  9.0 STATISTICAL METHODS PLANNED IN TH E PROTOCOL AND 
DETERMINATION OF SAM PLE SIZE  
9.1 General Considerations  
In general, continuous data will be summarized by descriptive statistics, including number of 
patients, mean, standard deviation, median, minimum, and maximum.  Categorical data will be 
summarized by the number and percentage of patients.  Unless otherwise specified, data 
collected during the dose escalation/schedule finding phase (Parts  1 and 3) will be summarized 
by dose cohort, and data c ollected during the dose expansion phase (Parts  2 and 4) will be 
summarized by tumor type.  
9.1.1 Efficacy  
All efficacy endpoints except OS and PFS will be analyzed using the response evaluable 
population  and the ITT population.  OS and PFS will be reported for t he ITT population .  All 
safety endpoints will be su mmarized using the safety population.  
A description of analysis methods and detailed definitions for efficacy and safety endpoints will 
be provided in the statistical analysis plan (SAP).  
9.2 Determination of Sample Size  
During Part  1, cohorts of at least 3  patients will be treated at each dose level.  Additional patients 
will be added to each dose cohort based on the scheme and rules outlined in Section  5.3.2 or 
Sponsor determination of the need for additional data to further evaluate the benefit/risk profile.  
It is estimated that approximately 50  patients will be enrolled into the Part  1 dose escalation 
phase. 
During Part  3, cohorts of at least 6  patients will be enrolled to each of the 3  dosing schedules in 
Cohort A (concurrent dosing) .  Additional patients will be added to each dose schedule based on 
the scheme and rules outlined in Section  5.3.5 or Sponsor determination of the need for 
additional data to further evaluate the benefit/r isk profile.  If a DLT is observed in 2 or more 
patients of 6 in Cohort  A, patients may enroll into Cohort B (staggered dosing), where 
ipilimumab will be staggered to be administered at a later cycle (e.g., Cycle  3 Day 1).  It is 
estimated that approximate ly 36 patients will be enrolled into the Part  3 dose escalation phase.  
During Parts  2 and 4, patients will be enrolled as described in Sections  5.3.4 and 5.3.6.  The 
sample size is strictly based on efficacy, specifically based on the target ORR relative to historic 
response rate.  The Fleming 2 -stage design ( Fleming, 1982) framework will be used as a guide 
for the tumor cohorts.  The to tal sample size for each expansion cohort (including patients treated 
at the RP2D during the dose escalation period) will be calculated using a normal approximation 
to provide a reasonable fal se-positive rate (FPR  < 10%) and false -negative rate (FNR  < 10%) 
based on assumptions of true (target) and historic ORR for each indication ( Table 24 and 
Table 25).  The historic and target response rate assumptions may change over time  and may 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 142 of 178 
Confidential and Proprietary   11 February 2020  need to be adjusted at the time of response data from thi s study are available.  The 2 -stage design 
provides an option to stop early for futility as well as allowing an early start for Phase  3 
preparation if a strong antitumor activity signal is o bserved.  However, the final decision will be 
based on the totalit y of overall treatment effect for multiple study endpoints and their 
associations with the tumor response rate.  Enrollment may continue into Part  2 while the 
planned number of patients for Part 1 are followed for efficacy -evaluable tumor assessments.  
There will be no stopping of enrollment to a tumor cohort for efficacy, although early planning 
for the next stage of clinical development may be initiated.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 143 of 178 
Confidential and Proprietary   11 February 2020  Table  24: True (Target) and Historic Objective Response Rate for Each 
Indicati on in Part  2 
Cohorta Indication  Objective 
Response Rate (%)  Sample Sizeb Futility  Efficacy  Reference for 
Historical ORR 
Assumption  Historical Target N1 N2 Total S1 S2 T1 T2 
1a MEL 1L 40 65 13 15 28 ≤ 5 ≤ 14 ≥ 10 ≥ 15 Robert, 2015 
1b MEL 2-3L, I-O 
relapse/ refractory  10 30 15 11 26 ≤ 1 ≤ 5 ≥ 4 ≥ 6 Unmet medical 
need 
1c MEL 2L BRAF wild 
type I-O relapse/ 
refractory  10 30 15 11 26 ≤ 1 ≤ 5 ≥ 4 ≥ 6 Unmet medical 
need 
1d MEL 1L following  
prior adjuvant therapy 10  30 16 12 28 ≤ 1 ≤ 5 ≥ 4 ≥ 6 Nomura, 2017;  
Weber, 2013 
2a RCC 1L  25 50 11 15 26 ≤ 2 ≤ 9 ≥ 6 ≥ 10 Topalian,  2012 
2b RCC 2-3L, I-O 
relapse/ refractory  5 25 15 11 26 ≤ 0 ≤ 3 ≥ 3 ≥ 4 Unmet medical 
need 
3a NSCLC regardless of 
PD-L1 expression  23 45 16 18 34 ≤3 ≤11 ≥7 ≥12 Garon 2015 ; 
Gettinger 2016 ; 
Carbone, 2017 
3a.1 NSCLC 1L PD -L1 
< 1% 8 30 12 8 20 ≤ 0 ≤ 3 ≥ 3 ≥ 4 
Garon, 2015; 
Carbone, 2017 3a.2 NSCLC 1L PD -L1 
≥ 1%-< 50% 14 40 8 10 18 ≤ 0 ≤ 4 ≥ 4 ≥ 5 
3a.3 NSCLC 1L PD -L1 
≥ 50% 25 55 11 9 20 ≤ 3 ≤ 7 ≥ 6 ≥ 8 
3b NSCLC 2L, I -O 
therapy naive 
following 
platinum-based 
therapy 20 40 20 16 36 ≤ 4 ≤ 10 ≥ 8 ≥ 11 Brahmer, 2015 
3c NSCLC 2L, I -O 
relapse/refractory  5 20 12 25 37 ≤0 ≤3 ≥3 ≥4 Unmet medical 
need 
3d.1 NSCLC, 1L 
nonsquamous  
(+ maintenance 
pemetrexed)  45 66 20 19 39 ≤ 9 ≤ 21 ≥ 14 ≥ 22 Gandhi, 2018 
3d.2 NSCLC, 1L 
nonsquamous 
(no maintenance 
pemetrexed)  45 66 20 19 39 ≤ 9 ≤ 21 ≥ 14 ≥ 22 Gandhi, 2018 
3e NSCLC 1L squamous 
in combination with 
platinum/taxane  20 40 20 16 36 ≤ 4 ≤ 10 ≥ 8 ≥ 11 Rizvi, 2016 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 144 of 178 
Confidential and Proprietary   11 February 2020  Table 24:  True (Target) and Historic Objective Response Rate for Each 
Indication in Part 2  (Contd)  
Cohorta Indication  Objective 
Response Rate (%)  Sample Sizeb Futility  Efficacy  Reference for 
Historical ORR 
Assumption  Historical Target N1 N2 Total S1 S2 T1 T2 
3f 3L+ NSCLC 
ALK-translocation/ 
ROS1 rearrangement 
positive 5 20 12 25 37 ≤0 ≤3 ≥3 ≥4 Unmet medical 
need 
3g 3L+ NSCLC, EGFR 
mutation/deletion  5 20 12 25 37 ≤0 ≤3 ≥3 ≥4 Unmet medical 
need 
4a Urothelial 1L 
Cis-ineligible  16 45 10 8 18 ≤1 ≤5 ≥4 ≥6 
Balar, 2017 Urothelial 1L 
(refused standard of 
care) 16 45 10 8 18 ≤1 ≤5 ≥4 ≥6 
4b Urothelial 2 -3L, I-O 
relapse/ refractory  5 25 13 7 20 0 ≤2 ≥3 ≥3 Patel, 2018 
5a TNBC 1-2L, I-O 
therapy naïve  10 26 21 17 38 ≤ 1 ≤ 6 ≥ 5 ≥ 7 Schmid, 2017 
5b TNBC 1-2L, I-O 
therapy 
naive + nab-paclitaxel  24 45 20 18 38 ≤ 5 ≤ 12 ≥ 9 ≥ 13 Forero-Torres, 
2015; 
Gradishar, 2005  
5c TNBC 1-2L, I-O 
therapy 
naive + eribulin 20 40 20 16 36 ≤ 4 ≤ 10 ≥ 8 ≥ 11 Kaufman,  2015; 
McIntyre,  2014 
6a HR+ breast cancer, 
I-O therapy naive 
following hormonal 
therapy 25 
(cytotoxic 
chemo-
therapy) 
 
5% (for 
single 
agent CPI)  45 
 
 
 
20 18 
 
 
 
12 21 
 
 
 
25 39 
 
 
 
37 ≤ 5 
 
 
 
0 ≤ 14 
 
 
 
≤ 3 ≥ 9 
 
 
 
≤ 3 ≥ 15 
 
 
 
≥ 4 Harris, 2006 ; 
Twelves, 2014  
 
 
Rugo 2016;   
Dirix 2018  
6b HR+ breast cancer, 
I-O therapy naive 
following hormonal 
and cytotoxic therapy  20 
(cytotoxic 
chemo-
therapy) 
 
5% (for 
single 
agent CPI)  40 
 
 
 
20 20 
 
 
 
12 16 
 
 
 
25 36 
 
 
 
37 ≤ 4 
 
 
 
0 ≤ 10 
 
 
 
≤ 3 ≥ 8 
 
 
 
≤ 3 ≥ 11 
 
 
 
≥ 4  
Harris, 2006;  
Twelves, 2014  
 
Rugo 2016;  
Dirix  
 

Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 145 of 178 
Confidential and Proprietary   11 February 2020  Table 24:  True (Target) and Historic Objective Response Rate for Each 
Indication in Part 2  (Contd)  
Cohorta Indication  Objective 
Response Rate (%)  Sample Sizeb Futility  Efficacy  Reference for 
Historical ORR 
Assumption  Historical Target N1 N2 Total S1 S2 T1 T2 
7 Gastric carcinoma 
2-3L, I-O therapy 
naïve 13 30 22 15 37 ≤ 2 ≤ 7 ≥ 7 ≥ 8 Kang, 2017 
8a CRC 2-3L, MSI-high, 
I-O therapy naïve 30 50 26 13 39 ≤ 7 ≤ 15 ≥ 13 ≥ 16 Overman, 2017  
8b CRC 3-4L, 
MSI-non-high, I-O 
therapy naïve  5 20 12 25 37 ≤ 0 ≤ 3 ≥ 3 ≥ 4 Le, 2015 
(mismatch repair 
proficient)  
Abbreviations:  cis = cisplatin; CPI = checkpoint inhibitor; CRC  = colorectal carcinoma; EGFR  = epidermal growth 
factor receptor;  HR = hormone-receptor positive; I -O = immuno-oncology; L  = line; MEL = melanoma; 
MSI = microsatellite  instability;  NA = not available; ORR  = objective response rate; NSCLC = non -small cell lung 
cancer; RCC = renal cell carcinoma; TNBC  = triple-negative breast cancer  
a. Cohort 3h is not included in this table but is disc ussed separately in the following paragraph.  
b. Total sample size for each expansion cohort is calculated using a normal approximation to provide a reasonable 
false-positive rate (FPR  < 10%) and false -negative rate (FNR  < 10%). 
 
For efficacy assessment of Coh ort 3h (patients with immuno -oncology relapsed -refractory 
NSCLC whose di sease has progressed on combination therapy of anti -PD-1/anti-PD-L1 with 
cytotoxic chemotherapy), the following statistical assumptions have been incorporated into the 
protocol.  For t his cohort, the Historical Comparator is single -agent docetaxel which sh owed 
9% overall response rate in a second -line NSCLC population ( Herbst, 2016).  With this historical 
control rate as null hypothesis, using a two -sided alpha of 0.05, 100  patients will provide over 
90% power to demonstrate s tatistical significance if the response rate of NKTR -214/nivolumab 
is 20% or more.  If the observed response rate in this cohort (ITT population ) is 18% or better, 
the lower bound of t he 95% confidence interval will rule out 10%  response rate.  
Two interim analyses will be conducted in Cohort  3h to gate the trial progression based on the 
ITT Population (see Section  9.5).  The first interim evaluation will be conducted when 20 
evaluable patients have been followed for 4 months or terminated from the study.  If 3  or more 
responses are observed, the trial may continue to the next stage.  The second interim analysis will 
be performed when 40  evaluable patients hav e been followed for 4  months or terminated from 
the study.  If there are 6  or more responders, the trial may continue to enroll approximately 
100 patients.  Enrollment will continue without pause during the conduct of the interim analyses.   
Approximately 936 patients will be enrolled into Part  2.  Additional patients may be added to 
selected expansion cohorts to further evaluate the benefit/risk profile  or the Sponsor may choose 
not to open or complete all expansion cohorts . 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 146 of 178 
Confidential and Proprietary   11 February 2020  Approximately 36 patients will b e enrolled into Part 3.  
Approximately 106 additional patients will be enrolled into Part  4. 
Table  25: True (Target) and Histori c Objective Response Rate for Each 
Indication in Parts  3 and 4  
Indication  Objective Response Rate  Sample Sizea Futility  Efficacy  
Historical  Target  N1 N2 Total  S1 S2 T1 T2 
RCC 1L 25 50 11 15 26 ≤ 2 ≤ 9 ≥ 6 ≥ 10 
NSCLC 1Lb 25 50 11 15 26 ≤ 2 ≤ 9 ≥ 6 ≥ 10 
Melanoma 1L  40 65 13 15 28 ≤ 5 ≤ 14 ≥ 10 ≥ 15 
Urothelial 1L  25 50 11 15 26 ≤ 2 ≤ 9 ≥ 6 ≥ 10 
Abbreviations:  L = line; N1, N2  = sample size at stage 1, 2; NSCLC = non -small cell lung cancer; RCC  = renal cell 
carcinoma; S1, S2  = futility boundary at stage 1, 2; T1, T2  = efficacy boundary at stage 1, 2  
a. Total sample size for each cohort is calculated using a normal approximation to provide a reasonable 
false-positive rate (FPR  < 10%) and false -negative rate (FNR  < 10%). 
b. Total sample size for 1L NSCLC is based on the assumption that a mixed population of PD -L1 positive and 
negative patients will be enrolled.  If unequal distribution of patients are enrolled, sample size may be modified 
accordingly.  
 
9.3 Safety Monitoring  
A Safety Review Committee consisting of representatives from the Sponsor’s Clinical 
Development, Drug Safety, Biostatistics, other functional representatives, as needed, and at least 
one site Investigator will meet at least quarterly durin g the Dose Escalation phase of the trial to 
review safety data for potential safety risks or more frequently if needed.  The Safety Review 
Committee will be convened to make a recommendation on the continuation, modification, or 
discontinuation of the stud y.   
9.4 Replacement of Pa tients  
Patients in Parts 1 and 3 who do not complete the DLT observation period for reasons other than 
a DLT will be replaced to provide sufficient number of patients included for the dose escalation 
decision.  During Parts  2 and 4, patients who were enrol led and did not meet the eligibility 
criteria will be replaced.  
9.5 Analysis Sets  
ITT Population/ Safety Population :  All patients who receive at least 1  dose (or partial dose) of 
study drug will be included in the analysis. 
DLT Population :  All patients who complete at least the DLT observation period or discontinue 
from the study treatment due to DLT will be included.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 147 of 178 
Confidential and Proprietary   11 February 2020  Pharmacokinetic Population :  All patients in the Safety Population who have evaluable analyte 
concentration -time profiles that allow for the com putation of meaningful PK parameter values.  
Response Evaluable Population :  Patients who have measurable disease (per RECIST  1.1) at 
baseline and also  have at least one post -baseline assessment of tumor response and (for Parts  2 
and 4) meet eligibility criteria are response evaluable.  
Any interim efficacy analysis based on the ITT population will exclude ongoing patients who do 
not have any post -baseline efficacy assessment due to insufficient follow -up. 
9.6 Planned Analyses  
9.6.1 Demographics and Baseline Characteristics  
Demographic data (age, sex, ethnicity, body weight) and baseline disease characteristics will be 
tabulated and summarized by dose cohort (for P arts 1 and 3) and by tumor type (for Parts  2 and 
4) and presented in data listings.  
9.6.2 Safety  
The primary endpoints of the study are to determine the MTD of NKTR -214 in combination with 
nivolumab  and in combination with nivolumab and ipilimumab .  Safety asses sments will be 
summarized separately for Parts 1 through 4 .  AEs and toxicity will be evaluated according to 
NCI CTCAE version  4.03.  Safety assessments will be performed by medical review of AEs and 
laboratory results.  
The incidence rate of DLTs will be e valuated by dose cohort for the DLT population.  
Treatment emergent AEs (TEAEs) will be summarized by preferred term, system organ class, 
NCI-CTCAE grade of severity, and relationship to the study treatment.  
A TEAE is defined as:  (regardless of intensity)  
• Any AE that happens after treatment initiation  
• AE that was present at time of treatment initiation but worsened after treatment initiation  
• AE that was present and resolved prior to treatment and reappeared after treatment initiation  
Vital signs (including change in weight) and clinical laboratory test results will be summarized 
descriptively by dose /schedule  (for Parts 1 and 3) and by tumor type (for Parts  2 and 4).  Any 
significant physical examination findings will be listed.  ECG data will be evaluated b y central 
review and abnormalities, if present, will be listed.  A separate listing and summary of all imAEs 
will be provided.  A listing and summary of patients who discontinued study drug(s) due to an 
AE will be provided.  
A data listing for deaths will b e provided.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 148 of 178 
Confidential and Proprietary   11 February 2020  9.6.3 Efficacy  
Efficacy analyses will be performed on data provided by the Investigator sites as well as from an 
independent radiology review for the following efficacy outcomes:  
• ORR using RECIST  1.1 
• Best overall response (BOR) using RECIST 1.1 
• Time to response (TTR) using RECIST  1.1 
• Duration of response (DOR) using RECIST  1.1 
• Clinical benefit rate (CBR) using RECIST  1.1 
• Overall Survival (OS)  
• PFS using RECIST  1.1 
The primary efficacy measurement is the ORR per RECIST  1.1 using the resp onse evaluable 
population.  Except as stated otherwise in the SAP, the ORR based on the Investigator’s 
assessment will be the primary efficacy endpoint and will be summarized using the response 
evaluable population.  ORR will also be summarized for the ITT  population based on an 
independent radiology review .  Any interim efficacy analysis based on the ITT population will 
exclude ongoing patients who do not have any post -baseline efficacy assessment due to 
insufficient follow -up.  The number and percentage of patients with CR or PR as their best 
overall response will be calculated.  The 95% confidence interval (CI) will be calculated using 
the exact binomial method.  In addition, the ORR analysis will be performed on the number of 
patients treated.  All tumor assessments and  response data will be listed.  The BOR will be 
summarized similarly using the response evaluable population.   
The TTR will be defined for patients who had confirmed CR or confirmed PR as the time from 
the date of f irst dose to date of first documented CR  or PR.  TTR will be summarized using 
descriptive statistics.  
DOR will be defined for patients who have confirmed CR or confirmed PR as the date from first 
documented CR or PR to the date of the first objectively doc umented disease progression per 
RECIST 1 .1 or death due to any cause, whichever is earlier.  Patients who do not have disease 
progression per RECIST 1.1 will be censored on the date of last evaluable tumor assessment.  
Patients who started any subsequent antineoplastic regimen , including target -lesion 
tumor-directed radiotherapy and target -lesion tumor -directed surgery, without a prior reported 
progression will be censored at the last evaluable tumor assessment prior to initiation of the 
subsequent antineoplastic therapy as described .  The DOR wi ll be estimated using the 
Kaplan-Meier method.  The 25%, median and 95% CI, and 75% quartiles will be summarized.  
CBR, defined as the number of patients with confirmed CR, confirmed PR, or SD, will be 
summarized simi larly to ORR using the response evaluabl e population and the ITT population .  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 149 of 178 
Confidential and Proprietary   11 February 2020  Additionally, CBR at 16  weeks (CBR16) and CBR at 24  weeks (CBR24), defined as confirmed 
CR, confirmed PR, or SD for ≥  16 weeks or ≥  24 weeks, respectively, will be summarized.  
PFS is defined as the time from the date of first dose to the date of the first objectively 
documented progressive disease per RECIST  1.1 or death, whichever  is first.  For patients who 
do not have date of disease progression per RECIST  1.1 and date of deat h, patients will be 
censored on the date  of last evaluable tumor assessment.  For patients who started a new 
antineoplastic regimen,  or had surgery or radiotherapy to the target lesion prior to disease 
progression per RECIST 1.1, patients will be censored on the date of last evaluable tumor 
assessment prior to receiving new treatment.  For patients whose disease progression or death 
appears after missing two consecutive tumor assessments, patients will be censored on the date 
of last evaluable tumor assessm ent.  Patients who are lost to follow up  will be censored on the 
date of their last evaluable tumor assessment.  Additional censoring rules will be discussed in the 
SAP. 
PFS will be estimated using the Kaplan -Meier method.  The 25%, median and 95% CI, and 75% 
quartiles will be summarized using  the ITT population . 
OS will be defined as the date of first dose to the date of death.  Patients who do not have a date 
of death will be censored on the last date for which a patient was known to be alive.  OS will be  
analyzed similarly to PFS.  
9.6.4 Immunogenici ty 
Validated assays will be used for the determination of anti -drug antibodies to NKTR -214 and 
related components, nivolumab, and ipilimumab in human serum.  Only patients who receive at 
least 1 dose of NKTR -214, nivolumab, and/ or ipilimumab and who provi de at least 
1 post-treatment sample will be evaluated.  Immunogenicity results will be analyzed 
descriptively by summarizing the number and percentage of patients who develop detectable 
anti-drug antibodies.  Samples  confirmed positive may also be evaluate d for neutralizing 
antibody activity. Anti -drug antibodies to NKTR -214, nivolumab, and ipilimumab will be 
analyzed according to a prespecified analysis plan.  
  
  
 
 
 
 
9.6.6 Pharmacokinetics  
Plasma concentrations of NKTR -214 and its metabolites, and serum concentrations of nivolumab 
and ipilimumab, will be measured using validated method(s).  Before analysis of samples, assay 

Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 150 of 178 
Confidential and Proprietary   11 February 2020  sensitivity, specificity, linearity, and reproducibility will be determined.  Pharmacokinetic 
parameters such as maximum concentration (C max), time to Cmax (Tmax), area under the curve 
(AUC), clearance (CL), volume of distribution (V d), and half -life (t1/2) will be estimated from 
concentratio n-time data where possible.  Pharmacokinetic data from this study may also be 
pooled with data from other clini cal studies for the purpose of PK modeling.  Pharmacokinetic 
parameters will be tabulated and summarized with descriptive statistics.  Select pha rmacokinetic 
parameter values will be correlated with select safety and response measurements for assessment 
of exposure-response relationships.  Data from patients prematurely ending participation in the 
study may be excluded from the PK data evaluation.  
9.7 Concomitant Medications  
All reported concomitant medications will be mapped using the World Health Organization  Drug 
Dictionary.  Concomitant medications will be tabulated in summary tables and data listings.  
9.8 Missing Data  
Statistical considerations and met hodology for handling missing data will be detailed in the 
Statistical Analysis Plan.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 151 of 178 
Confidential and Proprietary   11 February 2020  10.0 STUDY OR STUDY SITE TERMI NATION  
The Sponsor has the right to suspend or terminate the study  or part of the study  at any time for 
any reason.  
If an Investigator suspends or terminates their study site, the Investigator will promptly inform 
the Sponsor and the IRB/IEC and provide th em with a detailed written explanation.  Upon study 
completion, the Investigator will provide the Sponsor, IRB/IEC, and re gulatory agency with final 
reports and summaries as required by regulations.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 152 of 178 
Confidential and Proprietary   11 February 2020  11.0 QUALITY CONTROL AND QUALITY ASSURANCE  
The Sponsor will im plement and maintain quality control and quality assurance procedures with 
written SOPs to ensure that the study is conduc ted and data are generated, documented, and 
reported in compliance with the protocol, Good Clinical Practice (GCP), and applicable 
regulatory requirements.  
11.1 Changes to the Protocol  
The Investigator may not deviate from the protocol without a formal protocol  amendment having 
been established and approved by an appropriate IRB/Independent Ethics Committee (IEC), 
except when necessary to eli minate immediate hazards to the patient or when the change(s) 
involve only logistical or administrative aspects of the stu dy.  Any deviation may result in the 
patient having to be withdrawn from the study and rendering that patient nonevaluable.  All 
protocol deviations and the reasons for such deviations are to be documented in the source 
documents and reported to the Sponso r. 
Prior to formal protocol amendment, an administrative letter describing protocol changes may be 
used by the Sponsor where permitted .  The administrative letter will include a commitment to 
amending the protocol within a specified time frame and, followi ng approval by the IRB/IEC, 
will eliminate the requirement to document a protocol deviation for the described change.  
11.2 Monitoring  
In accordance with Code of Federal Regulations 21 CFR 312.56, International Conference on 
Harmonisation (ICH) GCP, and local re gulations, the clinical monitor will periodically inspect 
all electronic case report forms ( eCRFs ), study documents, research faciliti es, and clinical 
laboratory facilities associated with this study at mutually convenient times during and after 
completion  of the study.  As required by 21 CFR 312 Subpart D (Responsibilities of Sponsors 
and Investigators), ICH GCP, and local regulations, the monitoring visits provide the Sponsor 
with the opportunity to evaluate the progress of the study; verify the accuracy and completeness 
of eCRFs; ensure that all protocol requirements, applicable FDA, ICH GCP, and local 
regulations, and Investigator’s o bligations are being fulfilled; and resolve any inconsistencies in 
the study records.  This includes inspection of all doc uments and records that are required to be 
maintained by the Investigator, including, but not limited to, medical records (office, cli nic, or 
hospital) for the patients in this study.  The names and identities of all research patients will be 
kept in stric t confidence and will not appear on eCRFs or other records provided to or retained 
by the Sponsor.  The Investigational New Drug Appli cation (IND) regulations and ICH E6 
guidelines also require the Investigator to allow authorized representatives of the Sp onsor, 
IRB/IEC, FDA, and other relevant regulatory authorities direct access to study source records, 
and to inspect and make copies o f the same records.  The names and identities of the patients 
need not be divulged to the Sponsor; however, the records mu st nevertheless be available to be 
inspected for review.  This can be accomplished by blacking out the patient’s name and replacing 
the name with the patient’s study identification number.  If these requirements are in conflict 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 153 of 178 
Confidential and Proprietary   11 February 2020  with local regulatory restri ctions or institutional requirements, the Investigator must inform the 
Sponsor of these restrictions before initiation of the study.  
11.3 Direct Access to Source Data/Documents for Audits and Inspections  
Members of the Sponsor or designees may conduct monitorin g and auditing activities of a 
clinical site at any time during or after completion of the study.  The Investigator will be 
informed o f such activities.  
Representatives of the FDA or other regulatory agencies, including IRB/IEC representatives, 
may also co nduct an inspection or perform an audit of the study.  The 
investigator(s)/institution(s) will permit trial -related audits, IRB/IEC re view, and regulatory 
inspection(s) by providing direct access to source data/documents and study records.  If informed 
of such an inspection, the Investigator should notify the Sponsor immediately.  The Investigator 
will ensure that the inspectors and audi tors have access to the clinical supplies, study site 
facilities, and laboratory, and that all data (including original so urce documentation) and all 
study files are available, if requested.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 154 of 178 
Confidential and Proprietary   11 February 2020  12.0 ETHICS  
This study will be conducted to be consistent with the pri nciples that have their origin in 
Declaration of Helsinki and in accordance with FDA regulations (21  CFR § 11, 50, 54, 56,  and 
312), with the current ICH GCP guidelines (ICH  E6), as well as with any applicable regulatory 
authority, federal, state and/or lo cal laws and regulations.  
12.1 IRB/IEC Approval  
Before enrollment of patients into the study, as required by FDA regulations (2 1 CFR § 56), ICH 
GCP, applicable regulatory authority requirements, and local regulations, the current protocol 
and ICF will be review ed and approved by an appropriate IRB or IEC.  A letter documenting the 
IRB or IEC approval must be received by the Sponso r before the initiation of the study at a 
clinical site.  Amendments to the protocol will be subject to the same requirements as the 
original protocol.  
The Investigator, Sponsor, or designee will submit a progress report at least once yearly to the 
IRB or IEC.  However, the frequency of these reports will depend on IRB or IEC requirements.  
As soon as possible after completion or termina tion of the study, the Investigator will submit a 
final report to the IRB or IEC per the IRB or IEC requirements, and in c ompliance with FDA 
regulations, applicable regulatory authority requirements, and ICH  GCPs. 
The Investigator, the Sponsor, or designee  shall notify the IRB or IEC of any SAEs, suspected 
unexpected serious adverse reactions (SUSARs), or any other informatio n that may affect the 
safe use of the study drug(s) during the study, per the IRB or IEC local requirements, and in 
compliance with FD A regulations, country and local regulatory authority regulations, and ICH 
GCPs. 
12.2 Written Informed Consent  
Written documentation of informed consent must be obtained from each patient or legal 
representative before entering the study.  Patients will be info rmed of the nature of the study, and 
the ICF must be presented to each patient in the language in which th e patient is fluent. 
Informed consent will be obtained from and documented for each patient prior to the conduct of 
any protocol -specific procedures.  Signed and dated ICFs will be retained by the Investigator 
with the study records.  Each patient will be given a copy of the signed and dated ICF.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 155 of 178 
Confidential and Proprietary   11 February 2020  13.0 DATA HANDLING AND RE CORD KEEPING  
13.1 Data Collection Instruments and Source Documents  
13.1.1  Study Records  
During the s tudy, the investigator/institution should maintain adequate and accurate source 
documents and trial record s that include all pertinent observations on each of the site’s trial 
patients.  Source data should be attributable, legible, contemporaneous, origina l, accurate, and 
complete.  Changes to source data should be traceable, should not obscure the original en try, and 
should be explained if necessary (e.g.,  via an audit trail).  The Investigator should ensure the 
accuracy, completeness, legibility, and time liness of the data reported to the sponsor in the CRFs 
and in all required reports.  The investigator/inst itution should, at a minimum, maintain the trial 
documents as specified in Essential Documents for the Conduct of a Clinical Trial (ICH E6 
section 8) and as required by the applicable regulatory requirement(s).  The 
investigator/institution should take mea sures to prevent accidental or premature destruction of 
these documents.  
13.1.2  Data Collection Instruments  
Data collection instruments (DCIs) (e.g., eCRFs, electronic clinical outcomes assessments 
[eCOA], and paper forms) will be used in this study.  These instr uments are used to transmit the 
information collected during the performance of this study to the Sponsor or Sponsor’s designee 
and regulatory authori ties.  The Investigator must review the DCIs for completeness and 
accuracy and must approve all data, incl uding any changes made.  Furthermore, the Investigator 
retains full responsibility for the appropriateness and accuracy of all data collected in the D CIs. 
13.2 Retention of Essential Documents  
For sites in the US: All records and documents pertaining to the stu dy including, but not limited 
to, those outlined above will be maintained by the Investigator for a period of at least 2  years 
after FDA approval of t he drug or at least 2  years after withdrawal of the IND under which this 
study was conducted, whichever is  longer.  
For sites outside the US:  Essential documents should be retained until at least 2  years after the 
last approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketing applications in an ICH region or at least 2  years have elapsed since the 
formal discontinuation of clinical development of the investigational product.  These documents 
should be ret ained for a longer period, however, if required by the applicable regulatory 
requirements or by a n agreement with the sponsor.  It is the responsibility of the sponsor to 
inform the investigator/institution when these documents no longer need to be retaine d. 
To avoid any possible errors, the Investigator will contact the Sponsor before transferring or  
destroying any study records.  The Investigator will also promptly notify the Sponsor in the event 
of accidental loss or destruction of any study records.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 156 of 178 
Confidential and Proprietary   11 February 2020  13.3 Confidentiality  
Patient confidentiality will be maintained per local legal and regulatory requiremen ts and 
applicable US federal regulations and ICH GCP guidelines.  To comply with GCP guidelines and 
requirements, patient records will be reviewed during monit oring visits and audits conducted by 
the Sponsor, Sponsor's representatives, or health authoritie s.  During these activities, every 
reasonable effort will be made to keep medical information, including patient identifying 
information, as confidential as po ssible as required by law.  
13.4 Security Measures  
Sites will employ both technical and organizational  measures (such as, but not limited to, 
controlling access to personal patient data to only those with a need to know such data, data 
encryption, data anonymiz ation and pseudonymization, and so forth) to ensure patient and 
patient data privacy.  Sites will  adhere to a “privacy by design” and “privacy by default” 
approach in collecting, storing, and processing personal patient data.  
In the event of a breach of th e security measures used by the Site to ensure patient and patient 
data privacy, the Site will im mediately notify the Sponsor.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 157 of 178 
Confidential and Proprietary   11 February 2020  14.0 PUBLICATION POLICY  
All data are the property of the Sponsor.  Any formal presentation or publication of data from 
this study will  be considered for joint publication by the Sponsor personnel and Investigator(s).  
The Investigat or may be required to sign the clinical study report if it is to be used in a 
registration submission to the health authorities of some countries.  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 158 of 178 
Confidential and Proprietary   11 February 2020  15.0 REFERENCES  
1. Abraxane [package insert]. Summit, NJ : Celgene Corporation ; 2015. 
2. Abraxane Summary Basis of Approv al  
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21660_ABRAXANE_medr.P
DF 
3. Algazi A, Tsai KK, Takamura KT, et al. Intratumoral electroporation of plas mid IL-12 
can prime response to anti -PD1/PD-L1 blockade in patients with Stage III/IV -M1a 
melanoma. Abstract CT134. Presented at the 2016 annual Meeting of the American 
Association for Cancer Research, 16 -20 April 2016, New Orleans, LA.  
4. Balar AV, Galsky MD , Rosenberg JE, et al. Atezolizumab as first -line treatment in 
cisplatin-ineligible patients with  locally advanced and metastatic urothelial carcinoma: a 
single-arm, multicentre, phase 2 trial. Lancet. 2017;389:67 -76. 
5. Boyman O, Sprent J. The role of interl eukin-2 during homeostasis and activation of the 
immune system. Nat Rev Immunol. 2012;12:180 -190. 
6. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced 
Squamous -Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373:123 -35. 
7. Brayer J, Fishman M. Regression of metastatic clear cell kidney cancer with interleukin -2 
treatment follo wing nivolumab (anti -PD-1) treatment. J Immunother. 2014;37:187 -191. 
8. Carbone DP, Reck M, Paz -Ares L, et al. First -Line Nivolumab in Stage IV or Recurrent 
Non-Small-Cell Lung Cancer. N Engl  J Med. 2017;376:2415 -26. 
9. Cortes J, O'Shaughnessy J, Loesch D, et a l. Eribulin monotherapy versus treatment of 
physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 
open-label randomized study. Lanc et. 2011;377:914 -23. 
10. Daud AI, Loo K, Pauli ML, et al. Tumor immune profiling predicts response to  anti-PD-1 
therapy in human melanoma. J Clin Invest. 2016a;126:3447 -3452. 
11. Daud AI, Wolchok JD, Robert C, et al. Programmed death -ligand 1 expression and 
response to the anti -programmed death 1 antibody pembrolizumab in melanoma. J Clin 
Oncol. 2016b;34:4102 -4109. 
12. Dirix LY, Takacs I, Jerusalem G, et al. Avelumab , an anti-PD-L1 antibody, in patients 
with locally advanced or metastatic breast cancer: a phase 1b JAVE LIN Solid Tumor 
study. Breast Cancer Res Treat. 2018;167(3):671 -86. 
13. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in so lid 
tumors:  Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228 -247. 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 159 of 178 
Confidential and Proprietary   11 February 2020  14. Fleming TR. One -sample multiple testing procedure for phase II clinical trials. 
Biometrics. 1982;38:143 -51. 
15. Forero-Torres A, Varley KE, Abramson VG, et al. Translational Br east Cancer Research 
Consortium (TBCRC). TBCRC 019: A Phase II Trial of Nanoparticle Albumin -Bound 
Paclitaxel with or without the Anti -Death Receptor 5 Monoclonal Antibody Tigatuzumab 
in Patients with Triple -Negative Breast Cancer. Clin Cancer Res. 2015 Ju n 
15;21(12):2722 -9. 
16. Gandhi L, Rodríguez -Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in 
Metastatic Non -Small-Cell Lung Cancer. N Engl J Med. 2018; doi: 
10.1056/NEJMoa1801005. [Epub ahead of print].  
17. Garon EB, Rizvi NA, Hui R, et al. Pembrolizu mab for the treatment of non -small-cell 
lung cancer. N Engl J Med. 2015;372:2018 -28. 
18. Gassenmaier M, Lipp  HP, Scheu A, et al. Safety of shortened infusion times for 
combined ipilimumab and nivolumab. Cancer Immunol Immunother. 2018;67:135 -140. 
19. Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, Ready N, Gerber DE, 
Shepherd FA, Antonia S, Goldman JW, Juerge ns RA. Nivolumab monotherapy for first -
line treatment of advanced non –small-cell lung cancer. Journal of Clinical Oncology. 
2016 Sep 1;34(25):2980.  
20. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin -
bound paclitaxel compa red with polyethylated castor oil -based paclitaxel in women with 
breast cancer. J Clin Oncol. 2005;23:7794 -803. 
21. Haas CE, Nelsen JL. Drug -cytokine interactions. In Piscitelli SC, Rodvold KA, eds. Drug 
Interactions in Infectious Diseases. Human Press Inc, To towa NJ, USA. 200 5 pp 431-61. 
22. Harris LN, Broadwater G, Lin NU, et al. Molecular subtypes of breast cancer in relation 
to paclitaxel response and outcomes in women with metastatic disease: results from 
CALGB 9342. Breast Cancer Research. 2006;8(6):R66.  
23. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously 
treated, PD -L1-positive, advanced non -small-cell lung cancer (KEYNOTE -010): a 
randomised controlled trial. Lancet. 2016;387:1540 -50. 
24. Kang YK, Boku N, Satoh T, et al. Nivolumab in p atients with advanced gastric or gastro -
oesophageal junction cancer refractory to, or intolerant of, at least two previous 
chemotherapy regimens (ONO -4538-12, ATTRACTION -2): a randomised, double -blind, 
placebo-controlled, phase 3 trial. Lancet. 2017;390:24 61-71. 
25. Kaufman PA, Awada A, Twelves C, et al. Phase III open -label randomized study of 
eribulin mesylate versus capecitabine in patients with locally advanced or metastatic 
breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 
2015;33:594 -601. 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 160 of 178 
Confidential and Proprietary   11 February 2020  26. Le DT, Uram JN, Wang H, et al. PD -1 blockade in tumors with mismatch repair 
deficiency. N Engl J Med. 2015;372:2509 -20. 
27. McIntyre K, O'Shaughnessy J, Schwartzberg L, et al. Phase 2 study of eribulin mesylate 
as first-line therapy for locall y recurrent or metastatic human epidermal growth factor 
receptor 2 -negative breast cancer. Breast Cancer Res Treat. 2014;146:321 -8. 
28. Momtaz P, Park V, Panageas KS, et al. Safety of Infusing Ipilimumab Over 30  Minutes. J 
Clin Oncol. 2015;33:3454 -8. 
29. Nishino M , Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS. Developing 
a common language for tumor response to immunotherapy: immune -related response 
criteria using unidimensional measurements. Clinical Cancer Res. 2013;19(14):3936 -43. 
30. Nomura M, Otsuka A, Kondo T, et al. Efficacy and safety of retreatment with nivolumab 
in metastatic melanoma patients previously treated with nivolumab. Cancer Chemother 
Pharmacol. 2017;80:999 -1004. 
31. Overman MJ, McDermott R,Leach JL, et al.  Nivolumab in patients with metastat ic DNA 
mismatch repair -deficient or microsatellite instability -high colorectal cancer (CheckMate 
142): an open -label, multicentre, phase 2 study. 2017;18:1182 -91. 
32. Patel MR, Ellerton J, Infante JR, et al. Avelumab in metastatic urothelial carcinoma after 
platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of 
an open-label, phase 1 trial. Lancet Oncol. 2018;19:51 -64. 
33. Payne R, Glenn L, Hoen H, et al. Durable responses and reversible toxicity of high -dose 
interleukin -2 treatment of  melanoma and renal cancer in a Community Hospital 
Biotherapy Program. J Immunother Cancer. 2014;2:13.  
34. Rizvi NA, Hellmann MD, Brahmer JR, et al. Nivolumab in Combination With Platinum -
Based Doublet Chemotherapy for First -Line Treatment of Advanced Non -Small-Cell 
Lung Cancer. J Clin Oncol. 2016;34:2969 -79. 
35. Rizvi N, Antonia S,  Callahan MK, et al.  Impact of tumor mutation burden on the 
efficacy of nivolumab or nivolumab + ipilimumab in small cell lung cancer: an 
exploratory analysis of CheckMate 032  (Abstract 11063).  Presented at the International 
Association for the Study of Lung Cancer 18th World Conference on Lung Cancer, 
15-18 October 2017, Yokohama, Japan.  
36. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma 
without BRAF mutation . N Engl J Med. 2015;372:320 -30. 
37. Rugo HS, Delord JP, Im SA, et al. Safety and Antitumor Activity of Pembrolizumab in 
Patients with Estrogen Receptor –Positive/Human Epidermal Growth Factor Receptor 2 –
Negative Advanced Breast Cancer. Clinical Cancer Research . 2018;24(12):2804 -11. 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 161 of 178 
Confidential and Proprietary   11 February 2020  38. Schmid P, Cruz C, Braiteh F, et al. Atezolizumab in metastatic TNBC (mTNBC): 
long-term clinical outcomes and biomarker analyses. Cancer Res. 2017;77(13 
Suppl):Abstract  2986 Presented at the 2017 annual meeting of the American Associa tion 
for Cancer Research, 1 -5 April 2017.  Washington, DC.  
39. Scott M, Ratcliffe MJ, Sharpe A, et al. Concordance of tumor and immune cell staining 
with Ventana SP142, Ventana SP263, Dako 28 -8 and Dako  22C3 PD-L1 tests in NSCLC 
patient samples. DOI: 10.1200/J CO.2017.35.7_suppl.7 Journal of Clinical Oncology 35, 
no. 7_suppl (March 1 2017) 7 -7. 
40. Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab -paclitaxel in combination 
with carboplatin versus solv ent-based paclitaxel plus carboplatin as first -line therap y in 
patients with advanced non -small-cell lung cancer: final results of a phase III trial. J Clin 
Oncol. 2012;30:2055 -62. 
41. Topalian S, Hodi F, Brahmer J, et al. Safety, activity, and immune correlat es of anti-PD-1 
antibody in cancer. N Engl J Med 2012;366: 2443–2454. 
42. Tsao MS,  Kerr KM,  Kockx M, et al.  PD -L1 Immunohistochemistry Comparability Study 
in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.  J Thorac 
Oncol. 2018;13(9):1302 -11. doi: 10.1016/j.jtho.2018.05.013.  
43. Twelves C, Cortes J, Vah dat L, et al. Efficacy of eribulin in women with metastatic 
breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat. 
2014;148(3):553 -61. 
44. Wainberg ZA, Hochster HS, George B, et al. Phase I study of nivolumab (nivo) + 
nab-paclitaxel (nab -P) ± gemcitabine (Gem) in solid tumors: Interim results from the 
pancreatic cancer (PC) cohorts.  J Clin Oncol. 2017;3 5: 412-412. 
45. Weber JS, Kudchadkar RR, Yu B, et al. Safety, efficacy, and biomarkers of nivolumab 
with vaccine in ipilimumab -refractory or -naive melanoma. J Clin Oncol. 
2013;31:4311 -8. 
46. Wong MKK , Morse MA, McDermott DF, et al. Overall survival of metastatic melanoma 
patients treated with HD IL -2 followed by immune checkpoint blockade of the CTLA -4 
or the PD -1 pathways:  analysis of data on the current use of HD IL -2. J Immunother 
Cancer. 2015;3(S uppl 2):P359.  
47. Zídek Z, Anzenbacher P, Kmoníčková E. Current status and challenges of cytokine 
pharmacology. Br J Pharmacol . 2009;157:342 –61. 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 162 of 178 
Confidential and Proprietary   11 February 2020  APPENDIX 1: CLINICAL LABORATOR Y TESTS  
Descriptions of the laboratory tests performed in this study are  provided in the following 
appendices:  
• Appendix 1A : Laboratory Tests Performed in This Study 
• Appendix 1B : Local Clinical Laboratory Tests Obtained Prior to Study Drug  
                              Administration  
  
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 163 of 178 
Confidential and Proprietary   11 February 2020  Appendix 1A:   Laboratory Tests Performed in This Study  
Clinical Laboratory Tests  
Hematology  Chemistry  Serology  
• Hemoglobin (Hgb)  
• Hematocrit (HCT)  
• Red blood cell (RBC) count  
• Platelet count  
• White blood cell (WBC) count  
• Neutrophils  
• Lymphocytes 
• Monocytes  
• Eosinophils  
• Basophils  
• Mean corpuscular volume 
(MCV) 
• Mean corpuscular hemoglobin 
(MCH) 
• Mean corpuscular hemoglobin 
concentration (MCHC)  • AST (SGOT)  
• ALT (SGPT)  
• Alkaline phosphatase (ALP)  
• Gamma-glutamyl transferase  
(GGT) 
• Albumin 
• Creatinine  
• Calculated creatinine clearance  
• Calcium 
• Glucose 
• Total protein (TP)  
• Total bilirubin  
• Sodium 
• Potassium  
• Chloride 
• CO2 content or bicarbonate  
• Blood urea nitrogen (BUN)  
• Lactate dehydrogenase (LDH)  
• Uric acid • Hepatitis B surface antigen 
(HBsAg) 
• Hepatitis C virus antibo dy 
(anti-HCV) 
• Human immunodeficiency virus 
(HIV) antibody  
Additional Labs  
• Creatine kinase  
• Thyroid stimulating hormone 
(TSH) 
• Free thyroxine (T4)  
• Free or total triiodothyronine 
(T3) 
• Lipase 
• Amylase 
• Serum or urine pregnancy 
(HCG) 
Coagulation  
• Partial thromboplastin time 
(PTT) 
• Prothrombin time (PT)  
Urinalysis  
• Specific gravity  
• pH 
• Glucose 
• Protein 
• Bilirubin 
• Ketones 
• Leukocyte esterase  
• Blood For positive protein, white blood cell or blood, a 
microscopic examination including:  
• Red blood cells  
• White blood cells 
• Epithelial cells  
• Bacteria 
• Crystals 
• Casts 
Local laboratory will be used for Part  1 and Part 3; central laboratory will be used for Part  2 and Part 4.  
 
Protocol No . 16-214-02 Amendment 7.0   Bempegaldesleukin ( NKTR -214) 
Nektar Therapeutics   Page 165 of 178 
Confidential and Proprietary   11 February 2020  APPENDIX 2: SCHEDULE OF ELECTROCARDIOGRAM, V ITAL SIGNS, 
PHARMACOKINETICS, , AND 
IMMUNOGENICITY SAMPL E ASS ESSMENTS   
 

Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 167 of 178 
Confidential and Proprietary   11 February 2020  Appendix 2 Table 1: Part 2 - Assessment Schedule for NKTR -214 + Nivolumab (Contd)  
Event Screeninga Cycle 1 Cycle 2 Cycle 3 and Beyond  Post-treatment  
Day -28 to -1 Day 1b Day 2 Day 3 Day 8 Day 1 b Day 8 Day 1 b Day 8 EOT & 
Follow-up 
T=00:30 - 
01:00  Within 30 min 
of the end of 
214 infusion 
and before 
Nivolumab 
(Nivo) infusion   ECGd + 
PK-214f    PK-214  PK-214   
T=01:00 - 
01:30g Nivo Infusiong  Nivo 
Infusion    Nivo 
Infusion  Nivo 
Infusion   
T=01:30 - 2:00  End of Nivo 
Infusion  PK-nivo         
T=03:00 (± 30 min) SOI   ECGd + 
PK-214f         
T=03:00 SOI or 1 hour 
following the end of nivo 
infusion  VS    VS  VS   
T=06:00 + 2 hrs SOI   ECGd + 
PK-214f         
T=48:00 ± 4 hrs SOI     ECGd + 
PK-214f       
T=168:00 ± 4 hrs SOI      ECGd +  
PK-214f      
Abbreviations:  ; ECG = electrocardiogram; IG-214 = immunogenicity samples for NKTR -214; IG-nivo = immunogenicity 
samples for nivolumab; Nivo = Nivolumab; PK -214 = blood samples for pharmacokinetic (PK) analy ses of NKTR -214 and its metabolites; PK -nivo = blood 
samples for PK analyses of nivolumab; SOI = Start of NKTR -214 infusion; VS = vital signs  
Footnotes:  
a. All assessments are done at any time during the Screening Period and all other Screening assessments ar e outlined in the Schedule of Events (Section 1.2). 

Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 169 of 178 
Confidential and Proprietary   11 February 2020  Appendix 2 Table 2: Parts 3/4, Cohort A (Concurrent Dosing)  
• Schedule 1: Concurrent Dosing NKT R-214 0.006 mg/kg q3w + Nivo 360mg flat dose     + Ipi 1 mg/kg q6w  
• Schedule 2: Concurrent Dosing NKTR -214 0.006 mg/kg q3w + Nivo 1 mg/kg × 4 doses + ipi 3  mg/kg q3w  × 4 doses (then NKTR-214 0.006  mg/kg q3w + Nivo 360  mg q3w maintenance ) 
• Schedule 3: Concurr ent Dosing NKTR -214 0.006 mg/kg q3w + Nivo 3 mg/kg × 4 doses + ipi 1  mg/kg q3w  × 4 doses (then NKTR-214 0.006  mg/kg q3w + Nivo 360  mg q3w maintenance ) 
Event Screeninga Cycle 1 Cycle 2 Cycle 3 and Beyond  Post 
Treatment  
Day -28  
to -1 Day  
1b Day  
2 Day  
3 Day  
8 Day 
11 Day  
1b Day  
3 Day  
8 Day  
1b Day  
8 EOT &  
Follow-up 
Predose VS VS VSc 
(q1h 
x4) for 
Part 3; 
VSc 
(once) 
for Part 
4 VSc 
(q1h 
x2) for 
Part 3; 
VSc 
(once) 
for Part 
4 VSc 
(once) VSc 
(once) 
for 
Part 3 
only VS   VSc 
(once) VS VSc VSc (EOT 
only) 
 ECG ECGd + 
PK-214         PK-214     PK-214    
  PK-
nivo         PK-nivo     PK-nivo 
(Cycles 3, 
5, 7, 9, 
13, 
17,23,35)     
  
PK-ipi 
     PK-ipi 
(Schedules 
2&3 only)    PK-ipih 
Schedule 
1: Cycles 
3, 5, 7, 9, 
13, 17, 
23, 35 
Schedules 
2&3: 
Cycles 3, 
4, 5 and 7 
only   
Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 171 of 178 
Confidential and Proprietary   11 February 2020  Event Screeninga Cycle 1 Cycle 2 Cycle 3 and Beyond  Post 
Treatment  
Day -28  
to -1 Day  
1b Day  
2 Day  
3 Day  
8 Day 
11 Day  
1b Day  
3 Day  
8 Day  
1b Day  
8 EOT &  
Follow-up 
T=0:00 hr   Start of 30 
min NKTR -
214 
Infusion 
(SOI)  
214 
Infusio
n         214 
Infusion     214 
Infusion    
T=00:30 - 
01:00  Within 30 
min of the 
end of 214 
infusion and 
before 
Nivolumab 
(Nivo) 
infusion  
ECGd 
+PK-
214f     PK-214   PK-214   
T=01:00 - 
01:30g Nivo 
Infusiong  Nivo 
Infusio
n         Nivo 
Infusion     Nivo 
Infusion    
T=01:30 - 
02:00 End of nivo 
infusion  PK-
nivo                  
T=02:00 - 
02:30i  Ipilimumab 
(Ipi) 
infusioni   
Ipi 
infusio
n     Ipi 
infusion 
(Schedules 
2&3 only)    Ipi 
infusion 
Schedule 
1: only on 
cycles Ipi 
is given  
Schedules 
2&3: 
Cycles 3 
and 4 
only   
T=02:30 – 
03:00  End of Ipi 
infusion  PK-ipi            
T=03:00 (± 30 min) SOI   ECGd 
+PK-
214f         PK-214          
Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 172 of 178 
Confidential and Proprietary   11 February 2020  Event Screeninga Cycle 1 Cycle 2 Cycle 3 and Beyond  Post 
Treatment  
Day -28  
to -1 Day  
1b Day  
2 Day  
3 Day  
8 Day 
11 Day  
1b Day  
3 Day  
8 Day  
1b Day  
8 EOT &  
Follow-up 
T=03:00-04:00 SOI or 1 hr 
following the end of the 
last study drug inf usion 
(whether nivo or ipi)   
VS         VS     VS   
T=04:00-05:00 SOI or 2 
hrs following the end of the 
last study drug infusion 
(whether nivo or ipi)   
VS         
           
T=05:00-06:00 SOI or 3 
hrs following the end of the 
last study drug infusion 
(whether nivo or ipi)   
VS         
           
T=06:00 + 2 hrs SOI   ECGd 
+PK-
214f         
PK-214          
T=48:00 ± 4 hrs SOI       ECGd 
+ 
PK-
214f     
  PK-
214        
T=168:00 ± 4 hrs SOI      ECGd
+ 
PK-
214f  
  PK-214    
Footnotes and abbreviations appear at t he end of Appendix 2  
 
Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 173 of 178 
Confidential and Proprietary   11 February 2020  Appendix 2 Table 2: Parts 3/4, Cohort B (Staggered Dosing of Ipilimumab)  
• Schedule 1: Staggered Dosing NKTR -214 0.006 mg/kg q3w + Nivo 360mg flat dose     + Ipi 1 mg/kg q6w  
• Schedule 2: Staggered Dosing NKTR -214 0.006 mg/kg q3w + Nivo 1  mg/kg × 4 doses + ipi 3  mg/kg q3w  × 4 doses (then NKTR-214 0.006 mg/kg q3w + Nivo 360  mg q3w maintenance ) 
• Schedule 3: Staggered Dosing NKTR -214 0.006 mg/kg q3w + Nivo 3 mg/kg × 4 doses + ipi 1  mg/kg q3w  × 4 doses (then NKTR-214 0.006  mg/kg q3w + Nivo 360  mg q3w maintenance ) 
Event Screeninga Cycle 1 Cycle 2 Cycle 3j Cycle 4 and Beyondk Post 
Treatment  
Day -28  
to -1 Day  
1b Day  
2 Day  
3 Day  
8 Day 
11 Day  
1b Day  
8 Day  
1b Day 
3 Day  
8 Day  
1b Day  
8 EOT & 
Follow-up 
Predose  VS VS VS c (q1h 
x4) for 
Part 3; 
VS 
(once) for 
Part 4 VS c (q1h 
x2) for 
Part 3; 
VS 
(once) for 
Part 4 VS c 
(once) VS c 
(once) 
for 
Part 3 
only VS VS c 
(once) VS   VS c VS VS c  VSc  
(EOT 
only) 
 ECG ECGd + 
PK-214         PK-214   PK-214     PK-214    
 
 PK-
nivo              PK-
nivo     PK-nivo  
(Cycles 5, 
7, 9, 13, 
17, 23, 
35)     
 
        PK-ipih   PK-ipih  
Schedule 
1: Cycles 
5, 7, 9, 13, 
17, 23, 35  
Schedules 
2&3: 
Cycles 4, 
5, 6, 7, 9   
Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 175 of 178 
Confidential and Proprietary   11 February 2020  Event Screeninga Cycle 1 Cycle 2 Cycle 3j Cycle 4 and Beyondk Post 
Treatment  
Day -28  
to -1 Day  
1b Day  
2 Day  
3 Day  
8 Day 
11 Day  
1b Day  
8 Day  
1b Day 
3 Day  
8 Day  
1b Day  
8 EOT & 
Follow-up 
T=00:30 
- 01:00 Within 30 
min of the 
end of 214 
infusion 
and before 
Nivolumab 
(Nivo) 
infusion  ECGd 
+PK-
214f         PK-214   PK-214     PK-214    
T=01:00 
- 01:30g Nivo 
Infusiong  Nivo 
Infusio
n         Nivo 
Infusion   Nivo 
Infusion     Nivo 
Infusion    
T=01:30 
- 02:00 End of 
nivo 
infusion  PK-
nivo                     
T=02:00 
- 02:30i  Ipilimuma
b (Ipi) 
infusioni          Ipi 
infusion   Ipi 
infusion 
Schedule 
1: only on 
cycles Ipi 
is given  
Schedules 
2&3: 
Cycles 4, 
5, 6    
T=02:30 
– 03:00 End of Ipi 
infusion         PK-ipih      
T=03:00 (± 30 min) 
SOI  ECGd 
+PK-
214f           
  PK-214          
Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 176 of 178 
Confidential and Proprietary   11 February 2020  Event Screeninga Cycle 1 Cycle 2 Cycle 3j Cycle 4 and Beyondk Post 
Treatment  
Day -28  
to -1 Day  
1b Day  
2 Day  
3 Day  
8 Day 
11 Day  
1b Day  
8 Day  
1b Day 
3 Day  
8 Day  
1b Day  
8 EOT & 
Follow-up 
T=03:00-04:00 SOI 
or 1 hr following the 
end of the last study 
drug infusion 
(whether nivo or ipi)   VS         VS   VS     VS   
T=04:00-05:00 SOI 
or 2 hrs hr  following 
the end of the  last 
study drug infusion 
(whether nivo or ipi) 
- (for Part 3 only)   VS                        
T=05:00-06:00 SOI 
or 3 hrs hr  following 
the end of the last 
study drug infusion 
(whether nivo or ipi) 
- (for Part 3 only)   VS                        
T=06:00 + 2 hrs SOI   ECGd + 
PK-
214f             PK-214          
T=48:00 ± 4 hrs SOI       ECGd + 
PK-214f           PK-
214        
T=168:00 ± 4 hrs 
SOI     ECGd 
+ 
PK-
214f      PK-
214    
Abbreviations:  ; ECG = electrocardiogram; IG-214 = immunogenicity samples for NKTR -214; IG-nivo = immunogenicity 
samples for nivolumab; IG -ipi = immunogenicity samples for ipilimumab; Ipi = Ipilimumab; Nivo = Nivolumab; PK -214 = blood samples for pharmacokinetic 
(PK) analyses of NKTR -214 and its metabolite s; PK-ipi = blood samples for PK analyses of  ipilimumab; PK-nivo = blood samples for PK analyses of 
nivolumab; SOI = Start of NKTR -214 infusion; VS = vital signs;  

Protocol No. 16 -214-02 Amendment 7.0   Bempegaldesleukin (NKTR -214) 
Nektar Therapeutics   Page 178 of 178 
Confidential and Proprietary   11 February 2020  APPENDIX 3: CEREBROVASCULAR AC CIDENT ADVERSE EVENT  
MANAGEMENT ALGORITHM  
Table 26 provides a management algorithm for possible signs of CVA and follow-up of CVA.  
This general guideline constitutes guidance to the Investigator and  may be supplemented by 
discussions with the Medical Monitor representing the Sponsor.  
Table 26: Cerebrovascular Accident Adverse Event Management Algorit hm 
CEREBROVASCULAR ACCIDENT  
ADVERSE EVENT MANAGEMENT ALGORITHM  
This guideline pertains to all patients in the doublet or triplet immunotherapy  cohorts . 
For unexplained neurological symptoms (such as hemiparesis, confusion, dysarthria , or visual disturba nces) that 
may be associated with CVA : perform neurological imagi ng with MRI including diffusion -weighted imaging 
(DWI) as soon as feasible after initial presentation of symptoms , preferably within 24 hours  (DWI MRI is 
preferred, but if contraindicated , alternative imaging modalities may be used ). 
If imaging is consistent with a CVA, proceed to the following:  
1 For any new CVA events confirmed by imaging ( DWI MRI  is preferred, unless contraindicated) , 
regardless of neurological symptoms (e.g., cryptogenic CVA):  
• Discontinue study treatment for patients recei ving doublet and triplet immunotherapy  
For suspected TIA without clear alternative etiology:  
• Discontinue study treatment for patients receiving triplet immunotherapy  
• Study treatment for patients receivin g doublet immunotherapy may be continued only after c areful 
risk-benefit assessment by the Investigator  
2 Obtain a neurology consultation  
3 Perform l aboratory assessments ( complete blood count [ CBC] with differential, serum blood urea 
nitrogen [BUN], and creatinine)  
4 Consider cardiac echocardiogram (trans -esophageal as appropriate) to evaluate for potential source of 
emboli 
Abbreviations: CVA = cerebrovascular accident; DWI = diffusion -weighted imaging; MRI = magnetic resonance 
imaging; TIA = transient  ischemic attack.  
 